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ABSTRACT 
 
The use of plants for the prevention and treatment of various health diseases has 
been a practice that comes from the ancient civilizations. However, in recent years has been 
observed an increase in the use of herbal products. In developed countries is particularly 
worrying the increasing consumption of herbal weight loss medicines/dietary supplements as 
alternative or complement to the traditional programs of body weight reduction. In addition, 
this issue is even more serious because among the general population prevails the notion 
that herbal preparations are devoid of health risks due to the natural origin of the 
constituents. Indeed, only a minority recognizes that herbal medicinal products are complex 
mixtures of phytochemicals, which may be substrates, inhibitors or inducers of the same 
biological systems that are involved in the biodisposition of conventional drugs, existing, 
therefore, a high potential for clinically significant pharmacokinetic interactions. Accordingly, 
considering the close relationship between obesity and cardiovascular diseases, as well as the 
scarcity of scientific information available about the safety of herbal slimming medicinal 
products, it is absolutely justified to assess the potential for pharmacokinetic interactions 
between the most relevant herbal weight loss extracts and high-risk drugs required in 
multiple cardiovascular diseases such as the case of amiodarone (AM). Thus, from the 
perspective of protecting public health, it is warranted to characterize the interference of 
standardized herbal extracts commonly used in weight loss programs (e.g. Fucus vesiculosus, 
Paullinia cupana, Citrus aurantium and Carica papaya) on the pharmacokinetic profile of AM. 
This thesis emerged in this context and aimed to carry out the in vivo nonclinical 
systematic assessment of the potential for occurrence of significant herb-drug interactions 
between commonly used standardized herbal weight loss extracts and AM, a drug of narrow 
safety range widely used in clinical practice for the management of cardiovascular diseases. 
One technique of high performance liquid chromatography (HPLC) with diode-array 
detection (DAD) was developed and fully validated for adequate quantification of AM and its 
main metabolite (mono-N-desethylamiodarone) in human plasma in order to provide a 
useful analytical tool for clinical purposes. A second technique was developed and validated 
in plasma and heart, liver, kidney, and lung tissue homogenates of rats – species used for in 
vivo investigations. 
The herbal extracts that have more pronounced effects on the pharmacokinetics of 
AM were F. vesiculosus, P. cupana and C. papaya extracts. F. vesiculosus extract and P. 
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cupana extract following the co-administration with AM showed a significant reduction of 
the peak concentration of AM as well as a reduction in the extent of systemic exposure to 
AM. For the first time were reported herb-drug interactions between F. vesiculosus extract 
and P. cupana extract with AM, which determined a considerable decrease on AM 
bioavailability in rats. Therefore, the therapeutic efficacy of AM may be compromised by the 
concurrent administration of herbal slimming medicines/dietary supplements containing F. 
vesiculosus or P. cupana. 
On the other hand, it should be highlighted that the pre-treatment with C. aurantium 
extract significantly increased the peak concentration of AM, while the extension of systemic 
exposure was comparable between both groups. At last, in the rats pre-treated with C. 
papaya extract was observed a significant increase in the systemic exposure of AM.  
In conclusion, the findings reported along this thesis showed the relevance of 
screening herb-drug pharmacokinetic interactions. The knowledge of relevant herb-drug 
interactions is certainly useful to help in the preparation of appropriate herbal monographs 
such those in course by the Herbal Medicinal Products Committee (HMPC) of the European 
Medicines Agency (EMA). The availability of this kind of information gathered together in a 
single and easily accessible document (monograph) may be of great value to promote a more 
rational and safer use of herbal products, having high importance in terms of protecting the 
public health. 
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RESUMO 
 
O uso de plantas para a prevenção e tratamento de várias doenças tem sido uma 
prática desde as civilizações antigas. No entanto, nos últimos anos tem-se observado um 
aumento da utilização de produtos à base de plantas. Nos países desenvolvidos tem sido 
particularmente preocupante o aumento do consumo de produtos de 
emagrecimento/suplementos alimentares como alternativa ou complemento aos programas 
tradicionais de perda de peso corporal. Além disso, esta questão é ainda mais grave porque 
entre a população prevalece, em geral, a noção de que as preparações à base de plantas são 
desprovidas de riscos para a saúde devido à origem natural dos constituintes. De facto, 
apenas uma minoria reconhece que os produtos medicinais à base de plantas são misturas 
complexas de fitoquímicos, que podem ser substratos, inibidores ou indutores dos mesmos 
sistemas biológicos que estão envolvidos na biodisposição de fármacos convencionais, 
existindo, por isso, um elevado potential para interações farmacocinéticas significativas. Por 
conseguinte, considerando a relação estreita entre a obesidade e as doenças 
cardiovasculares, bem como a escassez de informação científica disponível sobre a segurança 
de produtos medicinais de emagrecimento à base de plantas, é absolutamente justificado 
avaliar-se o potencial de interação de base farmacocinética entre os extratos de 
emagrecimento de origem vegetal mais relevantes e fármacos de maior risco usados em 
várias doenças cardiovasculares, como é o caso da amiodarona (AM). Assim, tendo em 
perspetiva a proteção da saúde pública, justifca-se a caraterização da interferência de 
extratos padronizados de plantas medicinais comummente utilizadas em programas de perda 
de peso (por exemplo, Fucus vesiculosus, Paullinia cupana, Citrus aurantium e Carica papaya) 
no perfil farmacocinético da AM. 
Esta tese surgiu neste contexto e visou conduzir estudos não-clínicos in vivo para a 
avaliação do potencial de ocorrência de interações significativas extrato-fármaco entre os 
extratos padronizados para perda de peso e a AM, um fármaco de margem terapêutica 
estreita amplamente utilizada na prática clínica para o tratamento de doenças 
cardiovasculares. Para tornar estes estudos exequíveis, foi desenvolvida e validada uma 
técnica de cromatografia líquida (HPLC) com um detetor de fotodíodos (DAD) para a 
quantificação adequada da AM e do seu principal metabolito (mono-N-desetilamiodarona) 
em plasma humano, a fim de disponibilizar uma ferramenta analítica para aplicação clínica. A 
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segunda técnica foi desenvolvida e validada em plasma e em homogeneizados de tecido do 
coração, fígado, rim e pulmão de ratos – espécie utilizada nos ensaios in vivo. 
Os extratos vegetais testados que mostraram efeitos mais pronunciados na 
farmacocinética da AM foram o F. vesiculosus, a P. cupana e a C. papaya. Os extratos de F. 
vesiculosus e P. cupana após a coadministração com a AM mostraram uma redução 
significativa da concentração máxima de AM bem como uma redução na extensão de 
exposição sistémica à AM. Pela primeira vez foram descritas interações extrato-fármaco 
entre o extrato de F. vesiculosus e de P. cupana com a AM, que determinaram uma 
diminuição considerável na biodisponibilidade da AM em ratos. Portanto, a eficácia 
terapêutica da AM pode ser comprometida pela administração concomitante de extratos 
medicinais de emagrecimento/suplementos dietéticos que contêm F. vesiculosus ou P. 
cupana.  
Por outro lado, deve ser realçado que o pré-tratamento com extrato de C. 
aurantium aumentou significativamente o pico de concentração plasmática (Cmax) da AM, 
enquanto que a extensão de exposição sistémica foi comparável entre ambos os grupos. Por 
último, nos ratos pré-tratados com o extrato de C. papaya foi observado um aumento 
significativo da exposição sistémica à AM.  
Em conclusão, os resultados descritos ao longo desta tese mostram a relevância da 
investigação de interações farmacocinéticas extrato-fármaco. O conhecimento das 
interações relevantes extrato-fármaco é certamente útil para ajudar na elaboração de 
monografias apropriadas, tais como aquelas em curso pelo Comité dos Produtos Medicinais 
à Base de Plantas (HMPC) da Agência Europeia do medicamento (EMA). A disponibilidade 
deste tipo de informação reunida num documento único e de fácil acesso (monografia) pode 
ser de grande valia para promover uma utilização mais racional e segura dos produtos à base 
de plantas, tendo grande importância em termos de proteção da saúde pública. 
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3 
I. GENERAL INTRODUCTION 
 
I.1. INTRODUCTION 
 
The use of plants, parts of plants and isolated phytochemicals for the prevention and 
treatment of various health diseases has been a practice that comes from the ancient 
civilizations (SAHOO, MANCHIKANTI and DEY, 2010). However, in recent years has been 
observed an increase in the use of herbal products (BENT, 2008; PHUA; ZOSEL and HEARD, 
2009). A survey of the World Health Organization indicated that about 70-80% of the world 
populations rely on non-conventional medicines mainly of herbal sources in their primary 
health care (DEHGHANI et al., 2012). In fact, many patients worldwide have extensively used 
herbal products concomitantly with prescribed drugs. Some estimates indicate that 40-60% 
of the patients do not inform the health care providers about the concomitant use of herbal 
medicinal products with prescribed drugs (TARIRAI, VILJOEN and HAMMAN, 2010). 
There is a general belief that herbal medicines are safe because of the natural origin 
of its constituents. However, herbal medicines are not free of adverse effects and are not 
devoid of risks (e.g. herb-drug interactions) (HERMANN and VON RICHTER, 2012). On the 
contrary, considering that more people use herbal medicines to promote health or to 
control various chronic diseases, for which they are often taking concomitantly multiple 
prescribed or over-the-counter drugs, there is an increased possibility for pharmacokinetic 
and/or pharmacodynamic interactions (VIEIRA and HUANG, 2012).  
The use of herbal products is also complicated by other problems such as the lack of 
legislation imposing stricter control of herbal medicinal products and the lack of adequate 
quality control. Due to these reasons, the herbal products are frequently contaminated with 
heavy metals and adulterated with pharmaceuticals, and prohibited animal and plant 
ingredients. These contaminants could put unknowing consumers at risk of adverse side 
effects and drug interactions (TACHJIAN, MARIA and JAHANGIR, 2010). The lack of strict 
guidelines on the assessment of safety and efficacy, quality control, safety monitoring and 
knowledge of herbal medicines are the main shortcomings found in different regulatory 
systems and that should be improved in the future.  
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I.2. REGULATION OF HERBAL MEDICINES 
 
Despite its widespread use, there is still limited data on safety and efficacy of the 
herbal products currently on the market because herbal dietary supplements/medicines are 
mostly viewed as food supplements and not as drugs. In the United States they are not 
strictly regulated as drugs by the Food and Drug Administration (FDA). Instead, under the 
Dietary Supplement Health and Education Act (DSHEA), the dietary supplements can be 
marketed without evidence to support efficacy and safety of active ingredients and without 
regarding accuracy of active ingredients. If a dietary supplement appears to be unsafe after 
being marketed, the FDA can then decide to remove or not the product from the market 
(EGRAS et al., 2011). 
In the European Union the herbal medicinal products are regulated through the 
European Directive (2004/24/EC), which was prepared aiming at protecting public health and 
at the same time secure the free movement of herbal medicinal products within the 
Community. Although most of the individual herbal medicinal products are licensed 
nationally in each of the Member States, the process for licensing, the information required 
on herbal substances and the manufacturing process will be increasingly harmonized across 
the European Union. 
The European Directive (2001/83/EC) requires that an application for authorization 
to place an herbal medicinal product on the market has to be accompanied by a dossier 
containing results of pre-clinical and/or clinical trials carried out on the product and thus 
providing its quality, safety and efficacy. These results will not be necessary if the applicant 
can demonstrate by detailed references to published scientific literature that the constituent 
or the constituents of the medicinal product has or have a well-established medicinal use 
with recognized efficacy and an acceptable level of safety. However, even a long traditional 
use does not exclude all the concerns about product’s safety and, therefore, the competent 
authorities should be entitled to ask for all data necessary for assessing their safety. This is 
the so-called simplified registration procedure for certain traditional herbal medicinal 
products that presents particular characteristics especially the long use in folk medicine. In 
addition, the European Directive (2004/24/EC) also introduces a new subcategory of herbal 
medicinal products, the so called traditional herbal medicinal products, in which the safety 
needs to be shown while efficacy does not and only the traditional indications in specified 
conditions must be plausible.  
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The new classification of herbal medicinal products will require a change of 
regulatory competences, both at European and National level. Herbal medicines, previously 
considered as food supplements and regulated as food, will be now considered as medicinal 
products. Therefore, this implies a passage of jurisdiction firstly from the European food 
departments, first to the European Medicines Agency (EMA) and successively to the national 
regulatory agencies of drugs of Member States (CALAPAI, 2008).  
A new committee, the Herbal Medicinal Products Committee (HMPC), has been 
formed inside EMA with responsibility for herbal medicinal products. One of the objectives 
of the HMPC is to prepare a list of herbal substances, preparations and combinations for use 
in traditional herbal medicinal products. Thus, the EMA established an action Plan for Herbal 
Medicines 2010-2011 in which one of the objectives was to improve the output of the 
Committee on Herbal Medicinal Products, in particular by increasing the quality and number 
of Monographs and List entries. In each herbal monograph are defined the clinical 
indications, posology, method of administration, contraindications, precautions use, 
interactions, data on pregnancy, and other aspects (CALAPAI, 2008). This call for Monographs 
could be related to the widespread use of herbal products and probably to the increased 
risk of potential herb-drug interactions.  
In Portugal, the herbal medicines could be included in different legislation, according 
to their characteristics; the Decree-Law (136/2003, of June 28) includes the dietary 
supplements, which are under the jurisdiction of the Ministry of Agriculture, and the 
Decree-Law (176/2006, of August 30) contemplates the medicines. The legislation of the 
Decree-Law (176/2006, of August 30) referring to the Medicines Code transposes the 
European Directive (2004/24/EC). 
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I.3. HERB-DRUG INTERACTIONS 
 
The interactions of herbal medicines with drugs are a major safety concern, especially 
for drugs with a narrow therapeutic range [e.g. warfarin, digoxin and amiodarone (AM)]. As 
consequence potentially severe and perhaps even life-threatening adverse effects may occur 
because the pharmacokinetics and/or pharmacodynamics of the drug may be altered with 
clinical significance by the combination with herbal medicines (ZHOU et al., 2007). 
Furthermore, herbal medicines are particularly prevalent among older people. The 
elderly are more likely to receive several drugs together and are also more sensitive to 
chemicals. In addition, it must be borne in mind that herbal products are sometimes 
intended to be taken over a long period of time, which can imply an increased possibility for 
enzyme inhibition or induction and to potentiate other mechanisms of herb-drug 
interactions.  
A great public health concern and awareness about the subject of herb-drug 
interactions arose due to the discovery that St. John’s wort (Hypericum perforatum) was 
implicated in significant and unequivocal herb-drug interactions (PISCITELLI et al., 2000; 
MANNEL, 2004; CHAVEZ, JORDAN and CHAVEZ, 2006; MARKOWITZ and ZHU, 2012). This 
discovery could represent the “tip of the iceberg” of the literally thousands of available 
dietary supplements, many of which can similarly interact with concomitant medications. 
Consequently, some efforts to screen numerous botanical products are in progress given the 
widespread use of these herbal products among the general population (MARKOWITZ, VON 
MOLTKE and DONOVAN, 2008). In these studies are generally involved the more commonly 
used products and its influence on major metabolic enzymes has been investigated 
(MARKOWITZ and ZHU, 2012).  
 
I.3.1 MECHANISMS OF HERB-DRUG INTERACTIONS 
 
The phytochemicals are handled in the body through the same type of processes 
involved in drug biodisposition (VENKATARAMANAN, KOMOROSKI and STROM, 2006). 
Consequently, herb-drug interactions may occur through the same pharmacokinetic and 
pharmacodynamic mechanisms underlying drug-drug interactions (ZHOU et al., 2007; IZZO, 
2012).  
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The pharmacodynamic herb-drug interactions have been less studied than 
pharmacokinetic-based herb-drug interactions, but the implications of pharmacodynamic 
interactions are not less important in terms of changes in pharmacological response. 
Pharmacodynamic herb-drug interactions may involve changes in the pharmacological effects 
of the drug through additive or synergistic actions, i.e. potentiating the 
pharmacological/toxicological action of drugs, or antagonistic actions, i.e. the herbal 
medicines reduce the activity of drugs (TARIRAI, VILJOEN and HAMMAN, 2010; IZZO, 2012). For 
example, H. perforatum when taken with antidepressants belonging to the class of selective 
serotonin reuptake inhibitors can lead to a pharmacodynamic interaction known as the 
serotonin syndrome that is characterize by agitation, hyperthermia, diaphoresis, tachycardia, 
and muscular disturbances, which occurs as the result of high levels of serotonin in the brain 
(VENTOLA, 2010). 
Taking into account the principal objectives of the present thesis a main focus was 
given to the pharmacokinetic-based herb-drug interactions. The pharmacokinetic herb-drug 
interactions can occur as a result of changes in absorption, distribution, metabolism and 
excretion of drugs (Figure I.1). 
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Figure I.1 – Illustrative summary of possible pharmacokinetic and pharmacodynamic herb-
drug interaction mechanisms and their common potential outcomes (adapted from TARIRAI, 
VILJOEN and HAMMAN, 2010). 
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I.3.1.1 Herb-drug interactions at the level of oral drug absorption 
 
Herbal constituents are known to exert a major effect on intestinal enterocytes due 
to their high concentrations in the gut lumen (HU et al., 2005; IZZO et al., 2005). The 
intestinal enterocytes represent the first cell lining limiting the entry of orally administered 
drugs into the body. Several reports have indicated that human drug efflux transporters and 
also metabolizing enzymes are expressed at high levels in the villus tip of enterocytes, the 
primary site of absorption for orally administered drugs. The modulation of intestinal 
transporter proteins and metabolizing enzymes by herbal medicines represents a potentially 
important mechanism by which the bioavailability of co-administered drugs can be changed 
(HU et al., 2005).  
Herbal extracts can also change drug concentrations through inhibition or induction 
of uptake or efflux transporters. The efflux of drugs against a steep concentration gradient is 
mediated by the adenosine 5’-triphosphate (ATP) binding cassette (ABC) transporters [e.g. 
P-glycoprotein (P-gp) and multidrug resistance-associated protein-2 (MRP2)] (TARIRAI, 
VILJOEN and HAMMAN, 2010). P-gp (ABCB1) is a phosphorylated glycoprotein encoded by 
human MDR1 gene and murine mdr1a, mdr1b and mdr2 genes. P-gp is an ATP-dependent 
drug efflux pump that is expressed at high levels on the apical surfaces of epithelial cells in 
the liver, kidney, pancreas, small intestine, colon, adrenal gland and blood-brain barrier 
(ZHOU, LIM and CHOWBAY, 2004). P-gp limits the entry of xenobiotics to the systemic 
circulation from the intestine, promotes its hepatic elimination, minimizes the distribution 
through several vital organs and limits the reabsorption into the systemic circulation from 
the kidney tubules (VARMA et al., 2003; OZVEGY-LACZKA et al., 2005). The over-expression 
of P-gp has been associated with the clinical multi-drug resistance (MDR) phenotype (ZHOU, 
LIM and CHOWBAY, 2004). It has been suggested that P-gp plays an important role in 
increasing the exposure of susceptible drugs to cytochrome P450 (CYP) isoenzymes in the 
intestine through repeated cycling of drug into and out of the gut enterocytes via passive 
diffusion and active transport by P-gp-mediated efflux (DARWICH et al., 2010). Thus, in 
physiological conditions P-gp acts as a beneficial functional barrier minimizing the systemic 
exposure to xenobiotics, but it is also an undesirable barrier against certain pharmacological 
treatments involving P-gp substrate drugs (MARCHETTI et al., 2007). The activity of P-gp can 
be inhibited by competitive or noncompetitive mechanisms, which may potentially lead to 
toxic blood plasma concentrations of drugs that are P-gp substrates. On the other hand, the 
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induction of efflux transporters may result in sub-therapeutic plasma drug levels leading to 
treatment failure (TARIRAI, VILJOEN and HAMMAN, 2010).  
The organic anion transporting polypeptide 1b1 (OATP1B1) is a genetically 
polymorphic influx transporter expressed on the sinusoidal membrane of human 
hepatocytes, and mediates the hepatic uptake of many endogenous compounds as well as of 
several drugs (NIEMI, PASANEN and NEUVONEN, 2011). Co-administration of aliskiren and 
grapefruit juice results in reduced bioavailability of aliskiren, which is thought to be due to 
the inhibition of influx transporters (SEDEN et al., 2010). 
The alteration of gastrointestinal motility or the intestinal pH value following 
consumption of herbal medicines can also have a marked impact on the therapeutic 
outcomes resulting from the treatment with prescribed drugs. Herbal medicines that induce 
diarrhea shorten the transit time of the drug along the gastrointestinal tract and reduce the 
time of contact with the gastrointestinal epithelium, leading therefore to lower drug 
absorption. For example, Echinacea purpurea and H. perforatum are two herbs that are 
known to induce diarrhea and therefore may affect the absorption of drugs. On the other 
hand, herbal medicines capable to induce constipation may lead to the increase of the 
residence time of a drug over its absorption window due to prolongation of the transit time 
of the drug along the gastrointestinal tract (TARIRAI, VILJOEN and HAMMAN, 2010). 
The formation of insoluble herb-drug complexes in the gastrointestinal tract can also 
significantly reduce the bioavailability of drugs and therefore result in sub-therapeutic effects. 
Fibres such as psyllium and alginates may also chelate iron and drugs such as metformin and 
glibenclamide as shown in in vitro and in vivo studies (TARIRAI, VILJOEN and HAMMAN, 2010).  
 
I.3.1.2 Herb-drug interactions at the level of distribution  
 
Given that many herbal components are highly bound by plasma proteins, they may 
displace the drugs from plasma protein binding sites. However, there is rare clinical evidence 
for altered protein binding of drugs by herbal medicines. Even so, herbs such as meadow 
sweet and black willow, which contain pain-reducing salicylates, may displace highly protein-
bound drugs such as warfarin and carbamazepine, thus increasing the toxicity of the drugs 
(KUHN, 2002). 
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I.3.1.3 Herb-drug interactions at the level of metabolism 
The mechanisms responsible for the altered drug concentrations by concomitant 
administration of herbal medicines are mainly related with the induction or inhibition of 
hepatic and intestinal drug metabolizing enzymes and/or drug transporters (Figure I.2) 
(GOUWS et al., 2012).  
Herb-drug metabolic interactions can occur in the liver and in extra hepatic tissues 
such as the lung, kidney, gastrointestinal tract and gut mucosa due to the presence of CYP 
isoenzymes (TARIRAI, VILJOEN and HAMMAN, 2010). The phase I and phase II enzymes are 
responsible for the metabolism of constituents of herbal medicines as well as prescribed 
drugs. Among these enzymes, the CYP isoenzymes are the major catalysts involved in phase 
I drug biotransformation reactions for xenobiotic metabolism. The CYPs family is a large and 
diverse group of hemeproteins. The human CYPs are membrane-associated proteins that 
are located either in the inner membrane of mitochondria or in the endoplasmic reticulum 
of cells. In humans, CYPs are the major enzymes involved in drug metabolism and 
bioactivation, and they are responsible for almost 75% of the total drug metabolism (WANG 
and CHOU, 2010). The CYPs catalyze reactions such as hydroxylation, dealkylation, 
oxidation, and others, which usually increase the polarity of substrate molecules and 
facilitate their excretion (IOANNIDES and LEWIS, 2004). 
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Figure I.2 – Mechanisms and outcomes of pharmacokinetic herb-drug interactions involving 
drug metabolizing enzymes and transporters (adapted from GOUWS et al., 2012). 
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Herbal extracts can change drug metabolism through inhibition of hepatic and 
intestinal CYP isoenzymes, by means of reversible (competitive or noncompetitive) and 
irreversible inhibitory mechanisms (GOUWS et al., 2012). Consequently, inhibitory effects on 
a specific drug metabolizing system results in increased plasma concentrations of the 
substrate compound and, therefore, it can lead to drug toxicity (MARKOWITZ and ZHU, 
2012). In general, competitive inhibition is dose dependent and usually occurs within 24 h of 
ingestion of the inhibitor, although the time to reach maximal inhibition depends on the half-
life time of the affected drug and the inhibiting agent. When the inhibitor is discontinued, 
reestablishment of the baseline conditions is also dependent on the elimination rate of the 
affected drug and the inhibitor (SPINA, SANTORO and D’ARRIGO, 2008). Grapefruit juice 
(Citrus paradisi) affects the drug concentrations of several drugs including felodipine, 
nifedipine, simvastatin, lovastatin, losartan, midazolam, triazolam, terfenadine and 
cyclosporine. These interactions resulted in most of the cases in an increased drug exposure 
and they were generally mediated through inhibition of intestinal CYP enzymes, namely 
CYP3A4. The furanocoumarins present in grapefruit juice (e.g. 6’,7’-dihydroxybergamottin 
and bergamottin) have been proposed as active constituents that are able of modulating 
CYP3A4 (SEDEN et al., 2010).  
On the other hand, the induction of CYP isoenzymes can occur through binding to 
nuclear receptors, increasing the gene transcription, messenger ribonucleic acid (mRNA) and 
protein levels and decreasing protein degradation (GOUWS et al., 2012). Enzyme induction is 
a slow regulatory process that is dose and time dependent. The extent of induction is 
generally proportional to the dose of the inducing agent; because the process usually 
requires synthesis of the new enzyme, induction occurs with some delay after exposure to 
the inducing agent, generally from a few days to 1-2 weeks (SPINA, SANTORO and D’ARRIGO, 
2008). Modulation of phase II metabolic enzymes, such as uridine 5’diphospho-
glucuronyltransferases (UGT), can also result in drug interactions. Enzyme induction can 
have a profound effect on the pharmacokinetics of drugs metabolized by the susceptible 
enzyme, as it can lead to decreased plasma concentrations of an active compound and 
possibly to loss of clinical efficacy. In addition, herb-drug interactions are not limited to 
effects on either metabolizing enzymes or transporters alone but may involve a concerted 
effect on both. Therefore, this can result in complex drug interactions that are difficult to 
predict or manage and may occur when concurrent inhibition/induction of either 
metabolizing enzymes or transporters is experienced. This interplay due to overlap in 
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substrate specificity between metabolizing enzymes and efflux transporters has been 
identified as a complicating factor in the explanation of herb-drug interactions (GOUWS et al., 
2012). Several studies showed that H. perforatum affects the pharmacokinetics of many 
drugs by inducing P-gp transporter and CYP isoenzymes, such as CYP3A4, CYP2C19, and 
CYP2C9. H. perforatum decreases the plasma levels of alprazolam, amitriptyline, 
cyclosporine, digoxin, fexofenadine, imatinib mesylate, indinavir, irinotecan, methadone, oral 
contraceptives, simvastatin and tacrolimus (VENTOLA, 2010). 
  
I.3.1.4 Herb-drug interaction at the level of excretion 
 
Some herbs can also change the renal function and consequently may change the 
excretion of some drugs. For example, St. John´s wort may increase the renal excretion of 
digoxin, which is mediated by P-gp (JOHNE et al., 1999). 
 
The pharmacokinetic herb-drug interactions may be clinically relevant when 
considerable changes occur in pharmacokinetic parameters of the drug concomitantly 
administered with the herbal product. Pharmacokinetic parameters such as area under the 
concentration-time curve (AUC), peak plasma concentration (Cmax) and  the time to reach 
Cmax (tmax) are directly related to the drug’s efficacy and toxicity (TARIRAI, VILJOEN and 
HAMMAN, 2010) (Figure I.1). In addition, some examples of clinically relevant herb-drug 
interactions are summarized in Table I.1. From the information contained in Table I.1, it is 
evident that several cardiovascular drugs of narrow therapeutic range such as digoxin, 
warfarin and also AM were affected by herbal extracts.  
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I.4. AMIODARONE 
AM (C25H29I2NO3) [2-n-butyl-3-(3,5-diiodo-4-diethylaminoethoxy-benzoyl)-
benzofuran (Figure I.3)], a diiodinated benzofuran derivative was introduced into clinical 
practice as an antianginal agent in 1962, and in 1967 was developed for the treatment of 
ventricular and supraventricular tachyarrhythmias. Indeed, AM is one of the most widely 
used antiarrhythmic agents because of its high effectiveness (PAPIRIS et al., 2010), which is 
currently approved for the treatment of life-threatening recurrent ventricular arrhythmias, 
such as ventricular fibrillation or ventricular tachycardia, whenever other treatments are 
ineffective or have not been tolerated (PAPIRIS et al., 2010; VAN HERENDAEL and DORIAN, 
2010); this drug is also the antiarrhythmic agent most commonly used for the treatment of 
atrial fibrillation due to its superior efficacy over other drugs for maintaining normal sinus 
rhythm (GOLDSCHLAGER et al., 2007; PAPIRIS et al., 2010; BRENNER and DELACRÉTAZ, 2011; 
SCHWEIZER et al., 2011). 
AM has long been recognised as a drug having a narrow therapeutic window (STÄUBLI, 
1983; POLLAK, BOUILLON and SHAFER, 2000). Nevertheless, probably due to its atypical 
pharmacokinetic properties that are discussed below, and in contrast to other narrow 
therapeutic index drugs, the data on the clinical value of the use of AM plasma 
concentrations for routine therapeutic drug monitoring (TDM) have been conflicting (VAN
HERENDAEL and DORIAN, 2010). Some studies have suggested no correlation between 
plasma/serum concentration levels of AM and its efficacy or toxicity (ESCOUBET et al., 1986; 
CAMPBELL and WILLIAMS, 2001). On the other hand, some authors have shown that serious 
AM-induced toxicity is more likely at serum/plasma drug concentrations above 2.5 µg/mL 
(ROTMENSCH et al., 1984; POLLAK, and SHAFER, 2004). ROTMENSCH et al. (1983) also 
concluded that serum concentrations of AM below 2.5 µg/mL significantly improve the AM’s 
benefit-to-risk relationship. In spite of the lack of scientific consensus on this issue, different 
therapeutic plasma/serum concentration ranges for AM have been reported in literature, but 
the more typically accepted concentration range is 0.5-2.0 µg/mL (LESNE and PELLEGRIN, 1987; 
HUY et al., 1991; MANFREDI et al., 1995; IERVASI et al., 1997; PÉREZ-RUIZ et al., 2002; 
SHAYEGANPOUR, HAMDY and BROCKS, 2008). Indeed, in the absence of a loading-dose period, 
the monitoring of AM plasma concentrations at the beginning of treatment is expected to be 
unhelpful or misleading since a long time (4- to 6- week) is required to reach the steady-
state concentrations (SIDDOWAY, 1983); in fact, AM is a highly lipophilic drug presenting, 
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therefore, a marked deposition in tissues and, consequently, a large apparent volume of 
distribution and a long elimination half-life (HOSAKA, 2002). However, the monitoring of AM 
plasma concentrations may be of great value for the follow-up of patients with arrhythmias 
chronically treated with AM, differentiating treatment failure from suboptimal dosing and 
reducing the incidence of concentration-related adverse effects (ROTMENSCH et al., 1984). 
Thus, the availability of rapid, sensitive and reliable analytical methods for the determination 
of AM and its metabolites in biological matrices (particularly, plasma or serum) could be 
considered crucial to support the routine TDM in clinical practice. Furthermore, 
bioanalytical methods appropriately developed and fully validated to quantify AM and its 
metabolites in biological samples obtained from humans and different animal species also play 
an important role to support clinical and non-clinical pharmacokinetic studies, as well as to 
investigate, in more detail, the metabolic pathways of AM. Actually, despite the clinical use of 
AM for more than 40 years, new insights have been recently gained in the understanding of 
the metabolism and toxicity of the drug (HA et al., 2001a, 2001b, 2005; DENG et al., 2011; 
ZAHNO et al., 2011). 
I.4.1 PHARMACOKINETIC PROPERTIES 
In humans AM has unusual and complicated pharmacokinetic properties likely 
because of its high lipid solubility. After oral administration, AM presents a variable 
bioavailability (20-80%) and the Cmax is reached within 3-7 h following oral dosing (VAN
HERENDAEL and DORIAN, 2010). In addition, AM undergoes extensive enterohepatic 
recirculation before entry into the central compartment (systemic blood circulation) 
(FREEDMAN and SOMBERG, 1991) and it is also widely bounded (approximately 99.9%) to 
plasma proteins (VERONESE, MCLEAN and HENDRIKS, 1988). Following the systemic 
absorption, AM is extensively distributed to the body tissues with exceptionally high 
tissue/plasma partition coefficients (FREEDMAN and SOMBERG, 1991; OHYAMA et al., 2000; VAN
HERENDAEL and DORIAN, 2010). A three-compartment model seems to be the best to explain 
the AM’s kinetics (VAN HERENDAEL and DORIAN, 2010). The distribution half-life (t1/2alpha) of 
AM out of the central compartment to peripheral and deep tissue compartments may be as 
short as 4 h (FREEDMAN and SOMBERG, 1991). After the initial distribution phase (alpha phase), 
the highest levels of AM have been found in adipose tissue, lung, liver, and lymph nodes, 
which represent the deep compartment; on the other hand, the lowest concentrations of 
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AM have been observed in brain, muscles and thyroid, being part of the called peripheral 
compartment (VAN HERENDAEL and DORIAN, 2010). Consequently, due to the variable and 
extensive uptake into different tissues, AM is characterised by a very high apparent volume 
of distribution (Vd) (5000 L) and an extremely long elimination half-life (SHAYEGANPOUR, 
HAMDY and BROCKS, 2008; PAPIRIS et al., 2010). In particular, the terminal elimination half-life 
(t1/2beta) has shown to be long and variable (9-77 days) secondary to the slow elimination of 
the drug from the body tissues, primarily from fat tissue (FREEDMAN and SOMBERG, 1991).  
From the metabolic point of view, it has been accepted that AM undergoes extensive 
first-pass hepatic metabolism in humans (VAN HERENDAEL and DORIAN, 2010). Mono-N-
desethylamiodarone (MDEA) is the major metabolite of AM and it was the only known 
metabolite until the beginning of the 21st century (HA et al., 2001a). MDEA is a product of 
the most predominant metabolic route, N-deethylation, catalyzed by CYP isoenzymes. This 
metabolite is pharmacologically and toxicologically active and may contribute to the overall 
antiarrhythmic and toxic effects ascribed to the parent compound (SOYAMA et al., 2002; 
TRIVIER et al., 1993). However, AM may also be metabolised through other minor metabolic 
pathways, such as O-dealkylation, hydroxylation, deiodination, deamination, ω-carboxylation 
and glucuronidation (SOYAMA et al., 2002; HA et al., 2005; SHAYEGANPOUR, EL-KADI and 
BROCKS (2006); LOHMANN et al., 2008; DENG et al., 2011). HA et al. (2005) suggested that 
MDEA may be further cleared by hydroxylation to n-3-hydroxybutyl mono-N-
desethylamiodarone (3’OH-MDEA), dealkylation to di-N-desethylamiodarone (DDEA) and 
deamination to deaminated AM.  
More recently, using a modern bioanalytical methodology (ultraperformance liquid 
chromatography/quadrupole time-of-flight mass spectrometry), DENG et al. (2011) identified 
several novel AM metabolites in human bile; overall, 33 metabolites of AM were revealed in 
human bile, including 22 phase I and 11 phase II metabolites. In Figure I.3 are summarized the 
metabolic pathways for AM.  
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In fact, DENG et al. (2011) identified as major metabolites in human bile the MDEA 
and a novel metabolite 4’-carboxylamiodarone. This novel metabolite was biotransformed by 
oxidation of the n-butyl chain of AM by CYP isoenzymes to the ω-hydroxyl intermediate, 
followed by oxidation by alcohol dehydrogenase. The large variability of AM 
pharmacokinetics in humans may be explained by the greater insight of CYP isoenzymes and 
transporters involved in the formation and elimination of the metabolite 4’-
carboxylamiodarone. Despite some doubts about the existence of a deiodination pathway in 
previous studies, this minor pathway was confirmed by the presence of deiodinated 
metabolites in human bile. Furthermore, the glucuronidation of AM and of its phase I 
metabolites was identified as the most important conjugation pathway. The glucuronidation 
of AM together with biliary excretion was thought to be the final elimination process for AM 
(DENG et al., 2011). 
Despite pharmacokinetic parameters in rats are comparable with humans some 
differences exists, the t1/2beta observed in rat was found to be much lower than that found in 
humans, reflecting the lower Vd and higher clearance (CL) in rats (SHAYEGANPOUR, HAMDY 
and BROCKS, 2008). In addition, lower concentration levels of MDEA were reported in rats 
compared to humans (WYSS, MOOR and BICKEL, 1990; SHAYEGANPOUR, HAMDY and BROCKS, 
2008) that may be related with the higher CL values of MDEA than those of the parent drug 
in the rat. Indeed, there is also a difference in the hepatic extraction ratio of AM, which is 
higher in the rat than in human (SHAYEGANPOUR, HAMDY and BROCKS, 2008).  
In humans and rats has been demonstrated that AM is extensively biotransformed to 
MDEA by N-deethylation (ELSHERBINY and BROCKS, 2010; ELSHERBINY, EL-KADI and BROCKS, 
2010; WAN et al., 2011). This major metabolite was further biotransformed to 3’OH-MDEA 
that was found in plasma, liver, heart, lung and kidney in rats (Figure I.3) (HA et al., 2001a). 
Despite some differences, the rat shares with humans many of the pharmacokinetic 
properties of AM and has been regarded as one of the most used models among the small 
laboratory animals for studying some pharmacological and toxicological aspects concerning 
the AM (PLOMP et al., 1987, NAJJAR, 2001; ELSHERBINY and BROCKS, 2010).  
In the rabbit, some previous reports suggest that other metabolites of AM besides 
MDEA exist (KOZLIK et al., 2001). However, despite some doubts about the identity of the 
metabolites formed, it was confirmed that in rabbit liver microsomes MDEA was 
biotransformed to 3’OH-MDEA (HA et al., 2001b). Indeed, this metabolite (3’OH-MDEA) 
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was considered to be the major metabolite of MDEA in rabbit liver microsomes (Figure I.3) 
(HA et al., 2001a; SHAYEGANPOUR, HAMDY and BROCKS, 2008).   
In the dog, AM was biotransformed to the major metabolite MDEA being further 
dealkylated to DDEA (Figure I.3). DDEA was identified in plasma and myocardial tissue of 
dogs. It was found that this metabolite accumulates in myocardium at a higher extent than 
the parent drug (AM) (LATINI et al., 1984).  
 
 I.4.2 PHARMACODYNAMICS 
 
AM has electrophysiological characteristics of all four Singh Vaughan Williams classes 
(HAN, WILLIAMS and VANDERPUMP, 2009). The most prominent effect of long-term AM 
therapy is class III antiarrhythmic activity which prolongs cardiac action potential duration via 
potassium channel blockade (COHEN-LEHMAN et al., 2010; PAPIRIS et al., 2010). AM decreases 
conduction velocity by blocking sodium channels (class I activity) (PAPIRIS et al., 2010). AM 
has also anti-sympathetic properties (class II activity) in which there are non-competitive 
inhibition of α- and β-adrenergic receptors. Class IV activity produces negative chronotropic 
effects in nodal tissues via L-type calcium channel blockade. The anti-sympathetic action 
(Class II activity) and blockade of potassium and calcium channels (Class III and IV) are 
responsible for the slowing of conduction and prolongation of refractoriness in the sinus and 
atrioventricular nodes useful in the management of supraventricular arrhythmia (HAN, 
WILLIAMS and VANDERPUMP, 2009; CONNOLLY, 2013). The class III activity results in increases 
in prolongation on the rate-corrected QT (QTc) interval and also in atrial and ventricular 
refractoriness (CONNOLLY, 2013). AM suppresses sympathetic activities (SHIGA et al., 2011) 
and reduces heart rate during long-term administration almost to the same extent as most 
β-blockers (SINGH, 1996). MDEA has also similar electrophysiological actions although 
slightly less potent than those of AM (HAN, WILLIAMS and VANDERPUMP, 2009). 
 
I.4.2.1 Amiodarone-induced toxicity  
 
The wider therapeutic use of AM is limited due to its potential to induce some 
serious toxic effects, especially pulmonary toxicity, hepatotoxicity and thyroid dysfunction, 
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which have been reported mainly after long-term therapy (SEKI et al., 2008, LAFUENTE-
LAFUENTE et al., 2009; WOLKOVE and BALTZAN, 2009).  
The most serious toxic effects associated with AM therapy are related with 
pulmonary toxicity (SIDDOWAY, 2003). AM provokes both direct and indirect damage of the 
pulmonary parenchyma (SANTANGELI et al., 2012). The direct toxicity on the lung cells results 
from direct drug-induced phospholipidosis and the indirect toxicity is related to an immune-
mediated hypersensitivity (SIDDOWAY, 2003; SANTANGELI et al., 2012). The pulmonary 
toxicity induced by AM is more common in men, especially those with preexisting 
pulmonary diseases (SANTANGELI et al., 2012).  
The liver is an ideal environment for AM accumulation due to its high content of fat. 
Furthermore, the liver has an active role in AM metabolism particularly through the CYP-
metabolizing enzymes (SANTANGELI et al., 2012). An elevation of liver transaminase levels 
(hepatotoxicity biomarkers) is common in patients receiving long-term AM therapy 
(SIDDOWAY, 2003). Usually, such abnormalities in liver function tests are promptly reversible 
after AM discontinuation, although some cases of progressive hepatitis have been described 
even after withdrawal of the drug therapy. Diagnosis of hepatic toxicity is easily established 
through monitoring of hepatic enzymes during AM treatment, and the current guidelines 
recommend monitoring every 6 months. A prompt discontinuation of AM is the only 
available option to solve this pathological condition (SANTANGELI et al., 2012). 
In addition, AM is an iodinated benzofuran derivative with a molecular structure that 
closely resembles that of thyroid hormones. It contains about 37% of organic iodine by 
weight, from which 10% is deiodinated to yield free iodide. Given the daily maintenance dose 
of AM between 100 and 600 mg, about 3.5-21 mg of iodide are released into the systemic 
circulation, equivalent to 35-140-fold excess of the iodine reference daily intake of 100-150 
µg (HAN, WILLIAMS and VANDERPUMP, 2009). Hence, the disruption of the thyroid hormone 
synthesis and auto-regulation owing to excess of iodine concentrations from AM use may 
occur in some patients leading to either hypothyroidism or hyperthyroidism (thyrotoxicosis) 
(COHEN-LEHMAN et al., 2010). AM-induced hypothyroidism occurs when the intrathyroidal 
iodine levels are excessive reaching a critical point. This effect leads to the temporary 
inhibition of the iodine transport and of the thyroid hormone synthesis until the 
intrathyroidal stores return to normal levels (HAN, WILLIAMS and VANDERPUMP, 2009). This 
phenomenon is denominated Wolff-Chaikoff effect (HAN, WILLIAMS and VANDERPUMP, 2009; 
COHEN-LEHMAN et al., 2010). On the other hand, AM-induced thyrotoxicosis arises due to a 
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failure of thyroid auto-regulatory mechanism that is thought to lead to thyroid autonomy 
(COHEN-LEHMAN et al., 2010). This effect occurs by the addition of iodine substrate from AM 
that leads to excessive thyroid hormone synthesis and thyrotoxicosis (Jod-Basedow effect) 
(HAN, WILLIAMS and VANDERPUMP, 2009). This effect occurs typically in areas of iodine 
deficiency and in patients with underlying nodular or autoimmune thyroid disorders 
(COHEN-LEHMAN et al., 2010). 
I.4.3 DRUG-DRUG AND HERB-DRUG INTERACTIONS INVOLVING AMIODARONE 
AM has been associated to important clinical drug-drug interactions either of 
pharmacodynamic and/or pharmacokinetic nature (EDWIN, JENNINGS and KALUS, 2010; KARIMI 
et al., 2010; ROUGHEAD et al., 2010). Nonetheless, AM has usually been considered the 
perpetrator or interacting agent in the majority of pharmacokinetic-based drug interactions 
reported in literature (Table I.2), inducing a change (generally an increase) in serum/plasma 
levels of co-administered drugs [e.g. digoxin (LESKO, 1989; TRUJILLO and NOLAN, 2000), 
warfarin (LESKO, 1989; TRUJILLO and NOLAN, 2000; YAMREUDEEWONG et al., 2003), phenytoin 
(LESKO, 1989), simvastatin (BECQUEMONT et al., 2007; MAROT et al., 2011), cyclosporine
(CHITWOOD, ABDUL-HAGG and HEIM-DUTOV, 1993; YAMREUDEEWONG et al., 2003), flecainide 
(TRUJILLO and NOLAN, 2000) and lidocaine (SIEGMUND, WILSON and IMHOFF, 1993; HA et al., 
1996)]. 
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Effectively, only few studies have been published describing the interference of other 
compounds on the pharmacokinetics of AM (Table I.3). Focusing on some relevant drug-drug 
and herb-drug interactions, the systemic exposure to AM and MDEA was significantly 
reduced by the simultaneous administration of orlistat (ZHI et al., 2003). In addition, 
grapefruit juice completely inhibited the formation of the major metabolite of AM and 
increased the AUC and Cmax by 50% and 84%, respectively, in comparison with the control 
group. The inhibition of MDEA formation led to a decrease in the alterations caused by AM 
on PR and QTc intervals (LIBERSA et al., 2000). Accordingly, considering the existence of 
several drug-drug interactions and this relevant herb-drug interaction between grapefruit 
juice and AM, it is absolutely pertinent to investigate the effects of other extracts on the 
pharmacokinetic of AM (object drug). Particularly, considering the scarcity of scientific 
information available about the safety of herbal slimming medicines/supplements, it is 
absolutely pertinent to assess the potential for pharmacokinetic interactions between 
relevant herbal weight loss extracts and drugs required in multiple cardiovascular diseases. 
Therefore, it is justified to characterize the interference of standardized herbal extracts 
commonly used in weight loss programs (e.g. Fucus vesiculosus, Paullinia cupana, Citrus 
aurantium and Carica papaya) on the pharmacokinetic profile of AM. 
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I.5. FUCUS VESICULOSUS 
 
F. vesiculosus L. (Phaeophyta), also known as bladderwrack or kelp, is a brown-
colored, perennial, dioecious edible seaweed that forms dense belts in cold rocky littoral 
habitats covering large areas from a few decimeters below the water surface to a depth of 
several meters (DÍAZ-RUBIO, PÉREZ-JIMÉNEZ and SAURA-CALIXTO, 2009). F. vesiculosus is a 
member of the family Fucaceae belonging to the order Fucales (PARYS et al., 2010). This 
brown seaweed is commonly found on the littoral coast of Northern Atlantic Ocean, the 
Pacific Ocean and the Baltic Sea (FUJIMURA et al., 2002). The distribution of Fucus species in 
Portuguese Northwestern coastal zone seems to be first determined by the presence or 
absence of rocky substrata (CAIRRÃO et al., 2004). Several factors affect its growth such as 
substrate firmness exposure to ice and waves, salinity, wave force, light or competition 
among macroalgae (DÍAZ-RUBIO, PÉREZ-JIMÉNEZ and SAURA-CALIXTO, 2009). 
The major components that give the Fucus its reported health benefits are non-
digestible polysaccharides (dietary fibre) and polyphenols (DÍAZ-RUBIO, PÉREZ-JIMÉNEZ and 
SAURA-CALIXTO, 2009). Dietary fibre of F. vesiculosus is composed of fucans, alginates, 
laminaranes and cellulose, with fucoidan (Figure I.4) to be the predominant polysaccharide 
(RIOUX, TURGEON and BEAULIEU, 2007). The raw Fucus powder is rich in both soluble 
(10.52%) and insoluble (48.63%) fractions of dietary fibre (DÍAZ-RUBIO, PÉREZ-JIMÉNEZ and 
SAURA-CALIXTO, 2009). 
 
Figure I.4 – Chemical structure of fucoidan from Fucus vesiculosus (PIELESZ and KULEC, 2010). 
 
This brown alga also contains three types of phlorotannins that are termed fucols, 
where phloroglucinol units are connected by aryl-aryl bonds, fucophlorethols with ether and 
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aryl-aryl bonds, and phlorethols containing only ether bonds. From F. vesiculosus fifteen 
fucophlorethols with three to eight units of phloroglucinol and four fucols with two to four 
units of phloroglucinol were described (PARYS et al., 2010). Some phlorotannin oligomers, 
including trifucodiphlorethol A, trifucotriphlorethol A, fucotriphlorethol A, tetrafucol A and 
fucophlorethol A (PARYS et al., 2010; LIU and GU, 2012) have been isolated from F. 
vesiculosus (Figure I.5). The concentration in phlorotannins is genetically variable (KOIVIKKO 
et al., 2008) and is directly dependent on nutrient concentration in the environment. The 
phlorotannins are a toxic group of substances that are produced as a mean of protection 
against predators because Fucus species are a source of food for many herbivores (CAIRRÃO 
et al., 2004). Some of the polyphenols of F. vesiculosus, namely the phlorotannin oligomers 
trifucodiphlorethol A and trifucotriphlorethol A (Figure I.5), were recently found to inhibit 
drug-metabolizing enzymes like CYP1A (PARYS et al., 2010). 
F. vesiculosus has also in its composition proteins, minerals, iodine, vitamins and 
monounsaturated and polyunsaturated fatty acids (DÍAZ-RUBIO, PÉREZ-JIMÉNEZ and SAURA-
CALIXTO, 2009). 
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Figure I.5 – Chemical structures of phlorotannin oligomers isolated from Fucus vesiculosus: 
trifucodiphlorethol A, trifucotriphlorethol A, fucotriphlorethol A, tetrafucol A and 
fucotriphlorethol A (PARYS et al., 2010; LIU and GU, 2012). 
 
F. vesiculosus is claimed to be useful for the treatment of obesity, mainly due to its 
high levels in iodine, whose action is thought to be related to the stimulation of the thyroid 
gland and the subsequent effect on metabolic rate. Although iodine is considered the most 
prominent active ingredient of F. vesiculosus, the mucilage (dietary fibre), phytosterols and 
tetraterpenes are also important constituents responsible for its use in obesity management 
(MORO and BASILE, 2000; DÍAZ-RUBIO, PÉREZ-JIMÉNEZ and SAURA-CALIXTO, 2009). It is well 
known that aqueous extracts of this alga have shown various biological properties such as a 
potent anticoagulant activity (FUJIMURA et al., 2002). The presence of antioxidants and 
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functional components of dietary fibre in F. vesiculosus has promoted the development of a 
large number of functional ingredients and dietary supplements derived from this seaweed 
such as fucoidan powders, F. vesiculosus capsules or F. vesiculosus antioxidant extracts 
(DÍAZ-RUBIO, PÉREZ-JIMÉNEZ and SAURA-CALIXTO, 2009).  
Several properties of the F. vesiculosus with application in several areas have been 
discovered. In particular, strong adsorption effects were observed on the mucus membranes 
due to the presence of polysaccharides from F. vesiculosus. These results suggest that these 
adsorption effects may account for the therapeutic effects of mucilage-containing plants in 
the treatment of irritated buccal membranes (SCHMIDGALL, SCHNETZ and HENSEL, 2000). F. 
vesiculosus presents a complex carbohydrate specific lectin-like mucopolysaccharide. This 
complex carbohydrate was found to agglutinate Candida guilliermondii cells. A toxic effect of 
a lectin-like algal mucopolysaccharide from F. vesiculosus has been found to be exerted only 
on Escherichia coli and Neisseria meningitidis strains (OLIVEIRA et al., 2003).  
The fucoidan, a sulfated-polysaccharide present in F. vesiculosus showed to promote 
the contraction of collagen gels (FUJIMURA et al., 2000a). The mechanism of the promotion of 
gel contraction was related to an increased expression of integrin molecules on the 
fibroblasts surface (FUJIMURA et al., 2000b). In a study conducted by FUJIMURA et al. (2002) 
was investigated the topical application of an aqueous extract of F. vesiculosus on the 
thickness and the mechanical properties of human skin. It was observed a significant 
improvement in the elasticity, suggesting that this extract possesses anti-aging activities and 
should be useful for a variety of cosmetics (FUJIMURA et al., 2002). 
Several Fucus species have also demonstrated to be good biomarkers of 
environmental contamination through the enzymes of glutathione-S-transferase (GST). 
CAIRRÃO et al. (2004) investigated the activity of Fucus species as biomarkers using the family 
of GST enzymes, because they participate in a mechanism of detoxification catalyzing the 
conjugation of several xenobiotics with glutathione. As the presence of higher GST levels 
indicates a more contaminated site, it is possible to discriminate areas with different levels of 
pollution (CAIRRÃO et al., 2004). 
In addition, F. vesiculosus significantly increased the total number of days of the 
menstrual cycle, reduced circulating 17-β-estradiol levels, and elevated serum progesterone 
levels in premenopausal women with abnormal menstrual cycling histories. Furthermore, F. 
vesiculosus, as well as other brown kelp species, also induced a reduction of the plasma 
cholesterol levels (SKIBOLA, 2004).  
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I.6. PAULLINIA CUPANA 
 
P. cupana, also known as guarana, is a climbing plant of the family of Sapindaceae, 
native to the Amazon basin and cultivated in Brazil and Venezuela for its fruits (CAMPOS et 
al., 2011; PORTELLA et al., 2013). The seeds are rich in methylxanthines (caffeine, theophylline 
and theobromine) and also contain catechins (Figure I.6), epicatechins, saponins, tannins and 
proanthocyanidols, as well as trace concentrations of other compounds (KREWER et al., 
2011; KLEIN, LONGHINI and DE MELLO, 2012).  
 
Figure I.6 – Chemical structures of the major active compounds of Paullinia cupana: caffeine, 
theophylline, theobromine and (+)-catechin (HEARD, JOHNSON and MOSS, 2006).  
 
Several epidemiological and experimental investigations have described an association 
between the consumption of other foods rich in catechins and caffeine (coffee and tea) and a 
lower risk of morbidity and mortality from stroke, coronary heart disease and other causes. 
A possible causal factor associated with tea and coffee consumption is the role of bioactive 
compounds present in these foods in metabolic pathways related to body weight loss and a 
consequent reduction of the overall risk for developing metabolic syndrome (PORTELLA et al., 
2013). 
Guarana consumption is increasing in the world because it takes part in the 
composition of many commercial dietary supplements as a weight loss promoting adjuvant 
(LIMA et al., 2005). Guarana extract is used as stimulant of the central nervous system in 
cases of physical and mental stress, and as antidiarrheal, diuretic and antineuralgic (KLEIN, 
LONGHINI and DE MELLO, 2012), as well as in the therapeutics of depression, fatigue and 
migraine (LIMA et al., 2005). Its high caffeine content and stimulating properties makes P. 
cupana particularly attractive in weight loss programs, since it helps to increase the 
metabolic rate and can enhance thermogenesis. Indeed, P. cupana containing products are 
popular among athletes because of their ergogenic and “fat burning” effects (LIMA et al., 
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2005; BULKU et al., 2012). Previous experimental investigations have suggested that guarana 
has positive effects on lipid metabolism (LIMA et al., 2005), in body weight loss (BOOZER et 
al., 2001) and increases basal energy expenditure (BÉRUBÉ-PARENT et al., 2005). Furthermore, 
studies suggested that guarana exhibits a cardioprotective effect by inhibiting platelet 
aggregation (BYDLOWSKI, YUNKER and SUBBIAH, 1988; PORTELLA et al., 2013). All these positive 
effects may contribute to reduce the risk factors for cardiovascular diseases (PORTELLA et al., 
2013). However, as the consumption of guarana is growing in many countries, more studies 
on its functional properties are needed.  
Even so, a controlled study was recently performed to analyse the association 
between the habitual consumption of guarana and the prevalence of cardiometabolic diseases 
(obesity, hypertension, type 2 diabetes and dyslipidemia) in an elderly Amazonian population. 
The study suggests a lower prevalence of hypertension, obesity and metabolic syndrome in 
the subjects which self-reported the regular guarana consumption than in those subjects 
who never reported the ingestion of guarana. Additionally an association was found between 
guarana consumption and lower cholesterol (total and LDL) and advanced oxidative protein 
product (AOPP) levels. The potential beneficial effects of guarana on LDL levels and AOPP 
can provide a possible causal explanation for the lower prevalence of some cardiometabolic 
diseases in this population (KREWER et al., 2011).  
In fact, guarana has also shown to have antioxidant (BASILE et al., 2005), antimicrobial 
(BASILE et al., 2005), antimutagenic and anticarcinogenic effects (FUKUMASU, LATORRE and 
ZAIDAN-DAGLI, 2011). Some studies showed that guarana protects against testicular damage 
caused by cadmium exposition (LEITE et al., 2012) and improves memory (KENNEDY et al., 
2004). On the other hand, some studies have shown low toxicity associated with guarana 
ingestion (BITTENCOURT et al., 2013). 
P. cupana extract from seeds is currently approved in the United States as a food 
additive for use as natural flavouring agent and is considered a dietary supplement under the 
DSHEA of 1994 (HEARD et al., 2006). P. cupana is also listed in the official Brazilian 
Pharmacopoeia (ANTONELLI-USHIROBIRA et al., 2010). Therefore, it is not surprising that P. 
cupana is found today in a wide variety of drinks, foods, dietary/herbal supplements and 
pharmaceuticals (LIMA et al., 2005; ANTONELLI-USHIROBIRA et al., 2010). Consequently, the 
HMPC of European Medicines Agency launched a call to encourage submission of scientific 
data on P. cupana (Guarana) in order to prepare the corresponding herbal monograph 
(EUROPEAN MEDICINES AGENCY, 2011). In the final document recently published was 
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established that persons taking monoamine oxidase (MAO) inhibitor drugs should use P. 
cupana seeds with caution and was established that caffeine-containing preparations reduce 
the sedative actions and increase the side effects caused by sympathomimetic drugs 
(EUROPEAN MEDICINES AGENCY, 2013). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
General introduction 
 
 
35 
I.7. CITRUS AURANTIUM 
 
C. aurantium is the botanical name of a plant belonging to the family Rutaceae 
commonly known as bitter orange, sour orange, green orange, Seville orange, or zhi shi 
(BOUCHARD et al., 2005; HAAZ et al., 2006; HANSEN et al., 2013). The extract of the 
immature fruit or peel of bitter orange has been used in traditional Chinese medicine for 
relief of indigestion, abdominal pain, constipation, and dysenteric diarrhea (HANSEN et al., 
2011). However, C. aurantium extract and its primary protoalkaloid p-synephrine are 
nowadays widely used in weight loss and thermogenic products (STOHS, PREUSS and SHARA, 
2011a). In particular, after the sale of all ephedra-containing supplements were banned by 
FDA in 2004, the C. aurantium has gained an additional popularity as a safe alternative to 
Ephedra in herbal weight loss products (FOOD AND DRUG ADMINISTRATION and HHS, 2004; 
HANSEN et al., 2012, 2013). A recent survey in Southeastern City found that C. aurantium 
was among the top ten ingredients (between herbal/botanical, vitamins, minerals, amino acids 
and proteins, animal or insect and others) in non-prescription weight loss supplements 
(SHARPE et al., 2006). C. aurantium has been used in dietary supplements marketed for 
weight management products due to its claimed effects on metabolic processes, including an 
increase of the basal metabolic rate and lipolysis, and in appetite suppression (STOHS, PREUSS 
and SHARA, 2012). 
The alkaloids p-synephrine, also called synephrine that constitutes about 85% of the 
protoalkaloids present in C. aurantium, and to a lesser extent octopamine are believed to be 
the most active components of C. aurantium (FUGH-BERMAN and MYERS, 2004; PEIXOTO et al., 
2012). C. aurantium peel contains other protoalkaloidal constituents including hordenine, 
tyramine and N-methyltyramine (STOHS, PREUSS and SHARA, 2011a). The extract also contains 
furanocoumarins and flavonoids, including limonene, hesperidin, neohesperidin, naringin, and 
tangaretin (FUGH-BERMAN and MYERS, 2004). The active components in C. aurantium are 
closely related to endogenous neurotransmitters (epinephrine and norepinephrine) and 
ephedrine (Figure I.7). However, despite the structural similarities in particular with 
ephedrine (one of the main active constituents in the genus Ephedra), synephrine seems to 
exhibit little or no stimulant activity on the cardiovascular system and central nervous 
system. Indeed, their chemical differences appear to significantly change their 
pharmacokinetic properties, particularly their ability to cross the blood-brain barrier (STOHS, 
PREUSS and SHARA, 2011b). Even so, the safety and efficacy of C. aurantium have been 
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questioned (BENT, PADULA and NEUHAUS, 2004; FUGH-BERMAN and MYERS, 2004; HANSEN et 
al., 2013). In fact, a large number of case reports have associated the use of C. aurantium-
containing products with several adverse effects most of them involving the cardiovascular 
system and some herb-drug interactions have been reported. 
 
Figure I.7 – Chemical structures of synephrine, octopamine, ephedrine, epinephrine, 
norepinephrine and phenylephrine (FUGH-BERMAN and MYERS, 2004). 
 
Due to the structural similarities, it has been assumed that synephrine has similar 
binding properties to that observed for norepinephrine and ephedrine and m-synephrine. 
However, according to receptor binding studies, synephrine exhibits low binding affinity for 
the α-, β-1 and β-2 adrenoreceptors. The binding to α-adrenergic receptors generally results 
in vasoconstriction, the binding to β-1 adrenergic receptors results in cardiovascular 
contractility and increase heart rate, and the binding to β-2 adrenergic receptors results in 
bronchodilation. On other hand, synephrine has shown β-3 adrenorecetpor activity resulting 
in increased thermogenesis and lipolysis (associated with the physiological action of the 
compound) (STOHS, PREUSS and SHARA, 2011a).  
C. aurantium extracts marketed for weight-loss are prepared from dried fruit peels 
and may be associated with other compounds, mainly caffeine (BLANCK et al., 2007). Despite 
its inclusion in over-the-counter weight loss products, little evidence supports the use of C. 
aurantium alone to treat overweight and obesity (HAAZ et al., 2006). It has been shown that 
C. aurantium extracts increase lipolysis, thermogenesis and weight loss in both animal 
models and humans when tested in combination with other compounds, especially caffeine, 
which is also known to enhance the thermogenic properties of herbal weight-loss 
preparations (FUGH-BERMAN and MYERS, 2004; HAAZ et al., 2006). As the C. aurantium 
extracts, synephrine has also effectively promoted weight-loss and thermogenesis in humans 
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and in other mammalian species only in combination with other stimulants (CARPÉNÉ et al., 
1999; HOFFMAN et al., 2009; ROSSATO et al., 2011), although in pure form it has been 
effective in mice and rats (CALAPAI et al., 1999; ARBO et al., 2009; STOHS, PREUSS and SHARA, 
2011a). 
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I.8. CARICA PAPAYA 
 
C. papaya, also known as papaya, papaw or pawpaw, is the fruit of a tree-like 
herbaceous plant belonging to the only species in the genus Carica of the plant family 
Caricaceae (MING, YU and MOORE, 2007; KRISHNA, PARIDHAVI and PATEL, 2008; ARAVIND et 
al., 2013; THAM et al., 2013). Papaya is cultivated in tropical and subtropical and temperate 
regions worldwide, including Australia, Brazil, China, Hawaii, Malaysia and India (CANINI et 
al., 2007; AFZAN et al., 2012). Papaya is a fast growing rarely branching, semi-woody tropical 
fruit tree with a short juvenile phase of 3 to 8 months. Once it starts flowering, it will 
continue to flower and produce fruit throughout the year (MING, YU and MOORE, 2007). 
Different parts of the plant (fruits, leaves, barks, roots, flowers, seeds, and latex) as well as 
some of their extracts have been traditionally used worldwide in folk medicine to treat a 
wide range of ailments in humans (ANUAR et al., 2008; SADEK, 2012; NGUYEN et al., 2013).  
The fruits of C. papaya are one of the most commonly consumed throughout the 
world (ATHESH et al., 2012), constituting a nutritional source rich in fibre, minerals and 
antioxidant nutrients (SADEK et al., 2012). More specifically, papaya fruit is a good source of 
bioactive phytochemicals such as carotenoids (β-carotene, α-carotene, β-cryptoxanthin,      
α-cryptoxanthin, lutein, 9-cis-β-carotene), phenolic compounds (ferulic acid, caffeic acid, p-
coumaric acid, rutin, quercetin, kaempferol), and glucosinolates (benzyl glucosinolate, benzyl 
isothiocyanate) (Figure I.8) (NGUYEN et al., 2013). Unripe pulp of C. papaya also contains 
cardenolides which seem to have medicinal value for the treatment of congestive heart 
failure (ANUAR et al., 2008). Additionally, among other biologically active constituents, papaya 
also includes cysteine proteinases as chymopapain and papain (KOVENDAN et al., 2012; SADEK 
et al., 2012; ARAVIND et al., 2013). These two important proteolytic enzymes are widely 
known as being useful for the treatment of digestive disorders and disturbances of the 
gastrointestinal tract (SILVA et al., 2007; ARAVIND et al., 2013) and were found in the milky 
white latex extruded from fruits. The latex serves as an excellent meat tenderizer, for 
treatments of gangrenous wounds or burns, and is also used in cosmetic products, in the 
light industry and in food processing (SILVA et al., 2007). Apart from papain and chymopapain, 
C. papaya also contains a lipase (CPL). CPL is tightly bonded to the water-insoluble fraction 
of crude papain and is thus considered as a “naturally immobilized” biocatalyst (DOMÍNGUEZ 
DE MARÍA et al., 2006; SILVA et al., 2007).  
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Figure I.8 – Chemical structures of important compounds found in Carica papaya: lycopene, 
ferulic acid, protocatechuic acid, beta-carotene, chlorogenic acid, caffeic acid, beta-
cryptoxanthin, p-coumaric acid, 5,7-dimethoxy coumarin, quercetin, kaempferol, benzyl 
glucosinolate and benzyl isothiocyanate (NGUYEN et al., 2013). 
 
The nutrients of papaya as a whole improve cardiovascular system, protect against 
heart diseases, heart attacks, strokes and prevent colon cancer. The fruit prevents damage 
caused by free radicals that may cause some forms of cancer and is reported that it helps in 
the prevention of diabetic heart disease (ARAVIND et al., 2013). Extracts of the ripe fruits are 
used for a variety of medicinal purposes ranging from treatment of ringworm, malaria, and 
hypertension (SADEK et al., 2012), while the extracts of unripe fruit have been used in the 
treatment of ulcers (EZIKE et al., 2009) and diabetes (SADEK et al., 2012). In addition, the 
hypoglycemic and hypolipidemic effects of the aqueous seed extract of C. papaya have been 
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reported in rats (ADENEYE and OLAGUNJU, 2009). The ethanolic extract and water-soluble 
fraction of C. papaya also showed anti-hyperlipidemic activity in olive-treated rats (IVER et al., 
2011). More recently, ATHESH et al., (2012) reported the anti-obesity effect of aqueous fruit 
extract of C. papaya in rats fed on high fat cafeteria diet. Effectively, besides the proteolytic 
enzymes, chymopapain and papain, CPL can contribute to its lipolytic action, supporting its 
use in the management of obesity and digestive disorders (IZZO, 2004; KOVENDAN et al., 
2012; SADEK et al., 2012).  
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I.9. CARDIOVASCULAR DISEASES AND OBESITY: THE ROLE OF HERBAL MEDICINES 
 
Despite the great progress achieved in the past century in the prevention and 
treatment of cardiovascular diseases, they remain the leading cause of mortality in 
industrialized countries at the beginning of the 21st century. Cardiovascular diseases continue 
to represent a major public health concern today. Epidemiological, pathophysiological and 
clinical studies have clearly indicated that overweight and obesity are major independent risk 
factors for coronary heart disease, atrial fibrillation and heart failure (SCAGLIONE et al., 2004; 
ZALESIN et al., 2011), and they have deleterious effects on ventricular function, 
cerebrovascular disease, peripheral arterial disease and venous thromboembolism (DOUKETIS 
and SHARMA, 2005). Thus, bearing in mind the increasing prevalence of obesity, reaching 
pandemic proportions in developed countries, an overall increase in the incidence of 
cardiovascular diseases is still expected over the next years (BODARY, IGLAY and EITZMAN, 
2007). In consequence, it is also predictable the growing use of drugs currently available for 
the management of such cardiovascular diseases, existing among them drugs with a narrow 
therapeutic index such as AM (SINGH, 2008). 
Taking into account the multifactorial nature of cardiovascular diseases, it emerges 
the need of multifaceted treatment strategies, focusing on the patient rather than in single 
risk factors. In all circumstances, to improve the cardiometabolic risk profile and to reduce 
the incidence of cardiovascular complications, body weight reduction has been established as 
an essential and also popular therapeutic strategy (LEE et al., 2008; ALLCOCK, GARDNER and 
SOWERS, 2009). Hence, particularly worrying in developed countries is the increasing 
consumption of herbal weight loss medicines/dietary supplements as alternative or 
complement to the traditional programs of weight reduction. In addition, this issue is even 
more serious because among the general population prevails the notion that herbal 
preparations are devoid of health risks due to the natural origin of the constituents. Indeed, 
only a minority recognizes that herbal medicinal products are complex mixtures of 
phytochemicals, which may be substrates, inhibitors or inducers of the same biological 
systems that are involved in the biodisposition of conventional drugs, existing, therefore, a 
high potential for clinically significant pharmacokinetic interactions (CHAVEZ, JORDAN and 
CHAVEZ, 2006). Accordingly, considering the close relationship between obesity and 
cardiovascular diseases, as well as the scarcity of scientific information available about the 
safety of herbal slimming medicines/supplements, it is absolutely justified to assess the 
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potential for pharmacokinetic interactions between the most relevant herbal weight loss 
extracts and high-risk drugs required in multiple cardiovascular diseases such as the case of 
AM. Thus, from the perspective of protecting public health, it is warranted to characterize 
the interference of standardized herbal extracts commonly used in weight loss programs 
(e.g. F. vesiculosus, P. cupana, C. aurantium and C. papaya) on the pharmacokinetic profile of 
AM. 
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I.10. OBJECTIVES OF THIS THESIS 
 
The main goal of this thesis was to carry out an in vivo preclinical systematic 
investigation to assess the potential for the occurrence of significant herb-drug interactions 
between commonly used standardized herbal weight loss extracts (F. vesiculosus, P. cupana, 
C. aurantium and C. papaya) and AM, a drug of narrow safety range widely used in clinical 
practice for the management of cardiovascular diseases.  
Thus, an in vivo model (Wistar rat) was selected to study the pharmacokinetic 
interactions and an appropriate study design was adopted. Moreover, to obtain reliable data, 
it was necessary to develop and validate appropriate bioanalytical methods to quantify the 
analytes of interest in the biological matrices of the intended samples. In addition, a new 
bioanalytical tool was also develop to quantify AM and its main metabolite in human plasma, 
which may be useful to support the therapeutic drug monitoring of AM. 
 
The specific objectives were outlined for the implementation of this work: 
 
 Development and full validation of an analytical high-performance liquid 
chromatography method with diode array detection (HPLC-DAD) to simultaneously 
quantify AM and MDEA in human plasma using a sample preparation involving 
microextraction by packed sorbent (MEPS). The development of this HPLC 
technique enables to supply a new tool using an innovative sample preparation 
procedure to support the clinical monitoring of AM. 
 
 Development and full validation of an analytical HPLC-DAD method to 
simultaneously quantify AM and MDEA in rat matrices (plasma and heart, liver, kidney 
and lung tissue homogenates). The development and validation of this technique in 
rat matrices enable to support the further herb-drug pharmacokinetic studies. 
 
 Investigation of the interaction between each selected commercial standardized 
(certified) extracts (F. vesiculosus, P. cupana, C. aurantium or C. papaya) and AM in 
rats, following the simultaneous oral co-administration and after a 14-day pre-
treatment period with each of the extracts.  
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 Evaluation of the effect of a 14-day pre-treatment period with each selected extract 
(F. vesiculosus, P. cupana, C. aurantium or C. papaya) on the body weight of the rats.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
General introduction 
 
 
45 
I.11. BIBLIOGRAPHY 
 
ADENEYE, A.A.; OLAGUNJU, J.A. – Preliminary hypoglycemic and hypolipidemic activities of the 
aqueous seed extract of Carica papaya Linn. in Wistar rats. Biology and Medicine. 1:1 (2009) 
1-10. 
AFZAN, A. [et al.] – Repeated dose 28-days oral toxicity study of Carica papaya L. leaf extract 
in Sprague Dawley rats. Molecules. 17:4 (2012) 4326-4342. 
ALEMDAROGLU, N.C. [et al.] – Influence of green and black tea on folic acid pharmacokinetics 
in healthy volunteers: potential risk of diminished folic acid bioavailability. Biopharm. Drug 
Dispos. 29:6 (2008) 335-348. 
ALLCOCK, D.M.; GARDNER, M.J.; SOWERS, J.R. – Relation between childhood obesity and adult 
cardiovascular risk. Int. J. Pediatr. Endocrinol. 2009 (2009) doi: 10.115/2009/108187. 
ALMOG, S. [et al.] – Mechanism of warfarin potentiation by amiodarone: dose- and 
concentration- dependent inhibition of warfarin elimination. Eur. J. Clin. Pharmacol. 28:3 
(1985) 257-261. 
ANTONELLI-USHIROBIRA, T.M. [et al.] – Acute and subchronic toxicological evaluation of the 
semipurified extract of seeds of guaraná (Paullinia cupana) in rodents. Food Chem. Toxicol. 
48:7 (2010) 1817-1820. 
ANUAR, N.S. [et al.] – Effect of green and ripe Carica papaya epicarp extracts on wound 
healing and during pregnancy. Food Chem. Toxicol. 46:7 (2008) 2384-2389. 
ARAVIND, G. [et al.] – Traditional and medicinal uses of Carica papaya. Journal of Medicinal 
Plants Studies. 1:1 (2013) 7-15. 
ARBO, M.D. [et al.] – Subchronic toxicity of Citrus aurantium L. (Rutaceae) extract and p-
synephrine in mice. Regul. Toxicol. Pharmacol. 54:2 (2009) 114-117. 
ATHESH, K. [et al.] – Anti-obesity effect of aqueous fruit extract of Carica papaya L. in rats 
fed on high fat cafeteria diet. Int. J. Pharm. Pharm. Sci. 4:5 (2012) 327-330. 
BAILEY, D.G.; DRESSER, G.K.; BEND, J.R. – Bergamottin, lime juice, and red wine as inhibitors of 
cytochrome P450 3A4 activity: comparison with grapefruit juice. Clin. Pharmacol. Ther. 73:6 
(2003) 529-537. 
Chapter I 
 
 
46 
BASILE, A. [et al.] – Antibacterial and antioxidant activities of ethanol extract from Paullinia 
cupana mart. J. Ethnopharmacol. 2005 102:1 (2005) 32-36. 
BECQUEMONT, L. [et al.] – Amiodarone interacts with simvastatin but not with pravastatin 
disposition kinetics. Clin. Pharmacol. Ther. 81:5 (2007) 679-684. 
BENT, S. – Herbal medicine in the United States: review of efficacy, safety, and regulation: 
grand rounds at University of California, San Francisco Medical Center. J. Gen. Intern. Med. 
23:6 (2008) 854-859. 
BENT, S.; PADULA, A.; NEUHAUS, J. – Safety and efficacy of Citrus aurantium for weight loss. 
Am. J. Cardiol. 94:10 (2004) 1359-1361. 
BÉRUBÉ-PARENT, S. [et al.] – Effects of encapsulated green tea and Guarana extracts 
containing a mixture of epigallocatechin-3-gallate and caffeine on 24 h energy expenditure 
and fat oxidation in men. Br. J. Nutr. 94:3 (2005) 432-436. 
BITTENCOURT, L.S. [et al.] – The protective effects of guaraná extract (Paullinia cupana) on 
fibroblast NIH-3T3 cells exposed to sodium nitroprusside. Food Chem. Toxicol. 53 (2013) 
119-125.  
BLANCK, H.M. [et al.] – Use of nonprescription dietary supplements for weight loss is 
common among Americans. J. Am. Diet Assoc. 107:3 (2007) 441-447. 
BODARY, P.F.; IGLAY, H.B.; EITZMAN, D.T. – Strategies to reduce vascular risk associated with 
obesity. Curr. Vasc. Pharmacol. 5:4 (2007) 249-258. 
BOOZER, C.N. [et al.] – An herbal supplement containing Ma Huang-Guarana for weight loss: 
a randomized, double-blind trial. Int. J. Obes. Relat. Metab. Disord. 25:3 (2001) 316-324. 
BOUCHARD, N.C. [et al.] – Ischemic stroke associated with use of an ephedra-free dietary 
supplement containing synephrine. Mayo Clin. Proc. 80:4 (2005) 541-545.  
BOUTITIE, F. [et al.] – Amiodarone interaction with beta-blockers: analysis of the merged 
EMIAT (European Myocardial Infarct Amiodarone Trial) and CAMIAT (Canadian 
Amiodarone Myoardial Infarction Trial) databases. The EMIAT and CAMIAT Investigators. 
Circulation. 99:1 (1999) 2268-2275. 
BRENNER, R.; DELACRÉTAZ, E. – Dronedarone for the management of atrial fibrillation. Swiss 
Med. Wkly. 141 (2011) doi: 10.4414/smw.2011.13158. 
General introduction 
47 
BULKU, E. [et al.] – A novel dietary supplement containing multiple phytochemicals and 
vitamins elevates hepatorenal and cardiac antioxidant enzymes in the absence of significant 
serum chemistry and genomic changes. Oxid. Med. Cell. Longev. 3:2 (2012) 129-144.  
BYDLOWSKI, S.P.; YUNKER, R. L.; SUBBIAH, T. – A novel property of an aqueous guaraná extract 
(Paullinia cupana): inhibition of platelet aggregation in vitro and in vivo. Braz. J. Med. Biol. 
Res. 21:3 (1988) 535-538. 
CAIRRÃO, E. [et al.] – Glutathione-S-transferase activity of Fucus spp. As biomarker of 
environmental contamination. Aquat. Toxicol. 70:4 (2004) 277-286. 
CALAPAI, G. – European legislation on herbal medicines: a look into the future. Drug Saf. 31:5 
(2008) 428-431. 
CALAPAI, G. [et al.] – Antiobesity and cardiovascular toxic effects of Citrus aurantium 
extracts in the rat: a preliminary report. Fitoterapia. 70:6 (1999) 586-592. 
CAMPBELL, T.J.; WILLIAMS, K.M. – Therapeutic drug monitoring: antiarrhythmic drugs. Br. J. 
Clin. Pharmacol. 52 Suppl 1 (2001) 21S-34S. 
CAMPOS, M.P.O. [et al.] – Guarana (Paullinia cupana) improves fatigue in breast cancer 
patients undergoing systemic chemotherapy. J. Altern. Complement. Med. 17:6 (2011) 505-
512. 
CANINI, A. [et al.] – Gas chromatography-mass spectrometry analysis of phenolic compounds 
from Carica papaya leaf. J. Food Compost. Anal. 20:7 (2007) 584-590. 
CARPÉNÉ, C. [et al.] – Selective activation of beta 3-adrenoceptors by octopamine: 
comparative studies in mammalian fat cells. Naunyn Schmiedebergs Arch. Pharmacol. 359:4 
(1999) 310-321. 
CHAVEZ, M.L.; JORDAN, M.A.; CHAVEZ, P.I. – Evidence-based drug-herbal interactions. Life Sci. 
78:18 (2006) 2146-2157. 
CHITWOOD, K.K. ABDUL-HAGG, A.J.; HEIM-BUTHOY, K.L. – Cyclosporine-amiodarone 
interaction. Ann. Pharmacother. 27:5 (1993) 569-571. 
CHOW, H.H. [et al.] – Effects of repeated green tea catechin administration on human 
cytochrome P450 activity. Cancer Epidemiol. Biomarkers Prev. 15:12 (2006) 2473-2476. 
Chapter I 
48 
COHEN-LEHMAN, J. [et al.] – Effects of amiodarone therapy on thyroid function. Nat. Rev. 
Endocrinol. 6.1 (2010) 34-41. 
CONNOLLY, S.J. – Evidence-based analysis of amiodarone efficacy and safety. Circulation. 
100:19 (1999) 2025-2034. 
DARWICH, A.S. [et al.] – Interplay of metabolism and transport in determining oral drug 
absorption and gut wall metabolism: a simulation assessment using the “Advanced 
Dissolution, Absorption, Metabolism (ADAM)” model. Curr. Drug Metab. 11:9 (2010) 716-
729. 
DEHGHANI, F. [et al.] – Toxic effects of water/alcoholic extract of Syzygium aromaticum on 
sperm quality, sex hormones and reproductive tissues in male mouse. IUFS J. Biol. 72:2 
(2012) 95-102. 
DENG, P. [et al.] – Identification of amiodarone metabolites in human bile by 
ultraperformance liquid chromatography/quadrupole time-of-flight mass spectrometry. Drug 
Metab. Dispos. 39:6 (2011) 1058-1069. 
DÍAZ-RUBIO, M.E.; PÉREZ-JIMÉNEZ, J.; SAURA-CALIXTO, F. – Dietary fiber and antioxidant 
capacity in Fucus vesiculosus products. Int. J. Food Sci. Nutr. 60 Suppl 2 (2009) 23-34. 
DOMÍNGUEZ DE MARÍA, P. [et al.] – Carica papaya lipase (CPL): an emerging and versatile 
biocatalyst. Biotechnol. Adv. 24:5 (2006) 493-499. 
DOUKETIS, J.D.; SHARMA, A.M. – Obesity and cardiovascular disease: pathogenic mechanisms 
and potential benefits of weight reduction. Semin. Vasc. Med. 5:1 (2005) 25-33. 
EDWIN, S.B.; JENNINGS, D.L.; KALUS, J.S. – An evaluation of the early pharmacodynamic 
response after simultaneous initiation of warfarin and amiodarone. J. Clin. Pharmacol. 50:6 
(2010) 693-698. 
EGRAS, A.M. [et al.] – An evidence-based review of fat modifying supplemental weight loss 
products. J. Obes. 2011 (2011) doi: 10.1155/2011/297315. 
ELSHERBINY, M.E.; BROCKS, D.R. – The effect of CYP1A1 induction on amiodarone disposition 
in the rat. J. Pharm. Sci. 99:1 (2010) 539-548. 
General introduction 
 
 
49 
ELSHERBINY, M.E.; EL-KADI, A.O.; BROCKS, D.R. – The effect of beta-naphthoflavone on the 
metabolism of amiodarone by hepatic and extra-hepatic microsomes. Toxicol. Lett. 195:2-3 
(2010) 147-154. 
ESCOUBET, B. [et al.] – Amiodarone and N-desethylamiodarone concentrations in plasma, red 
blood cells, and myocardium after a single oral dose: relation to hemodynamic effects in 
surgical patients. Am. Heart J. 111:2 (1986) 280-285.  
EUROPEAN MEDICINES AGENCY – Call for scientific data for use in HMPC assessment work on 
Paullinia cupana Kunth, semen. EMA/HMPC/278492/2011, Committee on Herbal Medicinal 
Products (HMPC), 2011. 
EUROPEAN MEDICINES AGENCY – Community herbal monograph on Paullinia cupana Kunth ex 
H.B.K. var. sorbilis (Mart.) Ducke, semen. EMA/HMPC/897344/2011. Committee on Herbal 
Medicinal Products (HMPC), 2013. 
EZIKE, A.C. [et al.] – Carica papaya (Paw-Paw) unripe fruit may be beneficial in ulcer. J. Med. 
Food. 12:6 (2009) 1268-1273. 
FAN, L. [et al.] – Effect of Schisandra chinensis extract and Ginko biloba extract on the 
pharmacokinetics of talinolol in healthy volunteers. Xenobiotica. 39:3 (2009) 249-254.  
FOOD AND DRUG ADMINISTRATION; HHS – Final rule declaring dietary supplements containing 
ephedrine alkaloids adulterated because they present an unreasonable risk. Final rule. Fed. 
Regist. 69:28 (2004) 6787-6854. 
FREEDMAN, M.D.; SOMBERG, J.C. – Pharmacology and pharmacokinetics of amiodarone. J. Clin. 
Pharmacol. 31:11 (1991) 1061-1069. 
FUGH-BERMAN, A.; MYERS, A. – Citrus aurantium, an ingredient of dietary supplements 
marketed for weight loss: current status of clinical and basic research. Exp. Biol. Med. 229:8 
(2004) 698-704. 
FUJIMURA, T. [et al.] – Fucoidan is the active component of Fucus vesiculosus that promotes 
contraction of fibroblast-populated collagen gels. Biol. Pharm. Bull. 23:10 (2000a) 1180-1184.  
FUJIMURA, T. [et al.] – Effects of natural product extracts on contraction and mechanical 
properties of fibroblast population collagen gel. Biol. Pharm. Bull. 23:3 (2000b) 291-297. 
Chapter I 
 
 
50 
FUJIMURA, T. [et al.] – Treatment of human skin with an extract of Fucus vesiculosus changes 
its thickness and mechanical properties. J. Cosmet. Sci. 53:1 (2002) 1-9. 
FUKUMASU, H.; LATORRE, A.O.; ZAIDAN-DAGLI, M.L. – Paullinia cupana Mart. Var. sorbilis, 
guarana, increases survival of Ehrlich ascites carcinoma (EAC) bearing mice by decreasing 
cyclin-D1 expression and inducing a G0/G1 cell cycle arrest in EAC cells. Phytother. Res. 
25:1 (2011) 11-16. 
GOLDSCHLAGER, N. [et al.] – A practical guide for clinicians who treat patients with 
amiodarone: 2007. Heart Rhythm. 4:9 (2007) 1250-1259. 
GOUWS, C. [et al.] – Combination therapy of western drugs and herbal medicines: recent 
advances in understanding interactions involving metabolism and efflux. Expert Opin. Drug 
Metab. Toxicol. 8:8 (2012) 973-984.  
GURLEY, B.J. [et al.] – Gauging the clinical significance of P-glycoprotein-mediated herb-drug 
interactions: comparative effects of St. John’s wort, Echinacea, clarithromycin, and rifampin 
on digoxin pharmacokinetics. Mol. Nutr. Food Res. 52:7 (2008) 772-779. 
HA, H.R. [et al.] – Interaction between amiodarone and lidocaine. J. Cardiovasc. Pharmacol. 
28:4 (1996) 533-539. 
HA, H.R. [et al.] – Metabolism of amiodarone (part I): identification of a new hydroxylated 
metabolite of amiodarone. Drug Metab. Dispos. 29:2 (2001a) 152-158. 
HA, H.R. [et al.] – Metabolism of amiodarone. II. High-performance liquid chromatographic 
assay for mono-N-desethylamiodarone hydroxylation in liver microsomes. J. Chromatogr. B. 
757:2 (2001b) 3009-315. 
HA, H.R. [et al.] – Identification and quantitation of novel metabolites of amiodarone in 
plasma of treated patients. Eur. J. Pharm. Sci. 24:4 (2005) 271-279. 
HAAZ, S. [et al.] – Citrus aurantium and synephrine alkaloids in the treatment of overweight 
and obesity: an update. Obes. Rev. 7:1 (2006) 79-88. 
HAN, T.S.; WILLIAMS, G.R.; VANDERPUMP, M.P. – Benzofuran derivatives and the thyroid. Clin 
Endocrinol. 70:1 (2009) 2-13. 
HANSEN, D.K. [et al.] – Developmental toxicity of Citrus aurantium in rats. Birth Defects 
Res. B Dev. Reprod. Toxicol. 92:3 (2011) 216-223.  
General introduction 
 
 
51 
HANSEN, D.K. [et al.] – Physiological effects following administration of Citrus aurantium for 
28 days in rats. Toxicol. Appl. Pharmacol. 261:3 (2012) 236-247. 
HANSEN, D.K. [et al.] – Cardiovascular toxicity of Citrus aurantium in exercised rats. 
Cardiovasc. Toxicol. (2013) doi: 10.1007/s12012-013-9199-x. 
HEARD, C.M. [et al.] – In vitro transdermal delivery of caffeine, theobromine, theophylline 
and catechin from extract of Guarana, Paullinia Cupana. Int. J. Pharm. 317:1 (2006) 26-31. 
HERMANN, R.; VON RICHTER, O. – Clinical evidence of herbal drugs as perpetrators of 
pharmacokinetic drug interactions. Planta Med. 78:13 (2012) 1458-1477. 
HOFFMAN, J.R. [et al.] – Thermogenic effect of an acute ingestion of a weight loss 
supplement. J. Int. Soc. Sports Nutr. 6:1 (2009) doi: 10.1186/1550-2783-6-1. 
HOSAKA, F. [et al.] – Amiodarone distribution in human tissues after long-term therapy: a 
case of arrhythmogenic right ventricular cardiomyopathy. Heart Vessels. 16:4 (2002) 154-
156. 
HU, Z. [et al.] – Herb-drug interactions: a literature review. Drugs. 65:9 (2005) 1239-1282. 
HUY, C.P. [et al.] – Rapid microdetermination of amiodarone and its metabolite N. 
desethylamiodarone in plasma by high-performance liquid chromatography. Anal. Lett. 24:4 
(1991) 603-623. 
IERVASI, G. [et al.] – Acute effects of amiodarone administration on thyroid function in 
patients with cardiac arrhythmia. J. Clin. Endocrinol. Metab. 82:1 (1997) 275-280. 
IOANNIDES, C; LEWIS, D.F.V – Cytochromes P450 in the bioactivation of chemicals. Curr. 
Top. Med. Chem. 4:16 (2004) 1767-1788. 
IVER, D.; SHARMA, B.K.; PATIL, U.K. – Effect of ether- and water-soluble fractions of Carica 
papaya ethanol extract in experimentally induced hyperlipidemia in rats. Pharm. Biol. 49:12 
(2011) 1306-1310. 
IZZO, A.A. – Herb-drug interactions: an overview of the clinical evidence. Fundam. Clin. 
Pharmacol. 19:1 (2004) 1-16. 
IZZO, A.A. – Interactions between herbs and conventional drugs: overview of the clinical 
data. Med. Princ. Pract. 21:5 (2012) 404-428. 
Chapter I 
 
 
52 
IZZO, A.A. [et al.] – Cardiovascular pharmacotherapy and herbal medicines: the risk of drug 
interaction. Int. J. Cardiol. 98:1 (2005) 1-14. 
JOHNE, A. [et al.] – Pharmacokinetic interaction of digoxin with an herbal extract from St 
John’s wort (Hypericum perforatum). Clin. Pharmacol. Ther. 66:4 (1999) 338-345. 
KARIMI, S. [et al.] – Results of a safety initiative for patients on concomitant amiodarone and 
simvastatin therapy in a Veterans Affairs medical center. J. Manag. Care Pharm. 16:7 (2010) 
472-481. 
KENNEDY, D.O. [et al.] – Improved cognitive performance in human volunteers following 
administration of guarana (Paullinia cupana) extract: comparison and interaction with Panax 
ginseng. Pharmacol. Biochem. Behav. 79:3 (2004) 401-411. 
KLEIN, T.; LONGHINI, R.; DE MELLO, J.C. – Development of an analytical method using 
reversed-phase HPLC-PDA for a semipurified extract of Paullinia cupana var. sorbilis 
(guaraná). Talanta.  88 (2012) 502-506. 
KOIVIKKO, R. [et al.] – Variation of phlorotannins among three populations of Fucus 
vesiculosus as revealed by HPLC and colorimetric quantification. J. Chem. Ecol. 34:1 (2008) 
57-64. 
KOVENDAN, K. [et al.] – Antimalarial activity of Carica papaya (family: Caricaceae) leaf extract 
against Plasmodium falciparum. Asian Pac. J. Trop. Dis. 2: Suppl. 1 (2012) S306-S311. 
KOZLIK, P. [et al.] – Metabolism of amiodarone (Part III): identification of rabbit cytochrome 
P450 isoforms involved in the hydroxylation of mono-N-desethylamiodarone. Xenobiotica. 
31:5 (2001) 239-248. 
KREWER, C.C. [et al.] – Habitual Intake of Guaraná and Metabolic Morbidities: An 
Epidemiological Study of an Elderly Amazonian Population. Phytother. Res. 25 (2011) 1367-
1374. 
KRISHNA, K.L.; PARIDHAVI, M.; PATEL, J.A. – Review on nutritional, medicinal and 
pharmacological properties of Papaya (Carica papaya Linn.). Natural Product Radiance. 7:4 
(2008) 364-373. 
KUHN, M.A. – Herbal remedies: drug-herb interactions. Crit. Care Nurse. 22:2 (2002) 22-28. 
General introduction 
 
 
53 
LAFUENTE-LAFUENTE, C. [et al.] – Amiodarone concentrations in plasma and fat tissue during 
chronic treatment and related toxicity. Br. J. Clin. Pharmacol. 67:5 (2009) 511-519. 
LATINI, R. [et al.] – High-performance liquid chromatographic isolation and fast atom 
bombardment mass spectrometric identification of di-N-desethylamiodatone, a new 
metabolite of amiodarone in the dog. Biomed. Mass Spectrom. 11:9 (1984) 466-471. 
LEE, C.M. [et al.] – Indices of abdominal obesity are better discriminators of cardiovascular 
risk factors than BMI: a meta-analysis. J. Clin. Epidemiol. 61:7 (2008) 646-653.  
LEI, H.P. [et al.] – Effect of St. John’s wort supplementation on the pharmacokinetics of 
bupropion in healthy male Chinese volunteers. Xenobiotica. 40:4 (2010) 275-281. 
LEITE, R.P. [et al.] – Advantage of Guaraná (Paullinia cupana Mart.) supplementation on 
cadmium-induced damages in testis of adult Wistar rats. Toxicol. Pathol. 41:1 (2013) 73-79. 
LESKO, L.J. – Pharmacokinetic drug interactions with amiodarone. Clin. Pharmacokinet. 17:2 
(1989) 130-140. 
LESNE, M.; PELLEGRIN, P.L. – Rapid high-performance liquid chromatographic method for the 
determination of amiodarone and desethylamiodarone in human plasma and serum. J. 
Chromatogr. 415:1 (1987) 197-202. 
LIBERSA, C.C. [et al.] – Dramatic inhibition of amiodarone metabolism induced by grapefruit 
juice. Br. J. Clin. Pharmacol. 49:4 (2000) 373-378. 
LIMA, W.P. [et al.] – Lipid metabolism in trained rats: effect of guarana (Paullinia cupana 
Mart.) supplementation. Clin. Nutr. 24:6 (2005) 1019-1028. 
LIU, H.; GU, L. – Phlorotannins from brown algae (Fucus vesiculosus) inhibited the formation 
of advanced glycation endproducts by scavenging reactive carbonyls. J. Agric. Food Chem. 
60:5 (2012) 1326-1334. 
LOHMANN, W. [et al.] – Quantification of electrochemically generated iodine-containing 
metabolites using inductively coupled plasma mass spectrometry. Anal. Chem. 80:24 (2008) 
9769-9775. 
LU, W.J.; HUANG, J.D.; LAI, M.L. – The effects of ergoloid mesylates and ginkgo biloba on the 
pharmacokinetics of ticlopidine. J. Clin. Pharmacol. 46:6 (2006) 628-634. 
Chapter I 
 
 
54 
LUNDAHL, A. [et al.] – The effect of St. John’s wort on the pharmacokinetics, metabolism and 
biliary excretion of finasteride and its metabolites in healthy men. Eur. J. Pharm. Sci. 36:4-5 
(2009) 433-443. 
MAI, I. [et al.] – Hyperforin content determines the magnitude of the St. John’s wort-
cyclosporine drug interaction. Clin. Pharmacol. Ther. 76:4 (2004) 330-340. 
MANFREDI, C. [et al.] – Measurement of serum amiodarone and desethylamiodarone by 
HPLC: its usefulness in the follow-up of arrhythmic patients treated with amiodarone. Int. J. 
Clin. Pharmacol. Res. 15:2 (1995) 87-93. 
MANNEL, M. – Drug interactions with St John’s wort: mechanisms and clinical implications. 
Drug Saf. 27:11 (2004) 773-797. 
MARAGNO, I. [et al.] – Influence of amiodarone on oral digoxin bioavailability in healthy 
volunteers. Int. J. Clin. Pharmacol. Res. 4:2 (1984) 149-153.  
MARCHETTI, S. [et al.] – Concise review: Clinical relevance of drug-drug and herb-drug 
interactions mediated by the ABC transporter ABCB1 (MDR1, P-glycoprotein). Oncologist. 
12:8 (2007) 927-941. 
MARKOWITZ, J.S.; ZHU, H.J. – Limitations of in vitro assessments of the drug interaction 
potential of botanical supplements. Planta Med. 78:13 (2012)1421-1427. 
MARKOWITZ, J.S.; VON MOLTKE, L.L.; DONOVAN, J.L. – Predicting interactions between 
conventional medications and botanical products on the basis of in vitro investigations. Mol. 
Nutr. Food Res. 52:7 (2008) 747-754. 
MARKOWITZ, J.S. [et al.] – Effect of St. John’s wort on drug metabolism by induction of 
cytochrome P450 3A4 enzyme. JAMA. 290:11 (2003) 1500-1504. 
MAROT, A. [et al.] – Concomitant use of simvastatin and amiodarone resulting in severe 
rhabdomyolysis: a case report and review of the literature. Acta Clin. Belg. 66:2 (2011) 134-
136. 
MING, R.; YU, Q.; MOORE, P.H. – Sex determination in papaya. Semin. Cell. Dev. Biol. 18:3 
(2007) 401-408. 
MORO, C.O.; BASILE, G. – Obesity and medicinal plants. Fitoterapia. 71:Suppl 1 (2000) S73-82. 
General introduction 
55 
NADEMANEE, K. [et al.] – Amiodarone-digoxin interaction: clinical significance, time course of 
development, potential pharmacokinetic mechanisms and therapeutic implications. J. Am. 
Coll. Cardiol. 4:1 (1984) 111-116.  
NAJJAR, T.A. – Disposition of amiodarone in rats after single and multiple intraperitoneal 
doses. Eur. J. Drug Metab. Pharmacokinet. 26:1-2 (2001) 65-69. 
NGO, N. [et al.] – Identification of a cranberry juice product that inhibits enteric CYP3A-
mediated first-pass metabolism in humans. Drug Metab. Dispos. 37:3 (2009) 514-522. 
NGUYEN, T.T. [et al.] – Anticancer activity of Carica papaya: a review. Mol. Nutr. Food Res. 
57:1 (2013) 153-164. 
NIEMI, M.; PASANEN, M.K.; NEUVONEN, P.J. – Organic anion transporting polypeptide 1B1: a 
genetically polymorphic transporter of major importance for hepatic drug uptake. 
Pharmacol. Rev. 63:1 (2011) 157-181. 
NISTCH, J.; LÜDERITZ, B. – [Acceleration of amiodarone elimination by cholestyramine] Dtsch. 
Med. Wochenschr. 111:33 (1986) 1241-1244. 
NOLAN, P.E. JR. [et al.] – Pharmacokinetic interaction between intravenous phenytoin and 
amiodarone in healthy volunteers. Clin. Pharmacol. Ther. 46:1 (1989) 43-50. 
NOLAN, P.E. JR. [et al.] – Effect of phenytoin on the clinical pharmacokinetics of amiodarone. 
J. Clin. Pharmacol. 30:12 (1990) 1112-1119. 
OHYAMA, K. [et al.] – Inhibitory effects of amiodarone and its N-deethylated metabolite on 
human cytochrome P450 activities: prediction of in vivo drug interactions. Br. J. Clin. 
Pharmacol. 49:3 (2000) 244-253. 
OLIVEIRA, J.F. [et al.] – Assessment of the effect of Fucus vesiculosus extract on the labeling 
of blood constituents with technetium-99m and the histological modifications on the shape 
of the red blood cells. Food Chem. Toxicol. 41:1 (2003) 15-20. 
OZVEGY-LACZKA, C. [et al.] – Tyrosine kinase inhibitor resistance in cancer: role of ABC 
multidrug transporters. Drug Resist. Updat. 8:1-2 (2005) 15-26. 
PAPIRIS, S.A. [et al.] – Amiodarone: Review of pulmonary effects and toxicity. Drug Saf. 33:7 
(2010) 539-558. 
Chapter I 
56 
PARYS, S. [et al.] – In vitro chemopreventive potential of fucophlorethols from the brown 
alga Fucus vesiculosus L. by anti-oxidant activity and inhibition of selected cytochrome P450 
enzymes. Phytochemistry. 71:2-3 (2010) 221-229.  
PEIXOTO, J.S. [et al.] – Effects of Citrus aurantium (bitter orange) fruit extracts and p-
synephrine on metabolic fluxes in the rat liver. Molecules. 17:5 (2012) 5854-5869. 
PÉREZ-RUIZ, T. [et al.] – Development and validation of a capillary electrophoretic method 
for the determination of amiodarone and desethylamiodarone. Chromatographia. 56:1-2 
(2002) 63-67. 
PHUA, D.H.; ZOSEL, A.; HEARD, K. – Dietary supplements and herbal medicine toxicities – 
when to anticipate them and how to manage them. Int. J. Emerg. Med. 2:2 (2009) 69-76. 
PIELESZ, A.; KULEC, J. – Electrophoretic identification of fucoidan in Fucus vesiculosus L. Herba 
Polonica. 56:1 (2010) 28-34. 
PISCITELLI, S.C. [et al.] – Indinavir concentrations and St John’s wort. Lancet. 355:9203 (2000) 
547-548. 
PISCITELLI, S.C. [et al.] – The effect of garlic supplements on the pharmacokinetics of 
saquinavir. Clin. Infect. Dis. 34:2 (2002) 234-238.  
PLOMP, T.A. [et al.] – Pharmacokinetics and body distribution of amiodarone and 
desethylamiodarone in rats after oral administration. In Vivo. 1:5 (1987) 265-279. 
POLLAK, P.T.; BOUILLON, T.; SHAFER, S.L. – Population pharmacokinetics of long-term oral 
amiodarone therapy. Clin. Pharmacol. Ther. 67:6 (2000) 642-652. 
POLLAK, P.T.; SHAFER, S.L. – Use of population modeling to define rational monitoring of 
amiodarone hepatic effects. Clin. Pharmacol. Ther. 75:4 (2004) 342-351. 
PORTELLA, RDE L. [et al.] – Guaraná (Paullinia cupana Kunth) effects on LDL oxidation in 
elderly people: an in vitro and in vivo study. Lipids Health Dis. 12:12 (2013) doi: 
10.1186/1476-511X-12-12. 
QIU, F. [et al.] – Effect of danhsen extract on the activity of CYP3A4 in healthy volunteers. 
Br. J. Clin. Pharmacol. 69:6 (2010) 656-662. 
RAMOS, G. [et al.] – Peri-operative management of amiodarone patients. Rev. Bras. 
Anestesiol. 54:4 (2004) 573-581. 
General introduction 
 
 
57 
RIOUX, L.E.; TURGEON, S.L.; BEAULIEU, M. – Characterization of polysaccharides extracted 
from brown seaweeds. Carbohyd. Polym. 69:3 (2007) 530-537. 
ROSSATO, L.G. [et al.] – Synephrine: from trace concentrations to massive consumption in 
weight-loss. Food Chem. Toxicol. 49:1 (2011) 8-16 doi: 10.1016/j.fct.2010.11.007. 
ROTMENSCH, H.H. [et al.] – Amiodarone: individualizing dosage with serum concentrations. 
Pacing Clin. Electrophysiol. 6:6 (1983) 1327-1335. 
ROTMENSCH, H.H. [et al.] – Steady-state serum amiodarone concentrations: relationships 
with antiarrhythmic efficacy and toxicity. Ann. Intern. Med. 101:4 (1984) 462-469. 
ROUGHEAD, E.E. [et al.] – Prevalence of potentially hazardous drug interactions amongst 
Australian veterans. Br. J. Clin. Pharmacol. 70:2 (2010) 252-257. 
SADEK, K.M.  – Antioxidant and immunostimulant effect of Carica papaya Linn. aqueous 
extract in acrylamide intoxicated rats. Acta Inform. Med. 20:3 (2012) 180-185. 
SAHOO, N.; MANCHIKANTI, P.; DEY, S. – Herbal drugs: standards and regulation. Fitoterapia. 
81:6 (2010) 462-471. 
SANTANGELI, P. [et al.] – Examining the safety of amiodarone. Expert Opin. Drug Saf. 11:2 
(2012) 191-214. 
SCAGLIONE, R. [et al.] – Obesity and cardiovascular risk: the new public health problem of 
worldwide proportions. Expert Rev. Cardiovasc. Ther. 2:2 (2004) 203-212. 
SCHMIDGALL, J.; SCHNETZ, E.; HENSEL, A. – Evidence for bioadhesive effects of polysaccharides 
and polysaccharide-containing herbs in an ex vivo bioadhesion assay on buccal membranes. 
Planta Med. 66:1 (2000) 48-53. 
SCHWEIZER, P.A. [et al.] – Dronedarone: current evidence for its safety and efficacy in the 
management of atrial fibrillation. Drug Des. Devel. Ther. 5 (2011) 27-39. 
SEDEN, K. [et al.] – Grapefruit-drug interactions. Drugs. 70:18 (2010) 2373-2407. 
SEKI, S. [et al.] – Amiodarone increases the accumulation of DEA in human alveolar 
epithelium-derived cell line. Biol. Pharm. Bull. 31:7 (2008) 1449-1452. 
SHARPE, P.A. [et al.] – Availability of weight-loss supplements: results of an audit of retail 
outlets in a southeastern city. J. Am. Diet. Assoc. 106:12 (2006) 2045-2051. 
Chapter I 
 
 
58 
SHAYEGANPOUR, A.; EL-KADI, A.O.; BROCKS, D.R. – Determination of the enzyme(s) involved 
in the metabolism of amiodarone in liver and intestine of rat: the contribution of cytochrome 
P450 3A isoforms. Drug Metab. Dispos. 34.1 (2006) 43-50. 
SHAYEGANPOUR, A.; HAMDY, D.A.; BROCKS, D.R. – Pharmacokinetics of desethylamiodarone in 
the rat after its administration as the preformed metabolite, and after administration of 
amiodarone. Biopharm. Drug Dispos. 29:3 (2008) 159-166. 
SHIGA, T. [et al.] – Pharmacokinetics of intravenous amiodarone and its electrocardiographic 
effects on healthy Japanese subjects. Heart Vessels. 26:3 (2011) 274-281. 
SIDDOWAY, L.A. – Amiodarone: guidelines for use and monitoring. Am. Fam. Physician. 68:11 
(2003) 2189-2196. 
SIEGMUND, J.B.; WILSON, J.H.; IMHOFF, T.E. – Amiodarone interaction with lidocaine. J. 
Cardiovasc. Pharmacol. 21:4 (1983) 513-515. 
SILVA, J.A.T. [et al.] – Papaya (Carica papaya L.) biology and biotechnology. Tree and Forestry 
Science and Biotechnology. 1 (2007) 47-73. 
SINGH, B.N. – Antiarrhythmic actions of amiodarone: a profile of a paradoxical agent. Am. J. 
Cardiol. 78:Suppl. 4A (1996) 41-53. 
SINGH, B.N. – Amiodarone as paradigm for developing new drugs for atrial fibrillation. J. 
Cardiovasc. Pharmacol. 52:4 (2008) 300-305.  
SKIBOLA, C.F. – The effect of Fucus vesiculosus, an edible brown seaweed, upon menstrual 
cycle length and hormonal status in three pre-menopausal women: a case report. BMC 
Complement. Altern. Med. 4:10 (2004) doi:10.1186/1472-6882-4-10. 
SOYAMA, A. [et al.] – Amiodarone N-deethylation by CYP2C8 and its variants, CYP2C8*3 
and CYP2C8 P404A. Pharmacol. Toxicol. 91:4 (2002) 174-178. 
SPINA, E.; SANTORO, V.; D’ARRIGO, C. – Clinically relevant pharmacokinetic drug interactions 
with second-generation antidepressants: an update. Clin. Ther. 30:7 (2008) 1206-1227. 
STÄUBLI, M. [et al.] – Serum concentrations of amiodarone during long term therapy. 
Relation to dose, efficacy and toxicity. Eur. J. Clin. Pharmacol. 24:4 (1983) 485-494. 
STOHS, S.J.; PREUSS H.G.; SHARA M. – The safety of Citrus aurantium (bitter orange) and its 
primary protoalkaloid p-synephrine. Phytother. Res. 25:10 (2011a) 1421-1428. 
General introduction 
 
 
59 
STOHS S.J.; PREUSS H.G.; SHARA M. – A review of the receptor-binding properties of p-
synephrine as related to its pharmacological effects. Oxid. Med. Cell. Longev. (2011b)  doi: 
10.1155/2011/482973. 
TACHJIAN, A.; MARIA, V.; JAHANGIR, A. – Use of herbal products and potential interactions in 
patients with cardiovascular diseases. J. Am. Coll. Cardiol. 55:6 (2010) 515-525. 
TARIRAI, C.; VILJOEN, A.M.; HAMMAN, J.H. – Herb-drug pharmacokinetic interactions reviewed. 
Expert Opinion Drug Metab. Toxicol. 6:12 (2010) 1515-1538. 
TARTINI, R. [et al.] – Dangerous interaction between amiodarone and quinidine. Lancet. 
1:8285 (1982) 1327-1329. 
TAYLOR, S.E. – Amiodarone: an emergency medicine perspective. Emerg. Med. 14:4 (2002) 
422-429. 
THAM, C.S. [et al.] – Morphological study of bone marrow to assess the effects of lead 
acetate on haemopoiesis and aplasia and the ameliorating role of Carica papaya extract. Exp. 
Ther. Med. 5:2 (2013) 648-652. 
TRIVIER, J.M. [et al.] – Amiodarone N-deethylation in human liver microsomes: involvement 
of cytochrome P450 3A enzymes (first report). Life Sci. 52:10 (1993) PL91-96. 
TRUJILLO, T.C.; NOLAN, P.E. – Antiarrhythmic agents: drug interactions of clinical significance. 
Drug. Saf. 23:6 (2000) 509-532. 
VAN HERENDAEL, H.; DORIAN, P. – Amiodarone for the treatment and prevention of 
ventricular fibrillation and ventricular tachycardia. Vasc. Health Risk Manag. 6 (2010) 465-
472. 
VARMA. M.V. [et al.] – P-glycoprotein inhibitors and their screening: a perspective from 
bioavailability enhancement. Pharmacol. Res. 48:4 (2003) 347-359. 
VENKATARAMANAN, R.; KOMOROSKI, B.; STROM, S. – In vitro and in vivo assessment of herb 
drug interactions. Life Sci. 78:18 (2006) 2105-2115. 
VENTOLA, C.L. – Current issues regarding complementary and alternative medicine (CAM) in 
the United States: Part 2: Regulatory and safety concerns and proposed governmental policy 
changes with respect to dietary supplements. P T. 35:9 (2010) 514-522. 
Chapter I 
60 
VERONESE, M.E.; MCLEAN, S.; HENDRIKS, R. – Plasma protein binding of amiodarone in a patient 
population: measurement by erythrocyte partitioning and a novel glass-binding method. Br. J. 
Clin. Pharmacol. 26:6 (1988) 721-731. 
VIEIRA, M; HUANG, S.M. – Botanical-drug interactions: a scientific perspective. Planta Med. 
78:13 (2012) 1400-1415.  
XIN, H.W. [et al.] – Effects of Schisandra sphenanthera extract on the pharmacokinetics of 
tacrolimus in healthy volunteers. Br. J. Clin. Pharmacol. 64:4 (2007) 469-475. 
XIN, H.W. [et al.] – Effects of Schisandra sphenanthera extract on the pharmacokinetics of 
midazolam in healthy volunteers. Br. J. Clin. Pharmacol. 67:5 (2009) 541-546. 
WAN, J. [et al.] – Effects of neferine on the pharmacokinetic of amiodarone in rats. Biomed. 
Chromatogr. 25:8 (2011) 858-866. 
WANG, J.F.; CHOU, K.C. – Molecular modeling of cytochrome P450 and drug metabolism. 
Curr. Drug Metab. 11:4 (2010) 342-346. 
WOLKOVE, N.; BALTZAN, A. – Amiodarone pulmonary toxicity. Can. Respir. J. 16:2 (2009) 43-
48. 
WYSS, P.A.; MOOR, M.J.; BICKEL, M.H. – Single-dose kinetics of tissue distribution, excretion 
and metabolism of amiodarone in rats. J. Pharmacol. Exp. Ther. 254:2 (1990) 502-507. 
YAMREUDEEWONG, W. [et al.] – Potentially significant drug interactions of class III 
antiarrhythmic drugs. Drug Saf. 26:6 (2003) 421-438. 
YUAN, C.S. [et al.] – Brief communication: American ginseng reduces warfarin’s effect in 
healthy patients: a randomized, controlled trial. Ann. Intern. Med. 141:1 (2004) 23-27. 
ZAHNO, A. [et al.] – The role of CYP3A4 in amiodarone-associated toxicity on HepG2 cells. 
Biochem. Pharmacol. 81:3 (2011) 432-441.  
ZALESIN, K.C. [et al.] – Impact of obesity on cardiovascular disease. Med. Clin. North Am. 
95:5 (2011) 919-937. 
ZAREMBSKI, D.G. [et al.] – Impact of rifampin on serum amiodarone concentrations in a 
patient with congenital heart disease. Pharmacotherapy. 19:2 (1999) 249-251. 
General introduction 
 
 
61 
ZHI, J. [et al.] – Effects of orlistat, a lipase inhibitor, on the pharmacokinetics of three highly 
lipophilic drugs (amiodarone, fluoxetine, and simvastatin) in healthy volunteers. J. Clin. 
Pharmacol. 43:4 (2003) 428-435. 
ZHOU, S.; LIM, L.Y.; CHOWBAY, B. – Herbal modulation of P-glycoprotein. Drug Metab. Rev. 
36:1 (2004) 57-104. 
ZHOU, S.F. [et al.] – Identification of drugs that interact with herbs in drug development. 
Drug Discov. Today. 12:15-16 (2007) 664-673. 
 
 
CHAPTER II 
FIRST LIQUID CHROMATOGRAPHIC METHOD FOR THE SIMULTANEOUS 
DETERMINATION OF AMIODARONE AND DESETHYLAMIODARONE IN HUMAN PLASMA 
USING MICROEXTRACTION BY PACKED SORBENT (MEPS) AS SAMPLE PREPARATION 
PROCEDURE 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
First liquid chromatographic method for the simultaneous determination of AM and MDEA in human plasma using MEPS as sample preparation procedure 
65 
II. FIRST LIQUID CHROMATOGRAPHIC METHOD FOR THE SIMULTANEOUS DETERMINATION
OF AMIODARONE AND DESETHYLAMIODARONE IN HUMAN PLASMA USING 
MICROEXTRACTION BY PACKED SORBENT (MEPS) AS SAMPLE PREPARATION PROCEDURE 
II.1. ABSTRACT 
For the first time a simple and fast high-performance liquid chromatography (HPLC) 
method using a novel sample preparation procedure based on microextraction by packed 
sorbent (MEPS) was developed and validated for the determination of amiodarone (AM) and 
its main metabolite mono-N-desethylamiodarone (MDEA) in human plasma. 
Chromatographic separation of the analytes (AM and MDEA) and tamoxifen, used as internal 
standard (IS), was achieved within less than 5 min on a LiChroCART Purospher® Star C18
column (55 mm × 4 mm, 3 µm). The mobile phase consisting of 50 mM phosphate buffer 
with 0.1% formic acid (pH 3.1)/methanol/acetonitrile (45:5:50, v/v/v) was pumped 
isocratically at a flow rate of 1.2 mL/min. The detection was carried out at 254 nm. 
Calibration curves were linear (r2 ≥ 0.9976) in the ranges of 0.1-10 µg/mL for AM and 
MDEA. The limits of quantification were established at 0.1 µg/mL for AM and MDEA. The 
overall imprecision did not exceed 6.67% and inaccuracy was within ±9.84%. The overall 
mean recovery of AM and MDEA ranged from 58.6% to 68.2%. Neither endogenous nor 
tested exogenous compounds were found to interfere at retention times of the analytes 
(AM and MDEA) and IS. This new MEPS/HPLC method was also applied to real samples 
obtained from polymedicated patients receiving AM therapy. Thus, this bioanalytical method 
seems to be a useful tool for therapeutic drug monitoring of patients under AM treatment 
and also to support other clinical pharmacokinetic-based studies involving this drug, such as 
bioavailability/bioequivalence studies. 
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II.2. INTRODUCTION 
Amiodarone [2-n-butyl-3-(3,5-diiodo-4-diethylaminoethoxy-benzoyl)-benzofuran; 
AM] (Figure II.1) is one of the most frequently prescribed antiarrhythmic drugs despite the 
availability of novel antiarrhythmic agents (WOLKOVE and BALTZAN, 2009; PAPIRIS et al., 
2010). Nevertheless, the unusual pharmacokinetic properties of AM and its primary 
metabolite mono-N-desethylamiodarone (MDEA; Figure II.1) complicate the clinical use of 
the drug. Actually, the high lipid solubility of AM and MDEA leads to an extensive and 
variable accumulation of both compounds in different tissues, resulting in a marked delay in 
onset of pharmacological action and in a number of safety concerns particularly after several 
weeks to months of AM therapy (MCKENNA, ROWLAND and KRIKLER, 1983; VERONESE,
MCLEAN and HENDRIKS, 1988; CAMPBELL and WILLIAMS, 2001; WOLKOVE and BALTZAN, 2009). 
Therefore, the long-term use of AM is limited by serious or even life-threatening adverse 
events, such as thyroid dysfunction, pulmonary toxicity and hepatic toxicity (SEKI et al., 2008; 
LAFUENTE-LAFUENTE et al., 2009; WOLKOVE and BALTZAN, 2009). 
Figure II.1 – Chemical structures of amiodarone (AM), mono-N-desethylamiodarone 
(MDEA) and tamoxifen (TAM) used as internal standard (IS). 
Indeed, AM has long been recognised as a drug having a narrow therapeutic window 
(0.5-2.0 µg/mL) (STÄUBLI et al., 1983; LESNE and  PELLEGRIN, 1987; POLLAK, BOUILLON and 
SHAFER, 2000; PÉREZ-RUIZ et al., 2002; SHAYEGANPOUR, HAMDY and BROCKS, 2008). Several 
studies have reported that serious toxicity is more likely at AM serum/plasma 
concentrations above 2.5 µg/mL (ROTMENSCH et al., 1984; POLLAK and SHAFER, 2004); 
ROTMENSCH et al. (1983) also concluded that AM serum concentrations below 2.5 µg/mL 
significantly improve AM’s benefit-to-risk relationship. Furthermore, the therapeutic drug 
monitoring (TDM) of AM plasma concentrations may differentiate treatment failure from 
suboptimal dosing and may reduce the incidence of concentration-related adverse effects 
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(ROTMENSCH et al., 1984). On the other hand, the monitoring of AM and MDEA plasma 
concentrations may be of particular interest to compare different routes of administration 
(KOTAKE et al., 2006) and to assess the impact of the switching in drug formulation 
(innovator versus generic medicine) (SAURO et al., 2002). Therefore, AM can be used more 
safely when the clinician is aware of the concentrations the patient is exposed to and adjusts 
the dose as necessary. For that, the availability of a fast, sufficiently sensitive, and selective 
bioanalytical method to enable the reliable determination of AM and its pharmacologically 
active metabolite (MDEA) is required. 
Until now, a lot of bioanalytical methods have been reported in literature for the 
determination of AM and MDEA in human plasma and other biological fluids. However, in 
those methods the sample preparation has been carried out by means of liquid-liquid 
extraction (LLE) (STOREY and HOLT, 1982; GUPTA and CONNOLLY, 1984; MARCHISET et al., 
1984; SHIPE, 1984; HUTCHINGS, SPRAGG and ROUTLEDGE, 1986; LESNE and  PELLEGRIN, 1987; DE
SMET and MASSART, 1988; PACZKOWSKI et al., 1989; ROCHAS et al., 1989; JUENKE et al., 2004), 
solid-phase extraction (SPE) (SUSANTO, HUMFELD and REINAUER, 1986; VERBESSELT,
TJANDRAMAGA and DE SCHEPPER 1991; KOLLROSER and SCHOBER, 2002; KUHN, GOTTING and
KLEESIEK, 2010), protein precipitation (PP) (PLOMP et al., 1983; WEIR and UEDA, 1985; 
RAJENDRAN et al., 2006) and combining different procedures such as PP and LLE 
(GUMIENICZEK, MISZTAL and PRZYBOROWSKI, 1994; BOLDERMAN, HERMANS and MAESSEN, 2009).
Nevertheless, the recent developments in the field of sample preparation have been directed 
toward miniaturization and automation, and one of the latest developments was the 
emergence of microextraction by packed sorbent (MEPS), which was already used for the 
quantitative analysis of several drugs such as antidepressants (CHAVES et al., 2010), 
methadone (EL-BEQQALI and ABDEL-REHIM, 2007), acebutolol and metoprolol (EL-BEQQALI et 
al., 2007), atorvastatin (VLČKOVÁ et al., 2011), pravastatin (VLČKOVÁ et al., 2012), 
oxcarbazepine (SARACINO, TALLARICO and RAGGI, 2010), risperidone (SARACINO et al., 2010; 
MANDRIOLI et al., 2011) and remifentanil (SAID et al., 2011), among others. This novel 
approach for sample preparation is essentially a miniaturized version of SPE using 1-4 mg of 
sorbent packed either inside a syringe (100-250 µL) as a plug or between the barrel and the 
needle as a cartridge (ABDEL-REHIM, 2010, 2011). In fact, there is a constant need for the 
development of faster and more selective sample clean-up procedures and MEPS represents 
a new approach suitable for the rapid analysis of drugs and/or metabolites from biological 
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fluids. Nevertheless, to the best of our knowledge none bioanalytical assay was previously 
developed for the determination of AM using MEPS as sample preparation procedure. 
Thus, the aim of this work was to develop and fully validate, for the first time, a high-
performance liquid chromatography (HPLC) method for the simultaneous quantification of 
AM and MDEA in human plasma using the innovative MEPS technology for sample 
preparation. 
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II.3. MATERIALS AND METHODS 
II.3.1 CHEMICALS AND REAGENTS
AM (lot no. 078K1246) was purchased from Sigma-Aldrich (St. Louis, MO, USA) and 
MDEA (lot no. LB33020) was kindly supplied by Sanofi-Aventis (Paris, France). Tamoxifen as 
citrate salt (TAM; lot no. 035K1270) was obtained from Sigma-Aldrich (St Louis, MO, USA) 
and it was used as internal standard (IS). The chemical structures of these compounds are 
shown in Figure II.1. Methanol (HPLC grade) and acetonitrile (HPLC grade) were purchased 
from Fisher Scientific (Leicestershire, United Kingdom). Ultra-pure water (HPLC grade, >18 
MΩ) was prepared by means of a Milli-Q water apparatus from Millipore (Milford, MA, 
USA). All other reagents were of analytical grade: sodium phosphate monobasic purris p.a. 
(Sigma-Aldrich GmbH; Seelze, Germany), sodium phosphate dibasic anhydrous (Sigma-
Aldrich; St Louis, MO, USA), sodium dihydrogen phosphate dehydrate purum p.a. (Fluka 
Chemie; Buchs, Switzerland) and formic acid (98-100%) (Merck KGaA; Darmstadt, 
Germany). MEPS 100 µL syringe and MEPS BIN (barrel insert and needle) containing ~4 mg 
of solid-phase silica - C18 material (SGE Analytical Science, Australia) were purchased from 
ILC (Porto, Portugal). Blank human plasma from healthy blood donors was kindly provided 
by the Portuguese Blood Institute after the written consent of each subject and in 
accordance with the principles of Helsinki Declaration. 
II.3.2 STOCK SOLUTIONS, CALIBRATION STANDARDS AND QUALITY CONTROL SAMPLES
Stock solutions of AM, MDEA, and TAM (IS) at the concentration of 1 mg/mL were 
individually prepared by dissolving appropriate amounts of each compound in methanol. 
Appropriate volumes of each of the stock solutions of AM and MDEA were combined and 
diluted in methanol to obtain an intermediate solution at 100 µg/mL. Thereafter, stock and 
intermediate solutions were appropriately used to afford six combined spiking solutions at 
final concentrations of 0.5, 1, 2.5, 7.5, 20 and 50 µg/mL for AM and MDEA, which were used 
to spike blank human plasma in order to prepare plasma calibration standards at six different 
concentration levels: 0.1, 0.2, 0.5, 1.5, 4 and 10 µg/mL for AM and MDEA. The stock solution 
of IS was daily diluted with water-methanol (60:40, v/v) in order to obtain a working solution 
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of 25 µg/mL. All solutions were stored protected from light at approximately 4 ºC for one 
month, except the IS working solution which was prepared daily.  
Quality control (QC) samples were prepared independently in the same matrix 
(blank human plasma), at three different concentration levels, representing the low (QC1), 
middle (QC2) and high (QC3) ranges of the calibration curves. Aliquots of blank human 
plasma were appropriately spiked to achieve the concentrations for both analytes (AM and 
MDEA) of 0.3 µg/mL in QC1; 5 µg/mL in QC2 and 9 µg/mL in QC3. 
 
II.3.3 APPARATUS AND CHROMATOGRAPHIC CONDITIONS 
 
Chromatographic analysis was carried out using an HPLC system (Agilent 1260 
Infinity Quaternary LC system) coupled with a diode-array detector (Agilent 1260 Infinity; 
G1315D DAD VL). All instrumental parts were automatically controlled by Agilent 
ChemStation software (Agilent Technologies). 
The chromatographic separation of AM, MDEA and IS was achieved in less than 5 min 
and it was carried out at room temperature, by isocratic elution with a mobile phase of 50 
mM phosphate buffer with 0.1% formic acid (pH 3.1)/methanol/acetonitrile (45:5:50, v/v/v), at 
a flow-rate of 1.2 mL/min, on a reversed-phase LiChroCART® Purospher Star-C18 column 
(55 mm × 4 mm; 3 µm particle size) purchased from Merck KGaA (Darmstadt, Germany). 
The mobile phase was filtered through a 0.45 µm filter and degassed ultrasonically for 15 min 
before use. The injection volume was 20 µL and the wavelength of 254 nm was selected for 
the detection of all compounds (AM, MDEA and IS). 
 
II.3.4 SAMPLE PREPARATION AND EXTRACTION  
 
The sample preparation was previously optimized and the final conditions were as 
follows.  Each aliquot (100 µL) of human plasma samples, spiked with 20 µL (0.5 µg) of the IS 
working solution, was added of 300 µL of ice-cold acetonitrile. The mixture was vortex-
mixed for 30 s and centrifuged at 17000 rpm for 2 min at 4 ºC. Afterwards, the supernatant 
was transferred to a clean vial, diluted with 400 µL of ultra-pure water and this mixture 
volume was then submitted to MEPS procedure. Briefly, the MEPS sorbent (C18) was 
manually conditioned with 3 × 100 µL of methanol/formic acid (95:5, v/v) followed by          
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2 × 100 µL of ultra-pure water. After that, the whole volume of the diluted supernatant was 
drawn through the sorbent and ejected at a flow rate of approximately 10 µL/s (this 
procedure was performed twice). The sorbent was washed with 100 µL of ultra-pure water 
in order to remove interferences, and then the analytes were eluted with 100 µL of 
methanol/formic acid (95:5, v/v). An aliquot (20 µL) of the eluted sample was injected into 
the chromatographic system. To avoid the carryover the MEPS sorbent was sequentially 
washed/reconditioned with 30 × 100 µL of methanol/formic acid (95:5, v/v) and 2 × 100 µL 
of ultra-pure water before the application of following sample. The carryover was carefully 
investigate on MEPS sorbent and no effect was evident using the previously referred 
conditions after the extraction and analysis of successive aliquots at the highest standard 
concentrations followed by extraction and analysis of aliquots of blank plasma. Each MEPS 
device was re-used in about 100 extraction cycles before being discarded. 
II.3.5 METHOD VALIDATION
The described method was validated according to internationally accepted 
recommendations for bioanalytical method validation (SHAH et al., 2000; GUIDANCE FOR
INDUSTRY, 2001; EUROPEAN MEDICINES AGENCY, 2011). 
Selectivity was evaluated by analysing blank plasma samples from six different sources 
to ensure the absence of chromatographic interferences from endogenous compounds 
(matrix effects) at the retention times of MDEA, AM and IS. In addition, interferences from 
other drugs usually co-administered with AM in clinical practice were also evaluated 
injecting, under the optimized chromatographic conditions, standard solutions of these 
compounds at a concentration of 10 µg/mL.  
To evaluate the linearity of the analytical method, calibration curves were prepared 
using six calibration standards in the range of 0.1-10 µg/mL and assayed on five different days 
(n = 5). The calibration curves were constructed by plotting analytes (MDEA or AM)/IS peak 
area ratios as function of the corresponding nominal concentrations. The data were 
subjected to a weighted linear regression analysis (ALMEIDA, CASTEL-BRANCO and FALCÃO, 
2002). 
The limit of quantification (LOQ) was defined as the lowest concentration of the 
calibration curve that can be measured with acceptable inter and intraday precision and 
accuracy, which were assessed respectively by the coefficient of variation (CV) not 
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exceeding 20% and the deviation from nominal concentration value (bias) within ±20%. The 
LOQs for MDEA and AM were evaluated by analysing plasma samples which were prepared 
in five replicates (n = 5). The limit of detection (LOD) of the analytes, defined as the lowest 
concentration that can be distinguished from the noise level, was established as the 
concentration that yields a signal-to-noise ratio of 3:1. 
Intra and interday precision and accuracy were assessed by using plasma QC samples 
analysed in replicate (n = 5) at three concentration levels (low, medium and high QC 
samples) representative of the calibration range. The concentrations to be tested were 0.3, 5 
and 9 µg/mL for MDEA and AM. The acceptance criterion for intra and interday precision 
(expressed as percentage of CV) was a CV value equal to or lower than 15% (or 20% in the 
LOQ) and for accuracy (expressed as percentage of bias) was a bias value within ±15% (or 
±20% in the LOQ). 
The recovery of the analytes from human plasma samples was calculated using three 
QC samples and the procedure described in the section II.3.4. The recoveries of the analytes 
(MDEA and AM) were calculated by comparing the analytes peak area from extracted 
samples against the corresponding areas obtained by direct injection of solutions at the same 
theoretical concentrations. The recovery of the IS was determined at the concentration 
used in sample analysis by calculating the peak area ratio of the IS in extracted samples and 
non-extracted solutions. 
Human plasma stability of AM and MDEA was assessed at low (QC1) and high (QC3) 
concentration levels, in replicate (n = 5), at room temperature for 4 h, at 4 ºC for 24 h, at 
−20 ºC for 30 days, and at −80 ºC for 30 days to simulate sample handling and storage time 
in the freezer before analysis. The stability of AM and MDEA was also studied at 4 ºC during 
24 h in the processed samples (post-preparative stability) to simulate the time that samples 
can be in the auto-sampler before analysis. The effect of three freeze-thaw cycles on the 
stability of the analytes (AM and MDEA) was also investigated in plasma at −20 ºC and 
−80 ºC. Aliquots of spiked plasma samples (QC1 and QC3) were stored at −20 ºC and at 
−80 ºC for 24 h, thawed unassisted at room temperature, and when completely thawed 
samples were refrozen for 24 h under the same conditions until completing the three cycles. 
Stability was assessed comparing the data of QC samples analysed before (reference 
samples) and after being exposed to the conditions for stability assessment (stability 
samples); a stability/reference samples ratio of 85-115% was accepted as stability criterion 
(n = 5). 
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II.3.6 METHOD APPLICATION TO THE ANALYSIS OF REAL PLASMA SAMPLES
To evaluate the validity of the proposed bioanalytical method and its high selectivity 
for clinical application a set of real plasma samples obtained from ten polymedicated adult 
patients (5 males and 5 females) admitted at the Coimbra University Hospital and having in 
common the treatment with AM (200 mg tablets administered per os at different dosing 
regimens: once a day, twice a day or five days a week) were analysed. The blood samples 
were taken at the morning (7 am) and the informed consent was obtained from each subject. 
The analysis of these samples also represents an important approach to re-assess the 
selectivity of the developed method. Indeed, the number of different drugs co-prescribed 
with AM ranged from 6 (ID2, ID3 and ID5) to 19 (ID10) considering individually the patients, 
and were sixty-two different active pharmaceutical ingredients taking simultaneously all 
patients into account (ID1-ID10) (Table II.1). 
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II.4. RESULTS 
II.4.1 METHOD VALIDATION
II.4.1.1 Selectivity
The analysis of blank human plasma samples showed no endogenous interferences at 
the retention times of the compounds of interest (IS, MDEA and AM). Typical 
chromatograms of the extracts obtained from blank and spiked human plasma samples are 
shown in Figure II.2. Likewise, none of the tested drugs commonly co-prescribed with AM 
were found to interfere at the retention times of the chromatographic peaks of IS, MDEA 
and AM (Table II.2). 
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Figure II.2 – Typical chromatograms of extracted human plasma samples obtained by the 
MEPS/HPLC method developed: blank plasma (A); plasma spiked with internal standard [IS; 
tamoxifen (TAM)] and the analytes [mono-N-desethylamiodarone (MDEA) and amiodarone 
(AM)] at concentrations of the limit of quantification (0.1 µg/mL) (B) and at concentrations 
of the upper limit of calibration range (10 µg/mL) (C). 
First liquid chromatographic method for the simultaneous determination of AM and MDEA in human plasma using MEPS as sample preparation procedure 
 
 
77 
Table II.2 – Retention times of some drugs potentially co-prescribed with amiodarone (AM) 
examined as possible exogenous interferences. 
Drugs RT (min) Drugs RT (min) 
Analgesics/Antipyretics  Antiepileptics (continuation)  
Acetylsalicylic acid 0.53 Carbamazepine 0.68 
Paracetamol 0.40 Phenytoin 0.66 
Nimesulide 1.43 Topiramate ND 
Antiarrhythmics  Phenobarbital 0.57 
Flecainide 0.52 Antihypertensives  
Bepridil 1.59 Propranolol 0.45 
Verapamil 0.57 Amiloride 0.34 
Diltiazem 0.49 Nifedipine 1.15 
Adenosine 0.32 Candesartan 8.28 
Anticoagulants  Antipsychotics  
Warfarin 1.40 Chlorpromazine 0.72 
Antidepressants  Haloperidol 0.57 
Fluoxetine 0.65 Droperidol 0.44 
Sertraline 0.72 Sedatives/Hypnotics  
Imipramine 0.77 Alprazolam 0.76 
Trazodone 0.42 Clobazam 1.06 
Maprotiline 0.61 Diazepam 1.46 
Antiepileptics  Zolpidem 0.42 
Lamotrigine 0.39 Promethazine 0.54 
RT, retention time; ND, not detected within 20 min after the chromatographic injection. 
 
II.4.1.2 Calibration curves, limits of quantification and limits of detection 
 
The calibration curves obtained in human plasma for MDEA and AM were linear (r2 ≥ 
0.9976) over the concentration range of 0.1-10 µg/mL. Due to the wide calibration range 
established, and in order to counteract the heteroscedasticity detected, the use of weighted 
linear regression analysis was required. The calibration curves were subjected to weighted 
linear regression analysis using 1/x2 as the weighting factor. Indeed, taking into account the 
plots and the sums of absolute percentage relative error as statistical criteria, the best-fit 
weighting factor for both compounds (AM and MDEA) was shown to be 1/x2 between the 
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weighting factors usually tested under heteroscedasticity conditions (1/√x, 1/x, 1/x2, 1/√y, 1/y 
and 1/y2). The weighted regression equations (n = 5) of the calibration curves were              
y = 0.000238x − 0.000325 (r2 = 0.9987) for MDEA and y = 0.000222x + 0.000356              
(r2 = 0.9976) for AM, where y represents the analyte/IS peak area ratio and x represents the 
plasma concentration. The LOQs of the method were set at 0.1 µg/mL for MDEA and AM, 
with good precision (CV ≤ 6.67%) and accuracy (bias ± 5.29%) (Table II.3). The LODs were 
established at 0.02 µg/mL for MDEA and AM.  
 
II.4.1.3 Precision and accuracy 
 
The data for intra and interday precision and accuracy obtained from QC plasma 
samples at three different concentration levels (QC1, QC2 and QC3) are shown in Table II.3. 
The intra and interday CV values did not exceed 5.16%, and the intra and interday bias 
values varied between −9.84 and 0.78%.  
 
Table II.3 – Precision (% CV) and accuracy (% bias) for the determination of mono-N-
desethylamiodarone (MDEA) and amiodarone (AM) in human plasma samples at the 
concentrations of the limit of quantification (*) and at the low (QC1), middle (QC2) and high 
(QC3) concentrations of the calibration ranges (n = 5). 
Analyte Cnominal (µg/mL)
 Precision (% CV) Accuracy (% bias) 
Interday    
MDEA 0.1* 2.34 4.73 
 0.3 5.16 −3.96 
 5 3.46 0.78 
 9 2.51 −0.09 
AM 0.1* 4.20 5.21 
 0.3 2.09 −9.84 
 5 2.55 −7.51 
 9 2.74 −6.01 
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Table II.3 – Precision (% CV) and accuracy (% bias) for the determination of mono-N-
desethylamiodarone (MDEA) and amiodarone (AM) in human plasma samples at the 
concentrations of the limit of quantification (*) and at the low (QC1), middle (QC2) and high 
(QC3) concentrations of the calibration ranges (n = 5) (cont.). 
Analyte Cnominal (µg/mL) Precision (% CV) Accuracy (% bias) 
Intraday 
MDEA 0.1* 3.39 5.21 
0.3 4.29 0.20 
5 0.94 −0.57 
9 1.06 −1.47 
AM 0.1* 6.67 5.29 
0.3 2.53 −4.26 
5 2.63 −7.53 
9 1.44 −6.73 
Cnominal, nominal concentration; CV, coefficient of variation. 
II.4.1.4 Recovery
The recovery of MDEA and AM from human plasma samples spiked at three different 
concentration levels (QC1, QC2 and QC3) was evaluated and the results are presented in 
Table II.4. The mean recoveries of MDEA and AM ranged from 64.7 to 68.2% and 58.6 to 
62.3% respectively, and showed low CV values. The mean recovery of the IS was 61.0%, with 
a CV of 9.51%. 
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Table II.4 – Recovery (%) of mono-N-desethylamiodarone (MDEA) and amiodarone (AM) 
from human plasma samples at the low (QC1), middle (QC2) and high (QC3) concentrations 
of the calibration ranges (n = 5). 
Analyte Cnominal (µg/mL) 
Recovery (%) 
Mean ± SD CV (%) 
MDEA 0.3 65.9 ± 5.38 8.17 
 5 64.7 ± 0.83 1.28 
 9 68.2 ± 1.50 2.19 
AM 0.3 59.7 ± 4.71 7.89 
 5 58.6 ± 2.12 3.62 
 9 62.3 ± 1.73 2.78 
Cnominal, nominal concentration; SD, standard deviation; CV, coefficient of variation. 
 
II.4.1.5 Stability 
 
The stability of MDEA and AM in human plasma was evaluated under different 
circumstances, simulating the handling and sample storage conditions likely to be 
encountered during the analytical process, by analysing low and high QC samples in replicate 
(n=5). The results of the stability assays showed that no significant loss was observed for AM 
and MDEA in human plasma at room temperature for 4 h, at 4 ºC for 24 h, and at −20 ºC 
and −80 ºC for 30 days. The analytes also demonstrated to be stable in processed plasma 
samples at 4 ºC during 24 h. The stability data for MDEA and AM evaluated after three 
freeze-thaw cycles at −20 ºC and −80 ºC indicated that the stability criteria previously 
established were not fulfilled only at −20 ºC for QC3. The stability data are shown in Table 
II.5. 
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Table II.5 – Stability (values in percentage) of mono-N-desethylamiodarone (MDEA) and 
amiodarone (AM) in unprocessed plasma samples at room temperature for 4 h, at 4 ºC for 
24 h, after three freeze-thaw cycles (−20 ºC and −80 ºC), and at -20 ºC and −80 ºC for 30 
days; and in processed plasma samples left at 4 ºC for 24 h (n = 5). 
Analyte MDEA  AM 
Cnominal (µg/mL) 0.3 9  0.3 9 
Unprocessed plasma      
Room temperature (4 h) 94.4 94.9  93.6 93.7 
4 ºC (24 h) 91.6 91.9  96.1 90.3 
Freeze-thaw (3 cycles; −20 ºC) 86.0 81.3  91.5 84.6 
Freeze-thaw (3 cycles; −80 ºC) 97.0 89.1  103.3 93.1 
−20 ºC (30 days) 97.7 96.4  103.0 101.5 
−80 ºC (30 days) 97.2 90.8  96.6 97.5 
Processed plasma      
4 ºC (24 h) 96.6 104.2  98.4 108.5 
Cnominal, nominal concentration. 
 
II.4.2 ANALYSIS OF REAL PLASMA SAMPLES 
 
The MEPS/HPLC method was applied to the analysis of MDEA and AM in plasma 
samples taken from ten polymedicated patients orally treated with AM and the 
concentrations obtained are summarized in Table II.6, as well as the prescribed AM 
regimens. In addition, a representative chromatogram (ID10) of the analyses of such real 
plasma samples is also depicted in Figure II.3. As one can see, no interference from human 
plasma endogenous compounds or the co-administered drugs is apparent, and it is also 
clearly seen that the peak shape of the analytes (IS, MDEA and AM) and chromatographic 
resolution are similar to those obtained after the analysis of spiked human plasma samples. 
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Table II.6 – Plasma concentrations of amiodarone (AM) and mono-N-desethylamiodarone 
(MDEA) in real plasma samples obtained from polymedicated patients taking AM orally (200 
mg tablets) at different prescribed regimens. All samples were collected at the morning (7 
am). 
Patients Prescribed regimen 
Cmeasured (µg/mL) 
AM MDEA 
ID1 200 mg tablet (bid) / (9 am; 9 pm) 0.333 0.165 
ID2 200 mg tablet (5 days a week) / (7 pm) 0.622 0.234 
ID3 200 mg tablet (id) / (9 am) BLQ BLQ 
ID4 200 mg tablet (id) / (9 am) 0.129 BLQ 
ID5 200 mg tablet (5 days a week) / (7 pm) 0.512 0.236 
ID6 200 mg tablet (id) / (9 am) 0.122 0.118 
ID7 200 mg tablet (id) / (9 am) 0.124 BLQ 
ID8 200 mg tablet (id) / (9 am) 0.858 0.624 
ID9 200 mg tablet (id) / (9 am) 0.664 0.408 
ID10 200 mg tablet (id) / (9 am) 0.560 0.644 
ID, individual; Cmeasured, measured concentration; bid, twice a day; id, once a day; BLQ, below the limit of 
quantification (< 0.1 µg/mL). 
 
 
Figure II.3 – Representative chromatogram of the analysis of real plasma samples obtained 
from polymedicated patients under treatment with amiodarone (AM). Specifically, this 
chromatogram was generated by the analysis of the sample collected from patient ID10, 
which was also the most polymedicated patient; the plasma concentrations of mono-N-
desethylamiodarone (MDEA) and AM measured in this sample were respectively 0.644 
µg/mL and 0.560 µg/mL. 
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II.5. DISCUSSION 
For the first time a simple, fast and reliable MEPS/HPLC method was developed and 
fully validated for the simultaneous determination of AM and its main metabolite (MDEA) in 
human plasma. The optimized MEPS procedure enabled the validation of the method for the 
quantitative analysis of AM and MDEA within a wide concentration range (0.1-10 µg/mL), 
which includes the therapeutic window usually proposed for AM (0.5-2.0 µg/mL), and 
provided an acceptable extraction recovery (~60%) for all compounds of interest [TAM (IS), 
MDEA and AM].  
The MEPS procedure developed presents several advantages in comparison with the 
sample preparation techniques usually used in bioanalysis. Firstly, the MEPS procedure does 
not require the evaporation and reconstitution steps of the sample usually needed in most of 
the LLE or SPE techniques. In addition, after the initial protein precipitation step, the MEPS 
procedure herein developed could be automatable by using the automated analytical syringe 
eVol® or connecting MEPS on-line with HPLC. MEPS also presents a cost per analysis 
minimal compared to conventional SPE because each MEPS sorbent can be re-used several 
times before being discarded while SPE cartridges are indicated for single use. MEPS also 
enables the reduction of the solvent volume consumption and the sample preparation time. 
On the other hand, a small volume of plasma (100 µL) is required in this case in comparison 
with many other methods published that use larger sample volumes (0.5-2 mL) (STOREY and
HOLT, 1982; PLOMP et al., 1983; GUPTA and CONNOLLY, 1984; MARCHISET et al., 1984; SHIPE, 
1984; HUTCHINGS, SPRAGG and ROUTLEDGE, 1986; SUSANTO, HUMFELD and REINAUER, 1986;  
LESNE and PELLEGRIN, 1987; DE SMET and MASSART, 1988; PACZKOWSKI et al., 1989; ROCHAS et 
al., 1989; VERBESSELT, TJANDRAMAGA and DE SCHEPPER 1991; GUMIENICZEK, MISZTAL and
PRZYBOROWSKI, 1994; KOLLROSER and SCHOBER, 2002; RAJENDRAN et al., 2006). In fact, our 
method presents a LOQ for AM and MDEA similar or even lower than other methods that 
employed a larger volume of plasma (PLOMP et al., 1983; GUPTA and CONNOLLY, 1984; SHIPE, 
1984; WEIR and UEDA, 1985; LESNE and PELLEGRIN, 1987; DE SMET and MASSART, 1988; 
GUMIENICZEK, MISZTAL and PRZYBOROWSKI, 1994; JUENKE et al., 2004). However, there are 
also methods reported in literature presenting lower LOQs for AM and MDEA but making 
use of more expensive and sensitive detection systems, such as tandem mass spectrometry 
(KOLLROSER and SCHOBER, 2002; KUHN, GOTTING and KLEESIEK, 2010), or using higher 
volumes of sample (STOREY and HOLT, 1982; MARCHISET et al., 1984; PACZKOWSKI et al., 
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1989; ROCHAS et al., 1989; VERBESSELT, TJANDRAMAGA and DE SCHEPPER, 1991; RAJENDRAN et 
al., 2006; BOLDERMAN, HERMANS and MAESSEN., 2009). 
In addition, this bioanalytical method enables the rapid analysis of AM and MDEA in 
human plasma samples (less than 5 min) using the usual detection system and the simplest 
chromatography conditions found in clinical units. In this method the IS selected was TAM 
which is commercially available; in contrast, other analytical methods for determination of 
AM and MDEA used as IS a compound that is no longer available L8040 (a brominated 
analogue of AM) (STOREY and HOLT, 1982; PLOMP et al., 1983; MARCHISET et al., 1984; SHIPE, 
1984; WEIR and UEDA, 1985; SUSANTO, HUMFELD and REINAUER, 1986; LESNE and PELLEGRIN, 
1987; DE SMET and MASSART, 1988; PACZKOWSKI et al., 1989; ROCHAS et al., 1989; VERBESSELT,
TJANDRAMAGA and DE SCHEPPER, 1991; JUENKE et al., 2004). 
This method was also successfully applied to real plasma samples of highly 
polymedicated patients receiving treatment with AM. From the analysis of the Table II.6 it is 
evident that in some patients the concentrations of AM are below the proposed therapeutic 
range (0.5-2.0 µg/mL) and in patient ID3 the AM plasma concentration was found to be 
below the limit of quantification (BLQ; < 0.1 µg/mL). These findings may be explained by the 
short time of treatment with AM, since the patients have initiated AM therapy in the hospital 
few days (2-10 days) before sample collection. Indeed, as AM and MDEA have a huge 
apparent volume of distribution, it is likely to find BLQ levels at the end of the dosing 
interval during the first days of AM therapy. On the other hand, these results expose the 
urgent need for routine TDM of AM plasma/serum concentrations as a guide to individualize 
dosing regimens, even during the first days/weeks of treatment. 
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III. A RAPID HPLC METHOD FOR THE SIMULTANEOUS DETERMINATION OF AMIODARONE 
AND ITS MAJOR METABOLITE IN RAT PLASMA AND TISSUES: A USEFUL TOOL FOR 
PHARMACOKINETIC STUDIES 
 
III.1. ABSTRACT 
 
A rapid and sensitive high-performance liquid chromatography (HPLC) method was 
developed and validated in rat plasma and tissue (heart, liver, kidney and lung) homogenates 
for the determination of amiodarone (AM) and its main metabolite (mono-N-
desethylamiodarone, MDEA), using tamoxifen as internal standard. Chromatographic 
separation was achieved within less than 5 min on a LiChroCART Purospher® Star C18 
column (55 mm × 4 mm, 3 µm). The mobile phase consisting of phosphate buffer (50 mM) 
with 0.1% formic acid (pH 3.1)/methanol/acetonitrile (45:5:50, v/v/v) was pumped 
isocratically at a flow-rate of 1.2 mL/min. The detection was conducted at 254 nm for all 
compounds. Calibration curves were linear (r2 ≥ 0.995) in the range of 0.1-15 µg/mL for AM 
and MDEA. The limits of quantification were established at 0.1 µg/mL for both analytes. The 
overall data of precision and accuracy were in accordance with international guidelines for 
bioanalytical method validation. AM and MDEA were extracted from rat matrices by a liquid-
liquid extraction procedure and the mean recovery ranged from 59.9% to 97.6%. This novel 
HPLC method enables the fast and reliable determination of AM and MDEA from several rat 
matrices (plasma, liver, kidneys, lungs and heart) and was successfully applied in a preliminary 
pharmacokinetic study. 
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III.2. INTRODUCTION 
 
Amiodarone (AM; Figure III.1), despite the well-known safety concerns ascribed to 
the drug itself or its major metabolite mono-N-desethylamiodarone (MDEA; Figure III.1), 
remains one of the most prescribed and efficacious antiarrhythmic agents (VASSALO and 
THROMAN, 2007; VAN HERENDAEL and DORIAN, 2010; FREEMANTLE et al., 2011). Therefore, in 
spite of the recent clinical introduction of a new antiarrhythmic drug structurally related to 
AM – dronedarone – AM is expected to continue to be a valuable agent of the limited 
armamentarium of antiarrhythmic drugs. Indeed, some concerns about the long-term safety 
of dronedarone still persist (FOOD AND DRUG ADMINISTRATION, 2011). 
 
Figure III.1 – Chemical structures of amiodarone (AM), mono-N-desethylamiodarone 
(MDEA) and tamoxifen (TAM) used as internal standard (IS). 
 
AM presents some unfavourable and very unusual properties from the 
pharmacokinetic viewpoint, which certainly determine the pharmacodynamic and 
toxicological profiles (FUKUCHI et al., 2009; VAN HERENDAEL and DORIAN, 2010). In humans, 
AM has shown an erratic gastrointestinal absorption and, consequently, a variable oral 
bioavailability (20-80%) (VAN HERENDAEL and DORIAN, 2010). Moreover, AM has a huge body 
tissue distribution and a correspondingly long elimination half-life (WOLKOVE and BALTZAN, 
2009). Additionally, AM has been recognised as a drug of narrow serum/plasma therapeutic 
range (0.5-2.0 µg/mL) (PÉREZ-RUIZ et al., 2002; SHAYEGANPOUR, HAMDY and BROCKS, 2008) 
and has also been associated to important clinical drug interactions (ROUGHEAD et al., 2010). 
AM has usually been considered the precipitant or interacting agent in the majority of 
pharmacokinetic-based interactions reported in literature, inducing a change (usually an 
increase) in serum/plasma levels of co-administered drugs [e.g. digoxin (TRUJILLO and NOLAN, 
2000), warfarin (TRUJILLO and NOLAN, 2000), phenytoin (LESKO, 1989), theophylline (TRUJILLO 
and NOLAN, 2000) and simvastatin (MAROT et al., 2011)]. Nevertheless, contrary to the 
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expectations, few studies have been published describing the interference of other 
compounds on the pharmacokinetics of AM; specifically, the metabolism of AM was 
dramatically inhibited by grapefruit juice (LIBERSA et al., 2000), the systemic exposure to AM 
and MDEA was significantly reduced by the simultaneous administration with orlistat (ZHI et 
al., 2003) and, more recently, the exposure of rats to β-naphthoflavone (a polycyclic 
aromatic hydrocarbon) was found to increase the formation of MDEA probably through 
cytochrome P450 (CYP) induction (ELSHERBINY, EL-KADI and BROCKS, 2010). Thus, it is 
urgent to investigate in more depth the potential for relevant drug interactions where AM is 
considered the target of interaction (object drug). 
Because rat species share many of the pharmacokinetics properties of AM with 
humans, the rat has been regarded as one of the best models among the small laboratory 
animals for studying pharmaco-toxicological aspects concerning AM; although some 
metabolic differences exist, it has also been demonstrated that MDEA is the principal 
metabolite of AM in both species (PLOMP et al., 1987; NAJJAR, 2001; ELSHERBINY and BROCKS, 
2010; ELSHERBINY, EL-KADI and BROCKS, 2010). Hence, the availability of a simple, fast and 
inexpensive bioanalytical method to enable the reliable quantification of AM and its 
pharmacologically active metabolite MDEA in the matrices of rat plasma and tissues is 
essential to support many non-clinical assays. 
Thus far, a few methods have been reported in literature for the simultaneous 
determination of AM and MDEA in rat plasma and tissues; in addition, the published 
methods require considerably long analysis times (AL-DHAWAILIE, 1995; JUN and BROCKS, 
2001; SHAYEGANPOUR and BROCKS, 2003) and present other limitations such as complex and 
expensive sample pre-treatment procedures (MOOR, WYSS and BICKEL, 1988) or the use of 
costly analytical instrumentation [liquid chromatography-mass spectrometry (LC-MS)] which 
are not available in all laboratories (SHAYEGANPOUR, SOMAYAJI and BROCKS, 2007). Thus, a 
new liquid chromatography assay was herein developed in order to minimize a lot of 
limitations of the previous existing methods. 
This work describes a high-performance liquid chromatography (HPLC) method 
which was developed and fully validated for the rapid and simultaneous quantification of AM 
and MDEA from samples of rat plasma and tissues (heart, liver, kidney and lung). Because the 
method requires small volumes of rat plasma, it is also a valuable tool for application in 
pharmacokinetic studies with AM in which multiple, serial blood sample collection is desired 
from individual rats. 
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III.3. EXPERIMENTAL 
 
III.3.1 CHEMICALS AND REAGENTS 
 
AM (lot no. 078K1246) was purchased from Sigma-Aldrich (St. Louis, MO, USA) and 
MDEA (lot no. LB33020) was kindly supplied by Sanofi-Aventis (Paris, France). Tamoxifen 
(TAM; lot no. 035K1270), as citrate salt, was obtained from Sigma-Aldrich (St Louis, MO, 
USA) and it was used as internal standard (IS). The chemical structures of these compounds 
are shown in Figure III.1. Methanol (HPLC gradient grade) and acetonitrile (HPLC gradient 
grade) were purchased from Merck KGaA (Darmstadt, Germany) and VWR International 
(Leuven, Belgium), respectively. Ultra-pure water (HPLC grade, > 18 MΩ; home-made) was 
prepared by means of a Milli-Q water apparatus from Millipore (Milford, MA, USA). All other 
reagents were of analytical grade: sodium phosphate monobasic purris. p.a. (Sigma-Aldrich 
GmbH; Seelze, Germany), sodium phosphate dibasic anhydrous (Sigma-Aldrich; St Louis, 
MO, USA), sodium dihydrogen phosphate dehydrate purum p.a. (Fluka Chemie; Buchs, 
Switzerland) and formic acid (98-100%) (BDH Chemicals; Poole, England). 
 
III.3.2 BLANK RAT PLASMA AND TISSUES 
 
Adult male Wistar rats, weighing 300-380 g, were obtained from local animal facilities 
(Faculty of Health Sciences of the University of Beira Interior). The rats were maintained 
under controlled environmental conditions (temperature 20±2 ºC; relative humidity 55±5%; 
12-h light/dark cycle). All animals were allowed free access to a standard diet (4RF21, 
Mucedola, Italy) and water ad libitum until the experimental procedures. Rats not subjected 
to other pharmacological treatments were previously anesthetized with an intraperitoneal 
(i.p.) injection of a mixture of ketamine (90 mg/kg)/xylazine (10 mg/kg), and then used as 
source of the blank plasma and tissue (heart, liver, kidney and lung) samples required in the 
validation studies. For that, blood samples were collected into heparinized tubes after 
decapitation of anesthetized rats. The plasma was separated by centrifugation at 4000 rpm 
for 10 min (4 ºC) and stored at –20 ºC until use. After exsanguination, liver, kidneys, heart 
and lungs were quickly removed, weighed and homogenized in distilled water (3 mL of water 
per gram of tissue); the tissue homogenates were also stored at –20 ºC until use. All animal 
experimentation was conducted in accordance with the European Directive (2010/63/EU) 
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for the accommodation and care of laboratory animals and the experimental procedures 
were approved by the Portuguese Veterinary General Division. 
III.3.3 STOCK SOLUTIONS, CALIBRATION STANDARDS AND QUALITY CONTROL SAMPLES
Stock solutions of AM, MDEA, and TAM (IS) at concentration of 1 mg/mL were 
individually prepared by dissolving appropriate amounts of each compound in methanol. The 
stock solutions of AM and MDEA were adequately diluted with methanol to give 
intermediate solutions at 100 µg/mL. Thereafter, stock and intermediate solutions were 
appropriately used to afford six combined spiking solutions at final concentrations of 0.75, 
1.5, 3.75, 11.25, 37.5 and 112.5 µg/mL for AM and MDEA which were used to spike aliquots 
of blank rat plasma (150 µL), and also six combined spiking solutions at final concentrations 
of 2, 4, 10, 30, 100 and 300 µg/mL were used to spike aliquots of blank tissue (heart, liver, 
kidney and lung) homogenates (400 µL). These procedures allowed the preparation of 
calibration standards in all considered matrices at six different concentration levels 0.1, 0.2, 
0.5, 1.5, 5 and 15 µg/mL for AM and MDEA. The stock solution of IS was daily diluted with 
water-methanol (60:40, v/v) in order to obtain a working solution at 50 µg/mL. All solutions 
were stored at 4 ºC and protected from light for one month, except the IS working solution 
which was prepared on each day of analysis. Quality control (QC) samples were prepared 
independently in the same biological matrices [rat plasma and tissue (heart, liver, kidney and 
lung) homogenates]. 
III.3.4 APPARATUS AND CHROMATOGRAPHIC CONDITIONS
The chromatographic analysis was performed using a Waters HPLC system Milford, 
MA, USA) equipped with an in-line solvent degasser (AF), a quaternary pump with controller 
(model 600), a manual injector (Rheodyne 7725i) and a diode array detector (DAD–2996). 
All instrumental parts were automatically controlled by Empower software supplied from 
Waters Corporation (Milford, MA, USA). 
The chromatographic separation of the two analytes (AM and MDEA) and IS was 
achieved in approximately 5 min, at room temperature, by isocratic elution with a mobile 
phase of phosphate buffer (50 mM) with 0.1% formic acid (pH 3.1)/methanol/acetonitrile 
Chapter III 
98 
(45:5:50, v/v/v) pumped at a flow-rate of 1.2 mL/min, on a reversed-phase column 
LiChroCART Purospher Star (C18; 55 mm x 4 mm; 3 µm particle size) purchased from 
Merck KGaA (Darmstadt, Germany). The mobile phase was filtered through a 0.45 µm filter 
and degassed ultrasonically for 15 min before use. The injection volume was 20 µL and the 
wavelength of 254 nm was selected for the detection of all compounds (AM, MDEA and IS). 
III.3.5 SAMPLE PREPARATION AND EXTRACTION
The sample pre-treatment was previously optimized and the final conditions were as 
follows. Each aliquot (150 µL) of rat plasma samples was diluted with 150 µL of 0.1 M 
sodium phosphate buffer (pH 5) and spiked with 20 µL of the IS working solution (50 
µg/mL). The mixture was added of 500 µL of n-hexane (used as liquid-liquid extraction 
solvent), vortex-mixed for 30 sec and centrifuged at 17000 rpm for 2 min at 4 ºC. The upper 
organic layer was transferred to a clean glass tube and the sample was re-extracted twice 
more with n-hexane (500 µL each time) using the conditions previously described. The 
whole organic extract was evaporated to dryness under a nitrogen stream at 60 ºC and the 
residue was reconstituted in 100 µL of methanol. Following this, an aliquot of the 
reconstituted extracts (20 µL) was injected into the HPLC system for analysis. 
For the extraction from tissues, each aliquot (400 µL) of tissue (heart, liver, kidney 
and lung) homogenates was spiked with 20 µL of the IS working solution (50 µg/mL); then, 
the mixture was added of 400 µL of acetonitrile (used as protein precipitating agent), 
vortex-mixed for 1 min and centrifuged at 17000 rpm for 10 min at 4 ºC in order to 
precipitate the protein content. The supernatant was transferred to a new propylene tube 
and 1 mL of n-hexane (used as liquid-liquid extraction solvent) was added. The mixture was 
vortex-mixed for 1 min and centrifuged at 17000 rpm for 5 min at 4 ºC. The upper organic 
layer (n-hexane) was transferred to a clean glass tube and the sample was re-extracted twice 
more with n-hexane (0.8 mL each time) using the same conditions. The organic extract was 
evaporated to dryness, reconstituted and then injected into the HPLC system using the same 
procedures as mentioned above for rat plasma samples. 
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III.3.6 METHOD VALIDATION 
 
The described method was validated according to the general recommendations 
published in the last few years concerning the bioanalytical method validation and acceptance 
criteria for validation parameters: selectivity, linearity, sensitivity, precision and accuracy, 
sample dilution, recovery and stability (SHAH et al., 2000; GUIDANCE FOR INDUSTRY, 2001; 
EUROPEAN MEDICINES AGENCY, 2011). 
Selectivity was evaluated by comparing the chromatograms generated after the 
analysis of blank samples (plasma and heart, liver, kidney and lung homogenates) obtained 
from six different rats with those achieved from the corresponding spiked samples in order 
to investigate the existence of potential chromatographic interferences from endogenous 
compounds (matrix effects) at the retention times of AM, MDEA and IS. Additionally, 
interferences from drugs (ketamine, xylazine and heparin) usually used in experimental 
protocols of pharmacokinetic studies were also tested by injecting standard solutions of 
these compounds. 
The linearity of the analytical method was assessed in the range of 0.1-15 µg/mL for 
AM and MDEA. For that, calibration curves were prepared on five different days (n = 5) 
using spiked plasma and tissue (heart, liver, kidney and lung) homogenate calibration 
standards at six different concentration levels. Calibration curves were constructed by 
plotting the peak-area ratios (analyte/IS) as a function of the respective concentrations. The 
data were subjected to a weighted linear regression analysis using 1/x2 as the weighting 
factor for both analytes (AM and MDEA); this weighting factor was selected because it 
yielded the best fit of peak-area ratios versus concentration (ALMEIDA, CASTEL-BRANCO and 
FALCÃO, 2002). The limit of quantification (LOQ) for AM and MDEA, defined as the lowest 
concentration on the calibration curve that can be measured with acceptable intra and 
interday precision and accuracy, was assessed respectively by the percentage of coefficient of 
variation (% CV) not exceeding 20% and the percentage of deviation from nominal value (% 
bias) within ±20%. The LOQ was evaluated by analysing spiked plasma and tissue (heart, 
liver, kidney and lung) homogenate samples which were prepared in five replicates (n = 5). 
The limit of detection (LOD) of the analytes (AM and MDEA) in plasma and tissue (heart, 
liver, kidney and lung) homogenates was defined as the concentration that yields a signal-to-
noise ratio of 3:1. 
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Intra and interday precision and accuracy were assessed by using QC samples 
analysed in replicate (n = 5) at three concentration levels (low, medium and high QC 
samples) representative of the calibration range; the concentrations tested were 0.3, 7.5 and 
13.5 µg/mL for AM and MDEA. The acceptance criterion for intra and interday precision 
(expressed as % CV) was a CV not exceeding 15% (or 20% in the LOQ) and for accuracy 
(expressed as % bias) was a bias value within ±15% (or ±20% in the LOQ). 
The dilution effect (1:4) was also investigated in plasma and tissue (heart, liver, kidney 
and lung) homogenates with appropriate QC samples at 25 µg/mL for AM and MDEA in 
order to ensure that samples exceeding the highest concentration (15 µg/mL) of the 
calibration range could be appropriately diluted with the respective blank matrix and, 
precisely and accurately quantified. The precision and accuracy of diluted samples were 
determined in both intra and interday assays (n = 5). 
The recovery of the analytes (MDEA and AM) from plasma and tissue (heart, liver, 
kidney and lung) homogenate samples, submitted to the previously described pre-treatment 
procedures, was determined using QC samples at three concentration levels (low, medium 
and high QC samples) and analysed in replicate (n = 5). The recovery of the analytes was 
calculated by comparing the analyte peak-area of extracted QC samples against equivalent 
aqueous solutions. The recovery of the IS was also evaluated at the concentration used in 
the analysis of plasma and tissue homogenate samples. 
The stability of AM and MDEA was assessed in all matrices (plasma and tissue 
homogenates), at low (QC1) and high (QC3) concentration levels, during 4 h at room 
temperature, 24 h at 4 ºC, 30 days at –20 ºC and –80 ºC to simulate sample handling and 
storage time in the freezer before analysis (n = 5). Stability of the analytes (AM and MDEA) 
was also studied at 4 ºC during 24 h in the processed samples (post-preparative stability in 
methanol) to reproduce the time that samples can be in the auto-sampler before analysis. 
Finally, the stability of AM and MDEA was also evaluated after three freeze-thaw cycles at    
–20 ºC and –80 ºC. Aliquots of spiked samples (QC1 and QC3) were stored at –20 ºC and at 
–80 ºC for 24 h, thawed unassisted at room temperature, and when completely thawed 
samples were refrozen for 24 h under the same conditions until three cycles were 
completed. Stability was assessed comparing the data of QC samples analysed before 
(reference samples) and after being exposed to the conditions for stability assessment 
(stability samples); a stability/reference samples ratio of 85-115% was accepted as stability 
criterion (n = 5). 
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III.3.7 METHOD APPLICATION AND PHARMACOKINETIC ANALYSIS 
 
Following the oral administration of a single dose of AM to Wistar rats (300-380 g), 
the analytical method was applied to investigate the plasma pharmacokinetic profiles of AM 
and its major metabolite (MDEA), as well as AM and MDEA concentrations presented in the 
tissues (heart, liver, kidney and lung) at the end of the experiments (24 h post-dose). On the 
day before the pharmacokinetic study, a lateral tail vein of each rat (n = 5) was cannulated, 
under anaesthesia [ketamine (90 mg/kg)/xylazine (10 mg/kg); i.p. injection], by insertion of an 
Introcan® Certo IV indwelling cannula (22G; 0.9 x 2.5 mm) made of polyurethane (B. Braun 
Melsungen AG, Melsungen, Germany). The rats fully recovered from anaesthesia and were 
fasted overnight with free access to water. The day after, rats received 50 mg/kg of AM 
administered by oral gavage; the solution of AM (12.5 mg/mL) administered to the rats was 
extemporaneously prepared from a commercial injectable solution of AM (50 mg/mL), which 
was appropriately diluted with 5% dextrose solution. After the administration of AM, 
multiple serial blood samples (~0.3 mL) were collected into heparinized tubes at pre-
specified post-dose time points (0.25, 0.5, 1, 2, 4, 6, 8 and 12 h) through the catheter 
previously introduced in lateral tail vein of rats. In addition, at 24 h post-dose, under 
anaesthesia, blood and tissue (heart, liver, kidney and lung) samples were also harvested after 
decapitation of rats. The blood and tissue samples were immediately processed as indicated 
in the section III.3.2. The plasma and tissue homogenates obtained were frozen at –20 °C 
until analysis. All these animal experiments were conducted in accordance with the 
European Directive (2010/63/EU) for the accommodation and care of laboratory animals and 
the experimental procedures were approved by the Portuguese Veterinary General Division. 
The plasma concentration-time profiles obtained for AM and MDEA were submitted 
to a non-compartmental pharmacokinetic analysis using the WinNonlin® version 4.1 
(Pharsight Co, Mountain View, CA, USA). The peak concentrations of AM and MDEA in 
plasma (Cmax) and the time to reach Cmax (tmax) were obtained directly from the experimental 
data. Other pharmacokinetic parameters were estimated from the plasma concentration 
data obtained at each time point (0.25, 0.5, 1, 2, 4, 6, 8, 12 and 24 h): area under the 
concentration-time curve (AUC) from time zero to the last sampling time at which 
concentrations were at or above the LOQ of the method (AUC0-t), calculated by the linear 
trapezoidal rule; AUC from time zero to infinite (AUC0-∞), calculated from                   
AUC0-t + (Clast/kel), where Clast is the last quantifiable concentration and kel is the apparent 
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terminal elimination rate constant calculated by log-linear regression of the terminal segment 
of the concentration-time profile; apparent terminal elimination half-life (t1/2) and mean 
residence time (MRT). The plasma concentrations of AM and MDEA lower than the LOQ of 
the assay were taken as zero for all calculations. 
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III.4. RESULTS 
 
III.4.1 METHOD DEVELOPMENT 
 
Once identified from the literature the scarcity of bioanalytical methods available for 
the analysis of AM and its main metabolite (MDEA) in rat plasma and tissues, as well as their 
major analytical drawbacks, the development of the method herein described was conducted 
aiming to overcome as much as possible the current analytical limitations. To achieve 
satisfactory chromatographic separation associated with short chromatographic running 
times, a short reversed-phase LiChroCART® Purospher Star-C18 column (55 mm x 4 mm; 3 
µm particle size) was selected. In addition, the outstanding robustness and excellent pH-
stability indicated by the manufacturer, enabling the development of methods across a wide 
pH range (1.5-10.5) were characteristics considered in the column selection. Then, to 
optimize the best chromatographic conditions to separate the analytes (MDEA and AM) in 
the column, individual and combined solutions of the compounds were directly injected into 
HPLC system and several mobile phases were tested using a standard flow rate (1 mL/min); 
at the beginning, the focus was the chromatographic resolution of AM and MDEA. First, the 
absence of buffer and salt in the mobile phase was considered aiming to reduce the pressure 
and prolong the column lifetime, avoiding the formation of precipitates due to the limited 
solubility of salts in organic modifiers. Thus, considering the information available in 
literature and aiming to minimize the run time while maintaining a good chromatographic 
resolution between adjacent peaks, different mobile phases were tested consisting of only 
water and acetonitrile as organic modifier. However, an adequate chromatographic 
resolution between MDEA and AM and peak symmetry was achieved only after changing the 
aqueous portion of the mobile phase to 50 mM phosphate buffer with a pH value near to 3 
adjusted with formic acid. After that, the next step was the introduction of an IS (TAM); 
TAM was the compound selected to be used as IS because it is structurally related to 
analytes (AM and MDEA) and is commercially available; TAM showed a shorter retention 
time than the analytes by isocratic elution with a mobile phase of phosphate buffer (50 mM) 
with 0.1% formic acid (pH 3.1)/acetonitrile (50:50, v/v), but an overlap of TAM and MDEA 
chromatographic peaks was observed to an extent that prevented the individual peak 
integration. Trying to reach the complete chromatographic separation of the TAM and 
MDEA, a second organic modifier (methanol in a percentage of 5%) was included in the 
Chapter III 
  
 
104 
composition of the mobile phase. A mobile phase composed by phosphate buffer (50 mM) 
with 0.1% formic acid (pH 3.1)/methanol/acetonitrile (45:5:50, v/v/v) allowed the complete 
resolution of the three compounds (TAM, MDEA and AM). The flow rate was then set at 1.2 
mL/min (isocratic conditions) and all the compounds eluted in a short running time of 
approximately 5 min.  
In addition to the optimization of the chromatographic conditions for the separation 
and detection of the IS and analytes (MDEA and AM) after use of standard solutions, the 
development of an analytical method to quantify drugs or metabolites in biological samples 
also requires the development of a suitable sample extraction procedure. In fact, sample pre-
treatment is a vital step in bioanalysis, enabling the removal of proteins that can precipitate 
on the chromatographic column or eliminate potential matrix interferences. In this case, 
before selecting a liquid-liquid extraction (LLE) procedure to extract the analytes from rat 
plasma samples, other simpler and faster sample preparation approaches were tested, 
particularly the precipitation of proteins with methanol and acetonitrile; however, in these 
conditions, several peaks of endogenous substances appeared at the retention times of the 
compounds of interest (lacking selectivity). Afterward, to develop a simple and inexpensive 
analytical method, LLE procedures using low solvent volumes were considered instead of 
solid-phase extraction (SPE). Accordingly, several organic solvents (chloroform, 
dichloromethane, diethyl ether, ethyl acetate and n-hexane) were tested in order to 
optimize the selectivity and recovery. The organic solvent that allowed the best selectivity 
was n-hexane, and a good recovery was obtained by multiple (three) LLE steps using small 
volumes of solvent. Finally, the LLE procedure established for the preparation of rat plasma 
samples was selected, as previously described (section III.3.5). Because rat tissue (heart, liver, 
kidney and lung) samples are more complex than those of plasma, this makes the analysis of 
drugs or metabolites in such biological matrices more difficult and additional steps of sample 
preparation are usually required. Thus, to determine AM and MDEA concentrations in rat 
tissue samples, tissue homogenization was selected as the first step of tissue sample 
preparation. As for tissue homogenate samples the application of isolated procedures of 
protein precipitation or LLE did not provide enough chromatographic selectivity, the 
subsequent strategy consisted of a protein precipitation step followed by LLE procedures. 
Acceptable selectivity and recovery was achieved by protein precipitation with acetonitrile 
followed by LLE with n-hexane using the previously mentioned conditions (section III.3.5). 
Once available, an HPLC system coupled to a diode array detector (DAD) was used and the 
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maximum absorbance wavelengths of the analytes were investigated, presenting maximum 
absorbance at 240 nm for MDEA and AM, and at this wavelength the absorption of the IS 
was also near the maximum. However, to improve the selectivity of the analytical assay 
against the endogenous interferences of rat matrices, the wavelength selected was 254 nm 
instead of 240 nm. 
 
III.4.2 METHOD VALIDATION 
 
Selective extraction and chromatographic resolution of the compounds of interest 
(IS, MDEA and AM) from spiked rat plasma and tissue (heart, liver, kidney and lung) 
homogenate samples were successfully attained using the previously described sample 
preparation procedures and chromatographic conditions. Typical chromatograms obtained 
after analysis of the extracts of blank and spiked rat plasma and tissue homogenate samples 
are shown in Figure III.2. The chromatograms demonstrated that, in all blank rat matrices 
(plasma and heart, liver, kidney and lung tissue homogenates) no endogenous compounds 
interfered at the retention times of the IS and analytes (MDEA and AM). In addition, none of 
the tested drugs (ketamine, xylazine and heparin) frequently used in experimental protocols 
of pharmacokinetic studies were found to interfere at the retention times of the 
chromatographic peaks of IS, MDEA and AM. 
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Figure III.2 – Typical chromatograms of extracted rat samples: blank plasma (A); plasma 
spiked with mono-N-desethylamiodarone (MDEA) and amiodarone (AM) at 0.5 µg/mL (B); 
blank heart tissue homogenate (C); heart tissue homogenate spiked with MDEA and AM at 
0.5 µg/mL (D). As shown for heart tissue homogenate, similar chromatographic behaviour 
was obtained for corresponding samples of liver, kidney and lung tissue homogenates. 
The linearity of the analytical method in the calibration range of 0.1-15 µg/mL was 
demonstrated for both compounds (AM and MDEA) in all rat matrices (plasma, and heart, 
A rapid HPLC method for the simultaneous determination of AM and its major metabolite in rat plasma and tissues: a useful tool for pharmacokinetic studies 
 
 
107 
liver, kidney and lung tissue homogenates; r2 ≥ 0.995). The calibration curves were subjected 
to weighted linear regression analysis and the corresponding parameters are summarized in 
Table III.1. Under the experimental conditions described, the LOQ of the assay was set at 
0.1 µg/mL for AM and MDEA in all rat matrices investigated with acceptable precision and 
accuracy as shown in Table III.2. The LOD of the analytes (AM and MDEA) was established 
at 0.02 µg/mL in plasma and at 0.01 µg/mL in tissue (heart, liver, kidney and lung) 
homogenates. 
 
Table III.1 – Calibration curve parameters for mono-N-desethylamiodarone (MDEA) and 
amiodarone (AM) in rat matrices (plasma, and heart, liver, kidney and lung homogenates)        
(n = 5).a 
Matrix/Analyte Calibration standards (µg/mL) Slope (b) Intercept (a)  r2 
Plasma     
MDEA 0.1, 0.2, 0.5, 1.5, 5, 15 0.1394 –0.0019 0.998 
AM 0.1, 0.2, 0.5, 1.5, 5, 15 0.1654 –0.0017 0.999 
Heart homogenate    
MDEA 0.1, 0.2, 0.5, 1.5, 5, 15 0.3346 0.0028 0.999 
AM 0.1, 0.2, 0.5, 1.5, 5, 15 0.3645 0.0016 0.999 
Liver homogenate    
MDEA 0.1, 0.2, 0.5, 1.5, 5, 15 0.3542 0.0034 0.998 
AM 0.1, 0.2, 0.5, 1.5, 5, 15 0.3598 –0.0057 0.995 
Kidney homogenate    
MDEA 0.1, 0.2, 0.5, 1.5, 5, 15 0.3169 –0.0072 0.999 
AM 0.1, 0.2, 0.5, 1.5, 5, 15 0.3443 –0.0059 0.998 
Lung homogenate    
MDEA 0.1, 0.2, 0.5, 1.5, 5, 15 0.3823 –0.0049 0.998 
AM 0.1, 0.2, 0.5, 1.5, 5, 15 0.3783 –0.0092 0.998 
a Equation of the calibration curve: y = bx + a, where x is the analyte concentration, expressed in µg/mL, and y 
is the analyte to IS peak area ratio, expressed in arbitrary area units; r2, regression coefficient. 
 
The intra and interday precision and accuracy data of the assay using low, medium 
and high QC samples for plasma and tissue (heart, liver, kidney and lung) homogenates are 
shown in Table III.2. The overall intra and interday imprecision (% CV) not exceed 6.56% 
and the inaccuracy (% bias) was within ±7.94%. These data are in compliance with the 
international guidelines for the validation of bioanalytical methods. Therefore, the method is 
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precise and accurate for determination of AM and MDEA in rat plasma, and heart, liver, 
kidney and lung homogenate samples. The precision and accuracy was also demonstrated for 
the sample dilution (1:3) of plasma and tissue (heart, liver, kidney and lung) homogenates 
(Table III.2). These results show that a four-fold dilution with the corresponding blank rat 
matrices can be appropriately applied if the concentration of the analytes (AM and MDEA) in 
an assayed sample exceeds the highest concentration level of the calibration curve (15 
µg/mL).  
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The recovery values of AM and MDEA from rat matrices (plasma, and heart, liver, 
kidney and lung homogenates) are presented in Table III.3. The mean recoveries, taking AM 
and its major metabolite (MDEA) into account, ranged from 59.9% to 97.6%, and showed 
low CV values. The recovery of the IS from all rat matrices considered showed mean values 
between 72.6% and 91.7%, with CV values not exceeding 4.56%. 
Table III.3 – Recovery (%) of mono-N-desethylamiodarone (MDEA) and amiodarone (AM) 
from rat matrices (plasma, and heart, liver, kidney and lung homogenates) at low (QC1), 
middle (QC2) and high (QC3) concentrations of the calibration ranges (n = 5). 
Matrix/Analyte Cnominal (µg/mL) 
Recovery (%) 
Mean ± SD (n = 5) CV (%) 
Plasma 
MDEA 0.3 61.0 ± 4.23 6.93 
7.5 74.7 ± 0.70 0.94 
13.5 78.3 ± 2.20 2.81 
AM 0.3 88.7 ± 3.90 4.39 
7.5 96.9 ± 2.11 2.18 
13.5 97.6 ± 2.52 2.58 
Heart homogenate 
MDEA 0.3 59.9 ± 3.26 5.45 
7.5 71.0 ± 3.23 4.54 
13.5 77.0 ± 1.60 2.08 
AM 0.3 76.7 ± 0.47 0.61 
7.5 85.3 ± 3.20 3.76 
13.5 90.4 ± 2.20 2.43 
Liver homogenate 
MDEA 0.3 62.2 ± 3.42 5.50 
7.5 61.5 ± 1.37 2.22 
13.5 64.6 ± 3.93 6.09 
AM 0.3 63.4 ± 6.31 9.95 
7.5 75.6 ± 1.67 2.22 
13.5 79.3 ± 4.61 5.82 
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Table III.3 – Recovery (%) of mono-N-desethylamiodarone (MDEA) and amiodarone (AM) 
from rat matrices (plasma, and heart, liver, kidney and lung homogenates) at low (QC1), 
middle (QC2) and high (QC3) concentrations of the calibration ranges (n = 5) (cont.). 
Matrix/Analyte Cnominal (µg/mL) 
Recovery (%) 
Mean ± SD (n = 5) CV (%) 
Kidney homogenate   
MDEA 0.3 61.6 ± 3.62 5.88 
 7.5 72.0 ± 1.68 2.33 
 13.5 70.0 ± 1.89 2.70 
AM 0.3 73.7 ± 2.53 3.44 
 7.5 84.4 ± 1.81 2.15 
 13.5 83.0 ± 2.67 3.22 
Lung homogenate   
MDEA 0.3 79.8 ± 3.40 4.26 
 7.5 83.6 ± 0.78 0.93 
 13.5 83.8 ± 1.83 2.18 
AM 0.3 81.8 ± 4.85 5.93 
 7.5 87.2 ± 0.94 1.08 
 13.5 86.6 ± 1.65 1.91 
Cnominal, nominal concentration ; SD, standard deviation.  
 
From the stability data obtained in rat plasma and tissue (heart, liver, kidney and lung) 
homogenates no significant loss was observed for AM and MDEA when spiked QC samples 
(QC1 and QC3) were stored at room temperature for 4 h, at 4 ºC for 24 h, and at –20 ºC 
and –80 ºC for 30 days. The analytes (AM and MDEA) also demonstrated to be stable after 
three freeze-thaw cycles at –20 ºC and –80 ºC; in addition, no significant degradation 
occurred in processed samples (methanol extract) stored at 4 ºC for 24 h. Stability data are 
summarized in Table III.4. 
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Table III.4 – Stability (values in percentage) of mono-N-desethylamiodarone (MDEA) and 
amiodarone (AM) in unprocessed rat matrices (plasma, and heart, liver, kidney and lung 
homogenates) at room temperature for 4 h, at 4 ºC for 24 h, after three freeze-thaw cycles        
(–20 ºC and –80 ºC) and at –20 ºC and –80 ºC for 30 days; and in processed rat matrices 
(plasma, and heart, liver, kidney and lung homogenates) left at 4 ºC for 24 h (n = 5). 
Analyte MDEA  AM 
Cnominal (µg/mL) 0.3 13.5  0.3 13.5 
Unprocessed Plasma      
Room temperature (4 h) 100.7 97.0  104.6 95.4 
4 ºC (24 h) 101.8 94.6  102.6 95.2 
Freeze-thaw (3 cycles; –20 ºC) 104.7 94.7  103.6 96.5 
Freeze-thaw (3 cycles; –80 ºC) 101.5 109.3  104.3 111.8 
–20 ºC (30 days) 92.5 92.6  98.8 91.1 
–80 ºC (30 days) 89.5 93.3  94.0 97.0 
Processed Plasma      
4 ºC (24 h) 110.9 104.7  111.0 102.6 
Unprocessed heart homogenate     
Room temperature (4 h) 104.5 103.5  105.1 103.4 
4 ºC (24 h) 102.6 97.4  100.5 97.1 
Freeze-thaw (3 cycles; –20 ºC) 100.9 89.3  106.2 101.5 
Freeze-thaw (3 cycles; –80 ºC) 101.3 96.2  101.3 95.2 
–20 ºC (30 days) 95.3 91.2  111.5 89.7 
–80 ºC (30 days) 92.4 91.1  107.1 89.0 
Processed heart homogenate      
4 ºC (24 h) 104.3 95.8  104.1 96.3 
Unprocessed liver homogenate     
Room temperature (4 h) 99.2 106.6  100.6 104.9 
4 ºC (24 h) 99.5 98.9  103.1 100.3 
Freeze-thaw (3 cycles; –20 ºC) 110.6 110.9  94.5 111.6 
Freeze-thaw (3 cycles; –80 ºC) 113.1 107.9  98.6 89.5 
–20 ºC (30 days) 103.2 101.9  93.0 102.3 
–80 ºC (30 days) 108.3 97.6  98.3 98.9 
Processed liver homogenate      
4 ºC (24 h) 107.4 108.2  103.0 107.6 
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Table III.4 – Stability (values in percentage) of mono-N-desethylamiodarone (MDEA) and 
amiodarone (AM) in unprocessed rat matrices (plasma, and heart, liver, kidney and lung 
homogenates) at room temperature for 4 h, at 4 ºC for 24 h, after three freeze-thaw cycles        
(–20 ºC and –80 ºC) and at –20 ºC and –80 ºC for 30 days; and in processed rat matrices 
(plasma, and heart, liver, kidney and lung homogenates) left at 4 ºC for 24 h (n = 5) (cont.). 
Analyte MDEA  AM 
Cnominal (µg/mL) 0.3 13.5  0.3 13.5 
Unprocessed kidney homogenate     
Room temperature (4 h) 96.6 96.1  98.6 97.0 
4 ºC (24 h) 96.7 93.8  93.7 94.1 
Freeze-thaw (3 cycles; –20 ºC) 95.3 91.7  86.2 93.2 
Freeze-thaw (3 cycles; –80 ºC) 96.2 90.7  86.3 93.9 
–20 ºC (30 days) 94.3 92.5  86.4 90.5 
–80 ºC (30 days) 99.9 92.8  89.6 91.8 
Processed kidney homogenate     
4 ºC (24 h) 105.2 99.0  90.4 96.5 
Unprocessed lung homogenate     
Room temperature (4 h) 95.9 96.5  100.6 97.9 
4 ºC (24 h) 97.8 94.5  102.8 94.0 
Freeze-thaw (3 cycles; –20 ºC) 110.6 99.7  110.2 96.7 
Freeze-thaw (3 cycles; –80 ºC) 110.0 101.2  107.9 99.9 
–20 ºC (30 days) 86.3 94.5  90.2 85.4 
–80 ºC (30 days) 93.3 92.2  95.6 89.1 
Processed lung homogenate      
4 ºC (24 h) 110.8 101.8  108.7 101.3 
Cnominal, nominal concentration. 
 
III.4.3 METHOD APPLICATION AND PHARMACOKINETIC STUDY 
 
The HPLC method was successfully applied to the analysis of MDEA and AM in serial 
plasma samples taken over a period of time of 24 h from Wistar rats (n = 5) administered 
with a single oral dose of AM (50 mg/kg). The blood sample collection performed at 24 h 
post-dose involved a terminal procedure, and then, heart, liver, kidney and lung tissues were 
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excised after exsanguinations, allowing also the application of the method to the 
determination of AM and MDEA concentrations in rat tissue samples. 
The plasma concentration-time profiles obtained for AM and MDEA from each rat 
are depicted in Figure III.3. In Figure III.4 are also shown the corresponding mean plasma 
concentration-time profiles (n = 5) and the most significant pharmacokinetic parameters of 
AM and MDEA estimated by non-compartmental analysis are summarized in Table III.5. The 
concentrations of AM and MDEA measured in tissue (heart, liver, kidney and lung) and 
plasma samples at 24 h post-dose are shown in Table III.6. 
 
Figure III.3 – Individual plasma concentration-time profiles of amiodarone (AM) and mono-
N-desethylamiodarone (MDEA), over a period of 24 h, obtained from rats treated with a 
single dose of 50 mg/kg AM administered by oral gavage (n = 5).  
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Figure III.4 – Mean plasma concentration-time profiles of amiodarone (AM) and mono-N-
desethylamiodarone (MDEA), over a period of 24 h, obtained from rats treated with a single 
dose of 50 mg/kg AM administered by oral gavage. Symbols represent the mean values ± 
standard error of the mean (SEM) of five determinations per time point (n = 5). 
 
Table III.5 – Pharmacokinetic parameters estimated by non-compartmental analysis of the 
mean plasma concentration-time profiles of amiodarone (AM) and mono-N-
desethylamiodarone (MDEA) in rats after a single oral dose of 50 mg/kg of AM.  
Pharmacokinetic parametersa AM MDEA 
Plasma   
tmax (h) 1.0 8.0 
Cmax (µg/mL) 1.183 0.097 
AUC0-t (µg.h/mL) 12.868 1.129 
AUC0-∞ (µg.h/mL) 19.484 1.342 
t1/2el (h) 16.1 7.4 
MRT (h) 22.1 14.1 
aCmax and tmax are experimental values; AUC0-t, AUC0-∞, t1/2el and MRT values were calculated by non-
compartmental analysis from mean concentrations at each time point (n = 5). 
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Table III.6 – Plasma and tissue (heart, liver, kidney and lung) concentrations of amiodarone 
(AM) and mono-N-desethylamiodarone (MDEA) at 24 h post-dose in rats after a single oral 
dose of 50 mg/kg of AM (n = 5). 
Matrix/Concentration (24 h) AM MDEA 
Plasma (µg/mL)   
Rat 1 0.305 0.000 
Rat 2 0.306 0.102 
Rat 3 0.280 0.000 
Rat 4 0.250 0.000 
Rat 5 0.283 0.000 
Mean 0.285 0.020 
SD 0.0229 0.0456 
Heart tissue (µg/g)   
Rat 1 4.342 1.870 
Rat 2 4.795 2.134 
Rat 3 4.105 1.541 
Rat 4 4.071 1.598 
Rat 5 4.273 2.144 
Mean 4.317 1.857 
SD 0.2903 0.2854 
Liver tissue (µg/g)   
Rat 1 6.812 2.235 
Rat 2 7.492 2.582 
Rat 3 5.952 1.880 
Rat 4 6.565 1.852 
Rat 5 6.536 2.383 
Mean 6.671 2.186 
SD 0.5568 0.3176 
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Table III.6 – Plasma and tissue (heart, liver, kidney and lung) concentrations of amiodarone 
(AM) and mono-N-desethylamiodarone (MDEA) at 24 h post-dose in rats after a single oral 
dose of 50 mg/kg of AM (n = 5) (cont). 
Matrix/Concentration (24 h) AM MDEA 
Kidney tissue (µg/g)   
Rat 1 8.562 4.912 
Rat 2 8.990 5.107 
Rat 3 7.436 3.876 
Rat 4 6.541 3.413 
Rat 5 8.221 5.449 
Mean 7.950 4.551 
SD 0.9721 0.8654 
Lung tissue (µg/g)   
Rat 1 32.686 22.618 
Rat 2 33.544 24.839 
Rat 3 26.987 16.980 
Rat 4 33.598 21.306 
Rat 5 31.591 24.410 
Mean 31.681 22.031 
SD 2.7477 3.1596 
SD, Standard deviation. 
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III.5. DISCUSSION 
 
The HPLC method herein described presents important bioanalytical improvements 
over the few assays previously published for the quantification of AM and MDEA in rat 
plasma and tissue samples (MOOR, WYSS and BICKEL, 1988; AL-DHAWAILIE, 1995; JUN and 
BROCKS, 2001; SHAYEGANPOUR, SOMAYAJI and BROCKS, 2007) and the method was successfully 
applied to a preliminary pharmacokinetic study. The analytical method was fully validated in 
rat plasma and heart, liver, kidney and lung tissue homogenates, enabling the fast 
chromatographic analysis of AM and MDEA in such biological samples (in approximately 5 
min) using simple instrumentation and uncomplicated chromatographic conditions (isocratic 
elution and detection in UV spectral region); these aspects suggest that the method is 
appropriate for implementation in almost all laboratories, and fast bioanalytical assays are 
essential whenever a large number of samples have to be analysed. At this point, the full 
validation performed in all rat tissue matrices considered (heart, liver, kidney and lung) may 
not be necessary. Indeed, taking into account the general recommendations published in last 
few years concerning bioanalytical method validation, a partial validation could be acceptable 
for different matrices within a species (SHAH et al., 2000; GUIDANCE FOR INDUSTRY, 2001; 
EUROPEAN MEDICINES AGENCY, 2011). However, for the reliable application of this method to 
pharmacokinetic assays, the validation parameters selectivity, intraday precision and 
accuracy, and stability should be evaluated in any case in all intended biological matrices. 
Therefore, since the bioanalytical method was under development and implementation for 
the first time, a full validation was always considered to ensure greater confidence in the 
data. 
In this method, the plasma sample preparation only involves LLE, and for tissue 
sample preparation, an additional step of protein precipitation is employed. These 
procedures are significantly less expensive than those of the method developed by MOOR, 
WYSS and BICKEL (1988) which combines protein precipitation and SPE for both plasma and 
tissue samples. Despite the method described by MOOR, WYSS and BICKEL (1988) appears to 
be more sensitive for plasma (0.03 µg/mL as LOQ) than the method herein reported (0.1 
µg/mL as LOQ), it is necessary to take into account that the plasma sample volume used for 
analysis is higher in the first (500 µL versus 150 µL). This aspect is determinant when serial 
blood sample collection in survival, non-terminal pharmacokinetic studies is required; indeed, 
500 µL plasma sample volume is too large, compromising an experimental design involving 
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serial blood sample collection. AL-DHAWAILIE (1995) reported a method in which an 
appropriate volume of plasma to perform pharmacokinetic studies (100 µL) was used, but it 
was validated exclusively for the determination of AM, disregarding the main 
pharmacologically and toxicologically active metabolite (MDEA), and also presented as 
disadvantage a time-consuming chromatographic analysis (~14 min). JUN and BROCKS (2001) 
also developed and validated a method requiring small volumes of rat plasma (100 µL), but 
exclusively for the determination of AM. This method was improved some years later by 
SHAYEGANPOUR and BROCKS (2003) introducing also the metabolite (MDEA); however, the 
primary drawback was not overcome, because long chromatographic analysis times 
remained (~14 min). More recently, SHAYEGANPOUR, SOMAYAJI and BROCKS (2007) developed 
another method for AM and MDEA in rat plasma and tissues using an LC-MS assay, which 
required more expensive instrumentation that may not be available in all labs. In addition, in 
the method developed by SHAYEGANPOUR, SOMAYAJI and BROCKS (2007) the volume of n-
hexane required for LLE was approximately double that used in this method. 
As demonstrated in this work, the present method is a useful tool to support rat 
pharmacokinetic-based studies with AM, making it possible to characterize AM and MDEA 
plasma pharmacokinetic profiles in each rat. As expected, AM has shown an erratic and 
variable absorption from rat gastrointestinal tract (Figure III.3). In agreement with 
SHAYEGANPOUR, SOMAYAJI and BROCKS (2007), this preliminary pharmacokinetic study also 
showed that systemic exposure to MDEA (major metabolite) is much lower than that to 
AM, even following oral administration of the parent compound. Bearing in mind the plasma 
and tissue (heart, liver, kidney and lung) concentration data measured at 24 h post-dose 
(Table III.6), it was evident that higher concentrations of AM and MDEA were found in 
tissues than in plasma, supporting their greater plasma-tissue distribution. Additionally, these 
findings also support the extensive accumulation of AM and MDEA in rat lung tissue, which 
may explain why pulmonary toxicity is one of the most serious toxic effects associated with 
AM treatment. Indeed, the highest concentrations of AM and MDEA were observed in the 
rat lung and, at this level, the huge MDEA concentrations determined in lung tissue (more 
than 1000-fold) comparatively to those found in plasma. The results of this pharmacokinetic 
study corroborate the conclusions of recent non-clinical studies that have also linked the 
metabolite MDEA to pulmonary cytotoxicity induced by AM (ELSHERBINY, EL-KADI and 
BROCKS, 2010; MULDER et al., 2011). 
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IV. HERB-DRUG INTERACTION OF FUCUS VESICULOSUS EXTRACT AND AMIODARONE IN 
RATS: A POTENTIAL RISK FOR REDUCED BIOAVAILABILITY OF AMIODARONE IN CLINICAL 
PRACTICE 
 
IV.1. ABSTRACT 
 
Fucus vesiculosus is a seaweed claimed to be useful for obesity management. 
Therefore, considering the relationship between obesity and cardiovascular diseases, this 
work aimed to assess the potential for an herb-drug interaction among a standardized F. 
vesiculosus extract (GMP certificate) and amiodarone (AM; a narrow therapeutic index 
drug) in rats. In a first pharmacokinetic study, rats were simultaneously co-administered with 
a single-dose of F. vesiculosus (575 mg/kg, p.o.) and AM (50 mg/kg, p.o.); in a second study, 
rats were pre-treated during 14 days with F. vesiculosus (575 mg/kg/day, p.o.) and received 
AM (50 mg/kg, p.o.) on the 15th day. Rats of the control groups received the corresponding 
volume of vehicle. After analysis of the pharmacokinetic data it deserves to be highlighted 
the significant decrease in the peak plasma concentration of AM (55.4%) as well as the 
reduction of systemic exposure to the parent drug (~30%) following the simultaneous co-
administration of F. vesiculosus extract and AM. For the first time was reported an herb-
drug interaction between F. vesiculosus and AM which determined a considerable decrease 
on AM bioavailability in rats. Therefore, the therapeutic efficacy of AM may be compromised 
by the concurrent administration of herbal slimming medicines/dietary supplements 
containing F. vesiculosus. 
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IV.2. INTRODUCTION 
 
Amiodarone [2-n-butyl-3-(3,5-diiodo-4-diethylaminoethoxy-benzoyl)-benzofuran; 
AM] (Figure IV.1) is one of the most commonly prescribed antiarrhythmic drugs (VASSALLO 
and TROHMAN, 2007; VAN HERENDAEL and DORIAN, 2010; FREEMANTLE et al., 2011). Despite 
the well-known safety concerns ascribed to AM and its major metabolite [mono-N-
desethylamiodarone (MDEA); (Figure IV.1)], mainly pulmonary and hepatic toxicity as well as 
thyroid dysfunctions, AM has been considered the drug with best efficacy for the prophylaxis 
and treatment of a wide range of heart rhythm disorders (VAN HERENDAEL and DORIAN, 
2010; FREEMANTLE et al., 2011). In particular, AM is indicated for the treatment of severe 
rhythm disorders when other treatments are ineffective or have not been tolerated (VAN 
HERENDAEL and DORIAN, 2010). 
 
Figure IV.1 – Chemical structures of amiodarone (AM) and its major metabolite mono-N-
desethylamiodarone (MDEA). 
 
However, AM has some unfavourable and very unusual properties from the 
pharmacokinetic viewpoint, which certainly determine its pharmacodynamic and 
toxicological profiles (FUKUCHI et al., 2009; VAN HERENDAEL and DORIAN, 2010). In humans, 
AM has shown an erratic gastrointestinal absorption and, consequently, a variable oral 
bioavailability (SHAYEGANPOUR, HAMDY and BROCKS, 2008; WOLKOVE and BALTZAN, 2009); 
this antiarrhythmic agent has also a huge body tissue distribution (OHYAMA et al., 2000; VAN 
HERENDAEL and DORIAN, 2010) and a long elimination half-life (SHAYEGANPOUR, HAMDY and 
BROCKS, 2008). Moreover, AM has been recognised as a drug of narrow serum/plasma 
therapeutic range (0.5-2.0 µg/mL) (LESNE and PELLEGRIN, 1987; HUY et al., 1991; MANFREDI et 
al., 1995; IERVASI et al., 1997; PÉREZ-RUIZ et al., 2002; SHAYEGANPOUR, HAMDY and BROCKS, 
2008) and has also been associated to important clinical drug interactions (EDWIN, JENNINGS 
and KALUS, 2010; KARIMI et al., 2010; ROUGHEAD et al., 2010). Nonetheless, AM has usually 
been considered the precipitant or interacting agent in the majority of pharmacokinetic-
based drug interactions reported in literature, inducing a change (generally an increase) in 
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serum/plasma levels of co-administered drugs [e.g. digoxin (LESKO, 1989; TRUJILLO and 
NOLAN, 2000), warfarin (LESKO, 1989; TRUJILLO and NOLAN, 2000; YAMREUDEEWONG et al., 
2003), phenytoin (LESKO, 1989), theophylline (TRUJILLO and NOLAN, 2000) and simvastatin 
(BECQUEMONT et al., 2007; MAROT et al., 2011)]. Effectively, only few studies have been 
published describing the interference of other compounds on the pharmacokinetics of AM. 
Specifically, the metabolism of AM was dramatically inhibited by grapefruit juice (LIBERSA et 
al., 2000); the systemic exposure to AM and MDEA was significantly reduced by the 
simultaneous administration of orlistat (ZHI et al., 2003); and, more recently, the exposure of 
rats to β-naphthoflavone (a polycyclic aromatic hydrocarbon) was found to increase the 
formation of MDEA probably through cytochrome P450 (CYP) induction (ELSHERBINY, EL-
KADI and BROCKS, 2010). 
Clinical, pathophysiologic and epidemiological studies have clearly indicated that 
overweight and obesity are two of the major independent risk factors for coronary heart 
disease, atrial fibrillation and heart failure (SCAGLIONE et al., 2004; ZALESIN et al., 2011). Thus, 
given the increasing prevalence of obesity, reaching pandemic proportions in developed 
countries, it is expected a significant increase in the incidence of cardiovascular diseases 
(BODARY, IGLAY and EITZMAN, 2007), as well as in the clinical use of drugs such as AM (SINGH, 
2008). On the other hand, aiming to improve their cardiovascular status, the patients are 
also increasingly seeking complementary medicines for weight reduction and/or weight 
management, including herbal dietary supplements. Hence, over the last years, the 
consumption of herbal weight loss supplements has grown at an alarming rate never seen 
before (EGRAS et al., 2011). 
Fucus vesiculosus, traditionally known as bladderwrack, is a medicinal plant that is 
claimed to be useful for the treatment of obesity, mainly due to its high levels in iodine, 
whose action is thought to be related to the stimulation of the thyroid gland and the 
subsequent effect on metabolic rate. Although iodine is considered the most prominent 
active ingredient of F. vesiculosus, the mucilage (dietary fibre), phytosterols and 
tetraterpenes are also important constituents responsible for its use in obesity management 
(MORO and BASILE, 2000; DÍAZ-RUBIO, PÉREZ-JIMÉNEZ and SAURA-CALIXTO, 2009). In fact, 
based on F. vesiculosus powder, the major components are non-digestible polysaccharides 
composed in a large extent by both soluble (10.52%) and insoluble (48.63%) fractions of 
dietary fibre (DÍAZ-RUBIO PÉREZ-JIMÉNEZ and SAURA-CALIXTO, 2009). In addition, besides 
proteins, minerals, vitamins and fatty acids, F. vesiculosus also contains polyphenols 
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(ZARAGOZÁ et al., 2008; DÍAZ-RUBIO, PÉREZ-JIMÉNEZ and SAURA-CALIXTO, 2009) and some of 
them were recently found to inhibit drug-metabolizing enzymes like CYP1A (PARYS et al., 
2010). 
For all the reasons referred to above, and bearing in mind the high potential for co-
administration of F. vesiculosus medicinal/dietary preparations and AM, particularly in 
overweight or obese patients with cardiovascular diseases, it is urgent to generate data in 
order to assess the interference of F. vesiculosus on the pharmacokinetics of AM (a narrow 
therapeutic index drug). Furthermore, to the best of our knowledge, no study was 
previously conducted to evaluate the potential of interaction between F. vesiculosus and AM. 
Therefore, the present work was designed to investigate whether a commercial standardized 
F. vesiculosus extract may influence the pharmacokinetics of AM in rats, after their 
simultaneous oral co-administration, and following a 14-day F. vesiculosus pre-treatment 
period. 
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IV.3. MATERIALS AND METHODS 
 
IV.3.1 DRUGS AND MATERIALS 
 
Bladderwrack (F. vesiculosus L.) 0.10% dry aqueous extract (certificate of analysis 
number 201003344; provided as Supplementary data) obtained from thallus was purchased 
from EPO Istituto Farmochimico Fitoterapico s.r.l. (Milano, Italy). Carboxymethylcellulose 
sodium salt for preparation of extract suspension was obtained from Sigma (St. Louis, MO, 
USA). A commercial formulation (ampoules) of AM hydrochloride 50 mg/mL solution for 
intravenous injection was used for oral administration to rats after appropriate dilution with 
5% glucose intravenous solution for infusion (B.Braun Medical, Portugal). Other compounds 
used were sodium chloride 0.9% solution for injection (Labesfal, Portugal); heparin sodium 
5000 U.I./mL for injection (B.Braun Medical, Portugal); ketamine for injection (Imalgene 
1000) and xylazine for injection (Vetaxilaze 20). Introcan® Certo IV indwelling cannula (22G; 
0.9 × 2.5 mm) made of polyurethane from B. Braun (Melsungen AG, Melsungen, Germany). 
 
IV.3.2 ANIMALS  
 
Adult male Wistar rats (342 ± 28 g) of approximately 10 weeks old were obtained 
from local animal facilities (Faculty of Health Sciences of the University of Beira Interior, 
Covilhã, Portugal). The rats were maintained under controlled environmental conditions 
(temperature 20±2 ºC; relative humidity 55±5%; 12-h light/dark cycle). The animals were 
allowed free access to a standard rodent diet (4RF21, Mucedola, Italy) during almost all 
experimental procedures and tap water was available ad libitum. At night on the day before 
dosing with AM, a lateral tail vein of each rat was cannulated under anaesthesia [ketamine 
(90 mg/kg)/xylazine (10 mg/kg); i.p. injection] by insertion of an Introcan® Certo IV indwelling 
cannula (22G; 0.9 × 2.5 mm) used for serial blood sampling. The rats fully recovered from 
anaesthesia overnight and were fasted for 12-14 h before AM administration and maintained 
with free access to water; an additional fasting period (4 h post-dose) was considered to 
avoid the effect of food on the oral bioavailability of AM. Oral treatments of the rats with F. 
vesiculosus and AM were performed by gavage. Blood sampling was conducted in conscious 
and freely moving rats, which were appropriately restrained only at the moment of blood 
collection, except for the last blood sampling that was taken by a terminal procedure 
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(decapitation and exsanguination under anaesthesia). All the animal experiments were 
conducted in accordance with the European Directive (2010/63/EU) for animal experiments 
and the experimental procedures were reviewed and approved by the Portuguese 
Veterinary General Division. 
 
IV.3.3 EXPERIMENTAL DESIGN AND PHARMACOKINETIC STUDIES 
 
To investigate the effects of F. vesiculosus on the kinetics of AM, two separate and 
independent pharmacokinetic studies were designed: (1) a single oral co-administration study 
of F. vesiculosus extract and AM; and (2) a 14-day repeated oral pre-treatment study with F. 
vesiculosus extract followed by a single oral administration of AM on the 15th day. The dose 
of F. vesiculosus was selected according to the study of SKIBOLA (2004) and taking into 
account the Food and Drug Administration (FDA) Guidance for Industry on conversion of 
animal doses to human equivalent doses based on body surface area (GUIDANCE FOR 
INDUSTRY, 2005); additionally, a 10-fold potentiating interaction factor was considered. On 
the other hand, the oral dose of AM (50 mg/kg) was established because it has provided 
plasma concentrations of drug in rats within the plasma therapeutic range (SHAYEGANPOUR, 
JUN and BROCKS, 2005). In each day of the experiments F. vesiculosus extract was suspended 
in 0.5% carboxymethylcellulose aqueous solution affording a suspension of herbal extract at 
57.5 mg/mL. AM commercial injectable solution (50 mg/mL) was also appropriately diluted 
with 5% glucose solution to extemporaneously prepare an AM solution at 12.5 mg/mL. At 
this point, it should be noted that an AM injectable solution was used as starting drug 
material for oral administration, rather than AM tablets, to avoid the possible interference of 
tablet excipients on the bioavailability of AM in rats, thus ensuring better reproducibility, 
practicability and minimizing the presence of confounding factors that hindered the 
interpretation of the results. Appropriate volumes of F. vesiculosus extract suspension (10 
mL/kg of body weight) and of AM solution (4 mL/kg of body weight) were orally 
administered to rats by gavage. 
In the first pharmacokinetic study, twelve Wistar rats were randomly divided into 
two groups (experimental and control groups). Rats of the experimental group (n = 6) were 
concomitantly treated with a single-dose of F. vesiculosus extract (575 mg/kg, p.o.) and a 
single-dose of AM (50 mg/kg, p.o.); the extract suspension was administered right before 
AM. Rats of the control group (n = 6) received, instead of the F. vesiculosus extract 
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suspension, the corresponding volume of 0.5% carboxymethylcellulose aqueous solution 
(vehicle of the extract). 
In the second pharmacokinetic study, twelve Wistar rats were also randomly divided 
into two groups. Rats assigned to the experimental group (n = 6) were orally pre-treated 
with F. vesiculosus extract (575 mg/kg, p.o.) once daily for 14 consecutive days (sub-chronic 
pre-treatment). Rats allocated to the control group (n = 6) were administered with an 
equivalent volume of vehicle for the same period of time. During the pre-treatment period, 
the rats were kept in 12-h light/dark cycle animal room with controlled temperature and 
humidity, as indicated above (section IV.3.2); free access to a standard rodent diet and tap 
water was allowed. On 15th day, rats of both groups (experimental and control) were 
gavaged with a single dose of AM (50 mg/kg, p.o.).  
In both pharmacokinetic studies, the treatments with F. vesiculosus extract (or 
vehicle) and/or AM were always carried out on the morning between 9:00 am and 11:45 am. 
At night on the day before AM administration, the rats were anaesthetized for cannulation of 
a lateral tail vein and were fasted overnight as described above (section IV.3.2). On the day 
after, multiple serial blood samples (approximately 0.3 mL) were collected through the 
cannula into heparinized tubes before dosing and at 0.25, 0.5, 1, 2, 4, 6, 8 and 12 h following 
AM administration; then, at 24 h post-dose, blood and tissues (heart, liver, kidney and lung) 
were also harvested after decapitation of the rats. The blood samples were centrifuged at 
4000 rpm for 10 min (4 ºC) to separate the plasma which was stored at –20 ºC until 
analysis. After exsanguination, liver, kidneys, heart and lungs were excised and stored at       
–20 ºC; the organs were weighed and homogenized in distilled water (3 mL of water per 
gram of tissue) before analysis of tissue homogenates samples. 
 
IV.3.4 DRUG ANALYSIS 
 
Plasma and tissue concentrations of AM and its main metabolite (MDEA) were 
determined by using a liquid-liquid extraction (LLE) procedure followed by high-performance 
liquid chromatography-diode array detection (HPLC-DAD) assay previously developed and 
validated (RODRIGUES et al., 2013). Briefly, an aliquot of each plasma sample (150 µL) was 
diluted with 150 µL of 0.1 M sodium phosphate buffer (pH 5) and spiked with 20 µL of the IS 
working solution (50 µg/mL). The mixture was added of 500 µL of n-hexane (used as LLE 
solvent), vortex-mixed for 30 sec and centrifuged at 17000 rpm for 2 min at 4 ºC. The upper 
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organic layer was transferred to a clean glass tube and the sample was re-extracted two 
more times with n-hexane (500 µL each time) using the same experimental conditions. Then, 
the whole organic extract was evaporated to dryness under a nitrogen stream at 60 ºC and 
the residue was reconstituted in 100 µL of methanol. Following this, an aliquot of the 
reconstituted extracts (20 µL) was injected into the HPLC system for analysis. 
For the extraction from tissues, each aliquot (400 µL) of tissue (heart, liver, kidney 
and lung) homogenates was spiked with 20 µL of the IS working solution (50 µg/mL); then, 
the mixture was added of 400 µL of acetonitrile (used as protein precipitating agent), 
vortex-mixed for 1 min and centrifuged at 17000 rpm for 10 min at 4 ºC in order to 
precipitate the protein content. The supernatant was transferred to a new propylene tube 
and 1 mL of n-hexane (used as LLE solvent) was added. The mixture was vortex-mixed for 1 
min and centrifuged at 17000 rpm for 5 min at 4 ºC. The upper organic layer (n-hexane) was 
transferred to a clean glass tube and the sample was re-extracted two more times with n-
hexane (0.8 mL each time) using the same conditions. The organic extract was evaporated to 
dryness, reconstituted, and then injected into the HPLC system using the same procedures 
as mentioned above for rat plasma samples. The limit of quantification (LOQ) was 
established at 0.100 µg/mL for AM and MDEA in plasma and in tissue homogenates. 
 
IV.3.5 PHARMACOKINETIC ANALYSIS 
 
The plasma concentration versus time data for AM and MDEA obtained from each 
individual rat were submitted to a non-compartmental pharmacokinetic analysis using the 
WinNonlin® version 4.1 (Pharsight Co, Mountain View, CA, USA). The peak concentrations 
of AM and MDEA in plasma (Cmax) and the time to reach Cmax (tmax) were obtained directly 
from the experimental data. Other pharmacokinetic parameters estimated from the 
individual plasma concentration-time profiles were: area under the concentration-time curve 
(AUC) from time zero to the last sampling time at which concentrations were at or above 
the LOQ of the method (AUC0-t), calculated by the linear trapezoidal rule; AUC from time 
zero to infinite (AUC0-∞), calculated from AUC0-t + (Clast/kel), where Clast is the last 
quantifiable concentration and kel is the apparent terminal elimination rate constant 
calculated by log-linear regression of the terminal segment of the concentration-time profile; 
apparent terminal elimination half-life (t1/2el) and mean residence time (MRT). The 
concentrations lower than the LOQ of the assay were taken as zero for all calculations. 
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IV.3.6 EFFECT OF THE SUB-CHRONIC FUCUS VESICULOSUS TREATMENT ON BODY WEIGHT 
 
For the sub-chronic treatment study (a 14-day F. vesiculosus treatment period), the 
body weight of the rats receiving F. vesiculosus extract (575 mg/kg/day, p.o.; experimental 
group) or vehicle (control group) was adequately registered on the first day and on the last 
day (14th) of these treatments in order to examine the effect of F. vesiculosus extract on 
body weight changes. 
 
IV.3.7 STATISTICAL ANALYSIS 
 
Data were reported as the mean ± standard error of the mean (SEM). Comparisons 
between two groups were usually performed using unpaired two-tailed Student’s t-test; for 
body weight change comparisons within the same group the paired Student’s t-test was 
employed. A difference was considered to be statistically significant for a p-value lower than 
0.05 (p < 0.05). 
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IV.4. RESULTS 
 
IV.4.1 EFFECTS OF THE SIMULTANEOUS CO-ADMINISTRATION OF FUCUS VESICULOSUS ON 
AMIODARONE PHARMACOKINETICS 
 
The mean plasma concentration-time profiles (n = 6) of AM and its main metabolite 
(MDEA) obtained after intragastric co-administration of rats with a single-dose of F. 
vesiculosus extract (575 mg/kg, p.o.) or vehicle (control group) and a single-dose of AM         
(50 mg/kg, p.o.) are shown in Figure IV.2.  
  
Figure IV.2 – Mean plasma concentration-time profiles of amiodarone (AM) and mono-N-
desethylamiodarone (MDEA) obtained, over a period of 24 h, from rats simultaneously 
treated in single-dose with Fucus vesiculosus extract (575 mg/kg, p.o.), or vehicle (0.5% 
carboxymethylcellulose aqueous solution), and AM (50 mg/kg, p.o.) by oral gavage. Symbols 
represent the mean values ± standard error of the mean (SEM) of six determinations per 
time point (n = 6). *p < 0.05 and #p < 0.005 compared to control (vehicle). 
 
AM plasma concentrations were comparable in both groups at the initial absorption 
phase (up to 0.5 h) and at the elimination phase (8-24 h). Conversely, AM plasma 
concentrations in the group treated with F. vesiculosus were significantly lower than those in 
the control group over the 1-6 h post-dose time period (at least, p < 0.05). In the case of 
MDEA, the plasma concentrations were similar in both groups, with values near or below 
the LOQ (0.100 µg/mL) of the method. The main plasma pharmacokinetic parameters 
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estimated for AM and MDEA after non-compartmental analysis of their concentration-time 
profiles are summarized in Table IV.1.  
 
Table IV.1 – Pharmacokinetic parameters estimated by non-compartmental analysis of the 
plasma concentration-time profiles of amiodarone (AM) and mono-N-desethylamiodarone 
(MDEA, major metabolite of AM) obtained in rats after the simultaneous co-administration 
in single-dose of Fucus vesiculosus extract (575 mg/kg, p.o.), or vehicle (0.5% 
carboxymethylcellulose aqueous solution), with AM (50 mg/kg, p.o.) by oral gavage (n = 6, 
unless otherwise noted). 
Parameter AM Fucus 
 AM Vehicle 
AM MDEA  AM MDEA 
tmax (h) 3.00 ± 1.10 8.00 ± 2.00
a  1.83 ± 0.48 7.20 ± 1.36b 
Cmax (µg/mL) 0.615 ± 0.060* 0.114 ± 0.004
a  1.378 ± 0.179 0.125 ± 0.012b 
AUC0-t (µg.h/mL) 8.995 ± 0.725* ND  12.774 ± 0.688 ND 
AUC0-∞ (µg.h/mL) 15.675 ± 1.722
# ND  21.431 ± 2.077 ND 
kel (1/h) 0.0426 ± 0.0070 ND  0.0433 ± 0.0082 ND 
t1/2el (h) 18.29 ± 2.47 ND  20.73 ± 5.74 ND 
MRT (h) 27.24 ± 3.45 ND  28.64 ± 7.74 ND 
ND, not determined. 
an = 3; bn = 5. 
*p < 0.005, significantly different from the control group. 
#p = 0.059, versus control group. 
 
With co-administration of F. vesiculosus the mean Cmax of AM was significantly lower 
than that obtained in the control (vehicle) group (p < 0.005), while the mean time to reach 
tmax was attained later in the experimental group (3.00 ± 1.10 h) comparatively to the 
control group (1.83 ± 0.48 h). Statistically significant differences were also found for the 
AUC0-t pharmacokinetic parameter (p < 0.005) calculated from the plasma concentration-
time data obtained for AM in both groups; in contrast, these differences were not so evident 
for the AUC0-∞ parameter (p = 0.059) (Table IV.1). Taking into consideration the information 
derived from Figure IV.3, it is clear that following the simultaneous co-administration of F. 
vesiculosus and AM a remarkable decrease (55.4%) in the Cmax of drug was observed, as well 
as a reduction of 29.6% in the extent of systemic drug exposure (as assessed by AUC0-t).  
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Figure IV.3 – Ratios for the main plasma pharmacokinetic parameters (Cmax, AUC0-t and    
AUC0-∞) estimated for amiodarone (AM) in rats simultaneously treated in single-dose with 
Fucus vesiculosus extract (575 mg/kg, p.o.), or vehicle (0.5% carboxymethylcellulose aqueous 
solution), and AM (50 mg/kg, p.o.) by oral gavage.   
 
As suggested by the visual inspection of the elimination phase of plasma 
pharmacokinetic profiles of AM (Figure IV.2), the mean values estimated for the elimination 
pharmacokinetic parameters (kel, t1/2el and MRT) are comparable between experimental (F. 
vesiculosus) and control (vehicle) groups. Considering the scarcity of quantifiable plasma 
concentrations for MDEA obtained in both groups, only the Cmax and tmax pharmacokinetic 
parameters are presented in Table IV.1. 
On the other hand, to investigate some aspects related to the biodistribution of AM 
and MDEA in rats, the animals were killed at 24 h after dosing either in the presence or 
absence of the co-administration of F. vesiculosus and several tissues were excised and 
analysed. The mean concentrations of AM and MDEA determined in heart, lung, liver and 
kidney tissues, and also their plasma concentrations at the same time point (24 h), are shown 
in Figure IV.4. 
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Figure IV.4 – Mean plasma and tissue (heart, lung, liver and kidney) concentrations of 
amiodarone (AM) and mono-N-desethylamiodarone (MDEA) obtained, at 24 h post-dose, 
from rats simultaneously treated in single-dose with Fucus vesiculosus extract (575 mg/kg, 
p.o.), or vehicle (0.5% carboxymethylcellulose aqueous solution), and AM (50 mg/kg, p.o.) by 
oral gavage. Data are expressed as the mean values ± standard error of the mean (SEM) of 
six determinations (n = 6). 
 
As indicated in Figure IV.4, the tissue concentrations of AM and MDEA were 
markedly higher than those determined in plasma, and were absolutely noteworthy the 
levels found for both compounds (AM and MDEA) in the lung tissue. However, no significant 
differences were found in the concentrations of AM and MDEA in tissues (heart, liver, 
kidney and lung) collected from experimental (F. vesiculosus) and control (vehicle) groups  
(p > 0.05) at 24 h post-dose. 
 
IV.4.2 EFFECTS OF THE SUB-CHRONIC PRE-TREATMENT WITH FUCUS VESICULOSUS ON AMIODARONE 
PHARMACOKINETICS 
 
Rats were administered for 14 days with F. vesiculosus extract (575 mg/kg, p.o.) or 
vehicle (control group) in order to investigate a possible interference of the F. vesiculosus 
sub-chronic treatment on the pharmacokinetics of AM. The animals were given 50 mg/kg 
AM (p.o.) one day after the last treatment with F. vesiculosus or vehicle, and the mean 
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plasma concentration-time profiles (n = 6) of AM and its main metabolite (MDEA) are 
depicted in Figure IV.5.  
  
Figure IV.5 – Mean plasma concentration-time profiles of amiodarone (AM) and mono-N-
desethylamiodarone (MDEA) obtained, over a period of 24 h, from rats submitted to a 14-
day pre-treatment period with Fucus vesiculosus extract (575 mg/kg/day, p.o.), or vehicle 
(0.5% carboxymethylcellulose aqueous solution), and treated on the 15th day with a single-
dose of AM (50 mg/kg, p.o.) by oral gavage (n = 6). Symbols represent the mean values ± 
standard error of the mean (SEM) of six determinations per time point (n = 6). 
 
The corresponding pharmacokinetic parameters, calculated by using non-
compartmental analysis, are listed in Table IV.2.  
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Table IV.2 – Pharmacokinetic parameters estimated by non-compartmental analysis of the 
plasma concentration-time profiles of amiodarone (AM) and mono-N-desethylamiodarone 
(MDEA, major metabolite of AM) obtained in rats submitted to a 14-day pre-treatment 
period with Fucus vesiculosus extract (575 mg/kg/day, p.o.), or vehicle (0.5% 
carboxymethylcellulose aqueous solution), and treated on the 15th day with a single-dose of 
AM (50 mg/kg, p.o.) by oral gavage (n = 6, unless otherwise noted). 
ND, not determined. 
an = 2; bn = 3. 
 
Overall, it was observed a close overlap between the plasma pharmacokinetic profiles 
and no significant differences (p > 0.05) in the pharmacokinetic parameters were detected 
for AM and its main metabolite (MDEA) among the two groups (F. vesiculosus versus vehicle 
pre-treatment). Once again, the plasma concentrations of MDEA were near or below the 
LOQ (0.100 µg/mL) of the method in both groups of rats. Regarding the data shown in 
Figure IV.6, it is clear that the magnitude (as assessed by Cmax) and the extent (as assessed by 
AUC) of systemic exposure to AM is similar among experimental and control groups      
(AM Fucus versus AM Vehicle ratios near to unity). 
 
 
Parameter AM Fucus 
 AM Vehicle 
AM MDEA  AM MDEA 
tmax (h) 1.00 ± 0.00 7.00 ± 1.00
a  2.17 ± 0.60 7.33 ± 2.40b 
Cmax (µg/mL) 1.066 ± 0.199 0.108 ± 0.002
a  0.952 ± 0.157 0.119 ± 0.014b 
AUC0-t (µg.h/mL) 10.555 ± 0.674 ND  10.532 ± 0.889 ND 
AUC0-∞ (µg.h/mL) 13.786 ± 0.720 ND  15.325 ± 0.949 ND 
kel (1/h) 0.0594 ± 0.0051 ND  0.0533 ± 0.0082 ND 
t1/2el (h) 12.15 ± 1.12 ND  14.36 ± 1.85 ND 
MRT (h) 17.10 ± 1.45 ND  20.97 ± 2.42 ND 
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Figure IV.6 – Ratios for the main plasma pharmacokinetic parameters (Cmax, AUC0-t and    
AUC0-∞) estimated for amiodarone (AM) in rats submitted to a 14-day pre-treatment period 
with Fucus vesiculosus extract (575 mg/kg/day, p.o.), or vehicle (0.5% carboxymethylcellulose 
aqueous solution), and treated on the 15th day with a single-dose of AM (50 mg/kg, p.o.) by 
oral gavage. 
 
To examine the influence of a 14-day pre-treatment period with F. vesiculosus or 
vehicle (control group) on the distribution and metabolism of AM in rats, the concentrations 
of AM and its major metabolite (MDEA) were also determined in various tissues 
(additionally to plasma) at 24 h post-dose and the resultant mean concentrations are 
represented in Figure IV.7.  
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Figure IV.7 – Mean plasma and tissue (heart, lung, liver and kidney) concentrations of 
amiodarone (AM) and mono-N-desethylamiodarone (MDEA) obtained, at 24 h post-dose, 
from rats submitted to a 14-day pre-treatment period with Fucus vesiculosus extract (575 
mg/kg/day, p.o.), or vehicle (0.5% carboxymethylcellulose aqueous solution), and treated on 
the 15th day with a single-dose of AM (50 mg/kg, p.o.) by oral gavage. Data are expressed as 
the mean values ± standard error of the mean (SEM) of six determinations (n = 6). *p < 0.05 
compared to control (vehicle). 
 
As pointed out in Figure IV.7, the concentrations of both compounds (AM and 
MDEA) in tissues were distinctly greater than those measured in plasma, and the 
concentration levels found in lung tissue were exceptionally high in experimental (F. 
vesiculosus) and control (vehicle) groups. However, taking into account all the comparisons 
performed, only significant differences were detected between both groups for AM 
concentrations in liver tissue, being such concentrations lower in liver tissue of rats treated 
with F. vesiculosus extract (p < 0.05). 
 
IV.4.3. EFFECT OF THE SUB-CHRONIC FUCUS VESICULOSUS TREATMENT ON BODY WEIGHT 
 
The resulting changes in body weight of the rats submitted to a 14-day treatment 
period with F. vesiculosus extract (575 mg/kg/day, p.o) or vehicle are demonstrated in Figure 
IV.8.  
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Figure IV.8 – Effects on the body weight of the rats induced by the sub-chronic treatment 
(14-day period) with Fucus vesiculosus extract (575 mg/kg/day, p.o.) and vehicle (0.5% 
carboxymethylcellulose aqueous solution) by oral gavage. *p < 0.01 and **p < 0.001, 1st day 
versus 14th day. 
 
From the analysis of the data it is clear that the increase in body weight of rats 
treated with F. vesiculosus (p < 0.005) or treated with vehicle (p < 0.0005) was statistically 
significant between the 1st and 14th day. On the other hand, the increase in body weight of 
the rats of both groups (F. vesiculosus versus vehicle) was comparable.  
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IV.5. DISCUSSION 
 
Complementary and alternative therapies such as herbal or natural products are 
finding increasing use around the world despite the paucity of scientific evidence about their 
safety and efficacy. Accordingly, unexpected and significant herb-drug interactions may occur 
and put individuals at risk, particularly those people who use multiple medicines for co-
morbid conditions. These interactions may lead to therapeutic failure and/or toxic effects, 
especially for drugs characterized by a narrow therapeutic index (e.g. AM) (TACHJIAN, MARIA 
and JAHANGIR, 2010). Undoubtedly, the information now available on herb-drug interactions 
is scarce and, in many cases, inappropriate. Indeed, the information published about herb-
drug interactions has derived mainly from in vitro studies; however, as suggested by some 
authors, numerous herb-drug interactions reported in literature are irrelevant and 
misleading due to the use of inappropriately high concentrations of the extracts or their 
constituents lacking, therefore, in vivo relevance when their bioavailability is considered 
(COTT, 2008; MARKOWITZ, VON MOLTKE and DONOVAN, 2008). Since the in vitro data on 
herb-drug interactions cannot usually be directly extrapolated to the in vivo conditions, it is 
important to conduct well-designed in vivo non-clinical studies with enough potency for 
human extrapolation. 
Although safety issues are always important in the areas of pharmaceutical and food 
research, some safety data are already available in the literature for F. vesiculosus extracts. 
Indeed, acute toxicity studies performed in rats by ZARAGOZÁ et al. (2008) using two F. 
vesiculosus extracts indicated LD50 values of 1000-2000 (or >2000) mg/kg after oral dosing; 
on the other hand, the overall results obtained from a 4 week (sub-chronic) toxicity study 
conducted in rats with two oral doses of 200 mg/kg/day (low dose) and 750 mg/kg/day (high 
dose) indicated that no relevant signs of toxicity occurred even at the daily dose of 750 
mg/kg (ZARAGOZÁ et al., 2008). Moreover, LEITE-SILVA et al. (2007) demonstrated the 
absence of F. vesiculosus extract-mediated genotoxicity in cultured human lymphocytes and 
also evidenced its antigenotoxic activity against doxorubicin-induced DNA damage. PARYS et 
al. (2010) also reported potential chemopreventive activity of three fucophlorethols from F. 
vesiculosus. Thus, no safety issues were expected and none was observed at the dose of F. 
vesiculosus extract selected for the present study (575 mg/kg/day). 
The current work was planned to investigate in vivo the potential of interaction 
between F. vesiculosus extract and AM, using adult male Wistar rat as a whole-animal model. 
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The use of female rats was also hypothesized during the experimental design of these 
studies; however, only male Wistar rats were included because it has been reported that the 
pharmacokinetics of AM is not gender-dependent and also to avoid the potential 
interference of menstrual cycle hormones (possible confounding factors) (SANOFI-
SYNTHELABO PFIZER CANADA INC., 2010). Bearing in mind that drug-drug or herb-drug 
interactions mainly occur at the level of absorption and/or metabolic (inhibition or 
induction) pathways, the pharmacokinetic studies reported herein were designed to examine 
the interference of F. vesiculosus extract on the gastrointestinal absorption (simultaneous 
co-administration study) and metabolism of AM (14-day F. vesiculosus pre-treatment study). 
Our results clearly evidenced a significant decrease (55.4%) in the peak plasma 
concentration (Cmax) of drug following the simultaneous co-administration of the F. 
vesiculosus extract and AM, as well as a reduction of approximately 30% in the extent of 
systemic drug exposure (as assessed by AUC0-24h). On the other hand, no important effects 
were detected either on the magnitude or extent of systemic exposure to AM after the 
administration of the drug to pre-treated rats one day after the last treatment with F. 
vesiculosus extract or vehicle. Hence, taking these findings together, it is apparent that F. 
vesiculosus extract or its components interact with AM in the gastrointestinal tract, reducing 
significantly the bioavailability of the drug; actually, this interaction was identified as relevant 
only after the simultaneous co-administration in single-dose of F. vesiculosus extract and 
AM. Moreover, the similarity in plasma pharmacokinetic profiles of AM obtained from rats 
pre-treated for 14 days with F. vesiculosus extract or vehicle excludes the impact of F. 
vesiculosus-induced metabolism on the bioavailability and also supports the significance of 
the interaction with AM at the level of the gastrointestinal tract. ZHI et al. (2003) also 
observed in healthy volunteers a significant reduction of the absorption of AM induced by 
orlistat; this drug, a lipase inhibitor, significantly reduced the systemic exposure to AM by 
approximately 25% and a decrease of similar magnitude (~25%) was detected in the 
generation of the metabolite MDEA (the major metabolite of AM). According to ZHI et al. 
(2003) the absorption of highly lipophilic drugs such as AM may depend on the presence of a 
lipid phase in the gastrointestinal environment, which may be affected by the pharmacological 
action of orlistat. In fact, there are strong evidences supporting the effects of food upon the 
bioavailability of AM; effectively, the rate (Cmax) and extent (AUC0-t) of absorption of AM 
enhanced by 3.8 and 2.4-fold, respectively, in healthy volunteers who received a single-dose 
of the drug immediately after consuming a high-fat meal versus following an overnight fast 
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(MENG et al., 2001). The effects of food on the pharmacokinetics of AM were also studied in 
rats by SHAYEGANPOUR, JUN and BROCKS (2005) and the results obtained concerning the 
interference of lipids on the oral bioavailability of AM corroborated those reported in 
humans. 
Nevertheless, in this case, taking into account the great content of soluble dietary 
fibre present in F. vesiculosus, we hypothesize the occurrence of a physical-chemical 
interaction between dietary fibre (or other extract components) and AM in the 
gastrointestinal tract to explain the considerable decrease in the systemic 
exposure/bioavailability of AM in the rats simultaneously co-administered in single-dose with 
F. vesiculosus extract. However, further studies are needed to understand the mechanism 
associated to the herb-drug interaction reported herein for the first time (F. vesiculosus 
extract/AM). At this point it should be highlighted the overview recently published by 
COLALTO (2010) about the herbal interactions on absorption of drugs and underlying 
interaction mechanisms. Dietary fibre may reduce the drug absorption, when both are 
assumed nearly, by a mechanism of action similar to bile sequestration; herb-drug 
interactions at absorption level associated with dietary fibre have been reported, as instance, 
for lovastatin (RICHTER, JACOB and SCHWANDT, 1991), digoxin (BROWN and JUHL, 1976; 
BROWN, JUHL and WARNER, 1978), metformin (GIN, ORGERIE and AUBERTIN, 1989) and 
glibenclamide (NEUGEBAUER, AKPAN and ABSHAGEN, 1983). In addition, LODEIRO et al. (2012) 
recently reported that F. vesiculosus interacts with aluminum of acidic waters by a 
mechanism of adsorption, suggesting that these physicochemical data may be of interest in 
modeling drug-food interactions, particularly those referring to aluminum-containing 
antacids-food pharmacokinetic process produced in the gastrointestinal tract. Therefore, 
similar physicochemical adsorption mechanisms may occur between F. vesiculosus and AM. 
 It is well-recognised the central role that CYP or P-glycoprotein (P-gp) induction or 
inhibition play on drug-drug and herb-drug interactions. In fact, AM is a substrate of P-gp 
(SHAPIRO and SHEAR, 2002) and is metabolized by several CYP isoenzymes in rat (ELSHERBINY, 
EL-KADI and BROCKS, 2010). Hence, to check the possible interference of F. vesiculosus 
extract on the CYP or P-gp activity, the extract was administered for 14 days (575 
mg/kg/day, p.o.) until 24 h before applying AM; however, no significant influence was 
observed on the systemic (plasma) pharmacokinetics of AM in these circumstances. In these 
experimental conditions, it is only worthy of note the lower concentrations of AM in liver 
tissue, at 24 h post-dose, in rats pre-treated with F. vesiculosus extract (Figure IV.7). 
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Although this finding has not had in this case a significant impact on the magnitude of 
systemic exposition to AM, it is an interesting aspect to explore in further studies directed 
to evaluate the potential of enzyme induction by F. vesiculosus. Up to date, there is no 
evidence suggesting the hepatic metabolic induction of CYPs mediated by F. vesiculosus. On 
the contrary, the inhibition of CYP1A by trifucodiphlorethol A and trifucotriphlorethol A, 
compounds extracted from F. vesiculosus, was recently reported by PARYS et al. (2010).  
Overall, considering the rat plasma data generated in the present work and that 
reported from clinical studies following oral administration of AM, it is evident that MDEA is 
the major metabolite of AM in both species, even though differences will exist in their 
metabolite-to-parent ratios. Indeed, in our pharmacokinetic studies, the plasma 
concentrations of MDEA found in rat were significantly lower than those of AM, and were 
found at levels near or below the LOQ (0.100 µg/mL) of the bioanalytical assay. 
Furthermore, AM and MDEA were found in concentrations considerably lower in plasma 
than in tissues (heart, liver, lungs and kidneys) at 24 h post-dose, supporting their great 
plasma/tissue distribution; these differences were absolutely remarkable for plasma/lung 
tissue. These rat tissues were selected for bioanalysis of AM and MDEA because they 
represent important targets from therapeutic (heart), toxicological (liver and lungs) and 
pharmacokinetic (liver and kidneys) viewpoints.  
Based on data of herb-drug interaction between F. vesiculosus extract and AM, 
derived from this non-clinical investigation in rat, it is suggested that patients who are taking 
AM should avoid the concurrent administration of herbal slimming medicines/dietary 
supplements containing F. vesiculosus. In addition, in our experimental conditions, the sub-
chronic administration of F. vesiculosus extract to rats (575 mg/kg/day, 14-day period, p.o.) 
not evidenced efficacy on weight reduction (Figure IV.8). It is also true that results from 
animal experiments cannot be directly extrapolated to humans; however, bearing in mind 
the studies of SHAYEGANPOUR, JUN and BROCKS (2005) and MENG et al. (2001) the rat 
appears to be an appropriate animal model for man in this situation.  
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IV.7. SUPPLEMENTARY DATA 
 
Certificate of analysis of bladderwrack (Fucus vesiculosus L.) 0.10% iodine dry aqueous 
extract provided by EPO Istituto Farmochimico Fitoterapico  s.r.l. (N.: 201003344). 
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V. HERB-DRUG INTERACTION OF PAULLINIA CUPANA (GUARANA) SEED EXTRACT ON THE 
PHARMACOKINETICS OF AMIODARONE IN RATS 
 
V.1. ABSTRACT 
 
Paullinia cupana is used in weight-loss programs as a constituent of medicinal/dietary 
supplements. This study aimed to assess a potential herb-drug interaction among a 
standardized (certified) P. cupana extract and amiodarone (AM; narrow therapeutic index 
drug) in rats. In a first pharmacokinetic study rats were simultaneously co-administered with 
a single-dose of P. cupana (821 mg/kg, p.o.) and AM (50 mg/kg, p.o.), and in a second study 
rats were pre-treated during 14 days with P. cupana (821 mg/kg/day, p.o.) receiving AM (50 
mg/kg, p.o.) on the 15th day. Rats of the control groups received the corresponding volume 
of vehicle. Blood samples were collected at several time points after AM dosing, and several 
tissues were harvested at the end of the experiments (24 h post-dose). Plasma and tissue 
concentrations of AM and its major metabolite (mono-N-desethylamiodarone) were 
measured and analysed. A significant reduction in the peak plasma concentration (73.2%) and 
in the extent of systemic exposure (57.8%) to AM was found in rats simultaneously treated 
with P. cupana and AM; a decrease in tissue concentrations was also observed. For the first 
time an herb-drug interaction between P. cupana extract and AM is reported, which 
determined a great decrease on AM bioavailability in rats. 
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V.2. INTRODUCTION 
 
Paullinia cupana, commonly known as Guarana, is a climbing evergreen vine with small 
fruits and is native to the Amazon region (LIMA et al., 2005; CAMPOS et al., 2011). P. cupana 
seed extracts have been used in folk medicine since pre-Columbian times as stimulants, 
aphrodisiacs and tonics (CAMPOS et al., 2011). 
The seeds of P. cupana contain large amounts of methylxanthines (caffeine, 
theophylline and theobromine), saponins, and polyphenols, especially tannins, as well as trace 
concentrations of many other compounds (HEARD et al., 2006; KREWER et al., 2011; KLEIN, 
LONGHINI and DE MELLO, 2012). These constituents are probably responsible for the use of 
P. cupana seed extract in popular medicine as a stimulant of the central nervous system, in 
cases of physical and mental stress, and as an antidiarrheic, diuretic, and antineuralgic (KLEIN, 
LONGHINI and DE MELLO, 2012). Its high caffeine content and stimulating properties make P. 
cupana particularly attractive in weight-loss programs, since it helps increase the metabolic 
rate and can improve thermogenesis. Indeed, P. cupana (Guarana) containing products are 
popular among athletes because of their ergogenic and “fat burning” effects (BULKU et al., 
2012). Some studies have shown that P. cupana positively affects lipid metabolism (LIMA et 
al., 2005), enhances weight loss (BOOZER et al., 2001; OPALA et al., 2006) and increases basal 
energy expenditure (BÉRUBÉ-PARENT et al., 2005; KREWER et al., 2011). Thus, these data 
suggest that P. cupana has anti-obesity effects (BOOZER et al., 2001; BÉRUBÉ-PARENT et al., 
2005; OPALA et al., 2006; KREWER et al., 2011). Moreover, several studies have also ascribed 
to P. cupana antioxidant and cardioprotective effects (BYDLOWSKI, YUNKER and SUBBIAH, 
1988; BYDLOWSKI, D’AMICO and CHAMONE, 1991; KREWER et al., 2011; BULKU et al., 2012). 
P. cupana extract (from seed) is approved in the United States as a food additive and 
is considered a dietary supplement (HEARD et al., 2006); P. cupana is also listed in the official 
Brazilian Pharmacopoeia (ANTONELLI-USHIROBIRA et al., 2010). Therefore, it is not surprising 
that P. cupana (Guarana) is found today in a wide variety of drinks, foods, dietary/herbal 
supplements and pharmaceuticals (LIMA et al., 2005; ANTONELLI-USHIROBIRA et al., 2010). 
Consequently, perhaps concerned about the widespread use or potential abuse of P. cupana 
based products, the Committee on Herbal Medicinal Products (HMPC) of European 
Medicines Agency has recently launched a call to encourage submission of scientific data on 
P. cupana (Guarana) in order to prepare the corresponding herbal monograph (EUROPEAN 
MEDICINES AGENCY, 2011). 
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Given that obesity and overweight are increasing at an alarming rate in developed 
countries (PITTLER, SCHMIDT and ERNST, 2005), representing two of the major independent 
risk factors for cardiovascular diseases (SCAGLIONE et al., 2004; BODARY, IGLAY and EITZMAN, 
2007; ZALESIN et al., 2011), a great increase on the consumption of dietary/herbal 
supplements containing P. cupana is still expected. Since the concurrent use of these 
products with conventional drugs may lead to significant clinical herb-drug interactions, it is 
urgent to assess the interference of P. cupana seed extract on the kinetics of narrow 
therapeutic index drugs, such as amiodarone (AM) (SINGH, 2008). 
AM [2-n-butyl-3-(3,5-diiodo-4-diethylaminoethoxy-benzoyl)-benzofuran; (Figure V.1)] 
is one of the most widely prescribed antiarrhythmic agents for the treatment of atrial 
fibrillation and ventricular arrhythmias (PAPIRIS et al., 2010). From a pharmacokinetic 
viewpoint AM has unusual and complex properties (SHAYEGANPOUR, HAMDY and BROCKS, 
2008; VAN HERENDAEL and DORIAN, 2010), and it is recognised as a drug of narrow 
serum/plasma therapeutic range (0.5-2.0 µg/mL) (PÉREZ-RUIZ et al., 2002; SHAYEGANPOUR, 
HAMDY and BROCKS, 2008). Furthermore, AM has also been associated to important clinical 
drug interactions (EDWIN, JENNINGS and KALUS, 2010; KARIMI et al., 2010; ROUGHEAD et al., 
2010). Nevertheless, to the best of our knowledge, no study was conducted until now to 
evaluate herb-drug interactions between P. cupana (Guarana) and AM. 
 
Figure V.1 – Chemical structures of amiodarone (AM) and its major metabolite mono-N-
desethylamiodarone (MDEA). 
 
Taking into account all the reasons previously referred and considering the potential 
for co-administration of P. cupana medicinal products and AM, this work was planned to 
investigate if a commercial standardized (certified) extract of P. cupana seeds may influence 
the pharmacokinetics of AM in rats, following their simultaneous oral co-administration and 
after a 14-day P. cupana pre-treatment period. 
 
 
 
Chapter V 
 
 
160 
V.3. MATERIALS AND METHODS 
 
V.3.1 DRUGS AND MATERIALS 
 
Guarana (P. cupana L.) extract 12% caffeine obtained from fruit seeds was purchased 
from Bio Serae Laboratories (Bram, France); the corresponding certificate of analysis ref. 
410044 (batch 0805519) is provided as Supplementary Data. Carboxymethylcellulose sodium 
salt for preparation of extract suspension was obtained from Sigma (St. Louis, MO, USA). A 
commercial formulation (ampoules) of AM hydrochloride 50 mg/mL solution for intravenous 
injection was used for oral administration to rats after appropriate dilution with 5% glucose 
intravenous solution for infusion (B. Braun Medical, Portugal). Other compounds used were 
sodium chloride 0.9% solution for injection (Labesfal, Portugal); heparin sodium 5000 U.I./mL 
for injection (B. Braun Medical, Portugal); ketamine for injection (Imalgene 1000) and 
xylazine for injection (Vetaxilaze 20). Introcan® Certo IV indwelling cannula (22G; 0.9 × 2.5 
mm) made of polyurethane from B. Braun Melsungen AG (Melsungen, Germany). 
 
V.3.2 ANIMALS   
 
Adult male Wistar rats (310-380 g) of approximately 10 weeks old were obtained 
from local animal facilities (Faculty of Health Sciences of the University of Beira Interior, 
Covilhã, Portugal). The rats were maintained under controlled environmental conditions 
(temperature 20±2 ºC; relative humidity 55±5%; 12-h light/dark cycle). The animals were 
allowed free access to a standard rodent diet (4RF21, Mucedola, Italy) during almost all 
experimental procedures and tap water was available ad libitum. At night on the day before 
dosing with AM, a lateral tail vein of each rat was cannulated, under anaesthesia [ketamine 
(90 mg/kg)/xylazine (10 mg/kg); i.p. injection], by insertion of an Introcan® Certo IV 
indwelling cannula (22G; 0.9 × 2.5 mm) used for serial blood sampling. The rats fully 
recovered from anaesthesia overnight and were fasted for 12-14 h before AM administration 
and maintained with free access to water; to avoid the effect of food on the oral 
bioavailability of AM an additional fasting period was considered (4 h post-dose). Oral 
treatments of the rats with P. cupana extract and AM were performed by gavage. Blood 
sampling was conducted in conscious and freely moving rats, which were appropriately 
restrained only at the moment of blood collection, except for the last blood sampling that 
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was taken by a terminal procedure (decapitation and exsanguination under anaesthesia). All 
the animal experiments were conducted in accordance with the European Directive 
(2010/63/EU) for the accommodation and care of laboratory animals and the experimental 
procedures were reviewed and approved by the Portuguese Veterinary General Division. 
 
V.3.3 EXPERIMENTAL DESIGN AND PHARMACOKINETIC STUDIES 
 
Two separate and independent pharmacokinetic studies were designed to investigate 
the effects of P. cupana on the kinetics of AM: (1) a single oral co-administration study of P. 
cupana extract and AM; and (2) a 14-day repeated oral pre-treatment study with P. cupana 
extract and on the 15th day a single oral dose of AM was given. The dose of P. cupana was 
selected based on the dose recommended to humans by the supplier of the extract (Bio 
Serae Laboratories) and taking into account the Food and Drug Administration (FDA) 
Guidance for Industry on conversion of animal doses to human equivalent doses (GUIDANCE 
FOR INDUSTRY, 2005); additionally, a 10-fold potentiating interaction factor was considered. 
On the other hand, the single oral dose of AM (50 mg/kg) was established because it has 
provided plasma concentrations of AM in rats within the plasma therapeutic range 
(SHAYEGANPOUR, JUN and BROCKS, 2005). In each day of the experiments P. cupana extract 
was suspended in 0.5% carboxymethylcellulose aqueous solution affording a suspension of 
herbal extract at 82.1 mg/mL. AM commercial injectable solution (50 mg/mL) was also 
appropriately diluted with 5% glucose solution to extemporaneously prepare an AM solution 
at 12.5 mg/mL. Appropriate volumes of P. cupana extract suspension (10 mL/kg of body 
weight) and of AM solution (4 mL/kg of body weight) were orally administered to rats by 
oral gavage. 
In the first pharmacokinetic study, twelve Wistar rats were randomly divided into 
two groups (experimental and control groups). Rats of the experimental group (n = 6) were 
concomitantly treated with a single-dose of P. cupana extract (821 mg/kg, p.o.) and a single-
dose of AM (50 mg/kg, p.o.); the extract suspension was administered right before AM. Rats 
of the control group (n = 6) received, instead of the P. cupana extract suspension, the 
corresponding volume of 0.5% carboxymethylcellulose aqueous solution (vehicle of the 
extract). 
In the second pharmacokinetic study, twelve Wistar rats were also randomly divided 
into two groups. Rats assigned to the experimental group (n = 6) were orally pre-treated 
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with P. cupana extract (821 mg/kg, p.o.) once daily for 14 consecutive days (sub-chronic pre-
treatment). Rats allocated to the control group (n = 6) were administered with an equivalent 
volume of vehicle for the same period of time. During the pre-treatment period, the rats 
were kept in 12-h light/dark cycle animal room with controlled temperature and humidity, as 
indicated above (section V.3.2); free access to a standard rodent diet and tap water was 
allowed. On 15th day, rats of both groups (experimental and control) were gavaged with a 
single-dose of AM (50 mg/kg, p.o.).  
In both pharmacokinetic studies, the treatments with P. cupana extract (or vehicle) 
and/or AM were always carried out on the morning between 9:00 am and 11:45 am. At night 
on the day before AM administration, the rats were anaesthetized for cannulation of a lateral 
tail vein and were fasted overnight as described above (section V.3.2). On the day after, 
multiple serial blood samples (approximately 0.3 mL) were collected through the cannula 
into heparinized tubes before dosing and at 0.25, 0.5, 1, 2, 4, 6, 8 and 12 h following AM 
administration; then, at 24 h post-dose, blood and tissues (heart, liver, kidneys and lungs) 
were also harvested after decapitation of the rats. The blood samples were centrifuged at 
4000 rpm for 10 min (4 ºC) to separate the plasma which was stored at –20 ºC until 
analysis. After exsanguination, liver, kidneys, heart and lungs were excised and stored at       
–20 ºC; the organs were weighed and homogenized in distilled water (3 mL of water per 
gram of tissue) before analysis of tissue homogenates samples. 
 
V.3.4 DRUG ANALYSIS 
 
Plasma and tissue concentrations of AM and its main metabolite [mono-N-
desethylamiodarone (MDEA)] were determined by using a liquid-liquid extraction (LLE) 
procedure followed by high-performance liquid chromatography-diode array detection 
(HPLC-DAD) assay previously developed and validated (RODRIGUES et al., 2013). Briefly, an 
aliquot of each plasma sample (150 µL) was diluted with 150 µL of 0.1 M sodium phosphate 
buffer (pH 5) and spiked with 20 µL of the IS working solution (50 µg/mL). The mixture was 
added of 500 µL of n-hexane (used as LLE solvent), vortex-mixed for 30 sec and centrifuged 
at 17000 rpm for 2 min at 4 ºC. The upper organic layer was transferred to a clean glass 
tube and the sample was re-extracted two more times with n-hexane (500 µL each time) 
using the same experimental conditions. Then, the whole organic extract was evaporated to 
dryness under a nitrogen stream at 60 ºC and the residue was reconstituted in 100 µL of 
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methanol. Following this, an aliquot of the reconstituted extract (20 µL) was injected into 
the HPLC system for analysis. 
For the extraction from tissues, each aliquot (400 µL) of tissue (heart, liver, kidney 
and lung) homogenates was spiked with 20 µL of the IS working solution (50 µg/mL); then, 
the mixture was added of 400 µL of acetonitrile (used as protein precipitating agent), 
vortex-mixed for 1 min and centrifuged at 17000 rpm for 10 min at 4 ºC in order to 
precipitate the protein content. The supernatant was transferred to a new propylene tube 
and 1 mL of n-hexane (used as LLE solvent) was added. The mixture was vortex-mixed for 1 
min and centrifuged at 17000 rpm for 5 min at 4 ºC. The upper organic layer (n-hexane) was 
transferred to a clean glass tube and the sample was re-extracted two more times with n-
hexane (0.8 mL each time) using the same conditions. The organic extract was evaporated to 
dryness, reconstituted, and then injected into the HPLC system using the same procedures 
as mentioned above for rat plasma samples. The limit of quantification (LOQ) was 
established at 0.100 µg/mL for AM and MDEA in plasma and in tissue homogenates. 
 
V.3.5 PHARMACOKINETIC ANALYSIS 
 
The plasma concentration versus time data for AM and MDEA obtained from each 
individual rat were submitted to a non-compartmental pharmacokinetic analysis using the 
WinNonlin® version 4.1 (Pharsight Co, Mountain View, CA, USA). The peak concentrations 
of AM and MDEA in plasma (Cmax) and the time to reach Cmax (tmax) were obtained directly 
from the experimental data. Other pharmacokinetic parameters estimated from the 
individual plasma concentration-time profiles were: area under the concentration-time curve 
(AUC) from time zero to the last sampling time at which concentrations were at or above 
the LOQ of the method (AUC0-t), calculated by the linear trapezoidal rule; AUC from time 
zero to infinite (AUC0-∞), calculated from AUC0-t + (Clast/kel), where Clast is the last 
quantifiable concentration and kel is the apparent terminal elimination rate constant 
calculated by log-linear regression of the terminal segment of the concentration-time profile; 
apparent terminal elimination half-life (t1/2el) and mean residence time (MRT). The 
concentrations lower than the LOQ of the assay were taken as zero for all calculations. 
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V.3.6 EFFECT OF THE SUB-CHRONIC PAULLINIA CUPANA TREATMENT ON BODY WEIGHT 
 
For the sub-chronic treatment study (a 14-day P. cupana treatment period), the body 
weight of the rats administered with P. cupana extract (821 mg/kg/day, p.o.; experimental 
group) or vehicle (control group) were adequately registered on the first day and on the last 
day (14th) of these treatments in order to examine the effect of P. cupana extract on body 
weight changes. 
 
V.3.7 STATISTICAL ANALYSIS 
 
Data were reported as the mean ± standard error of the mean (SEM). Comparisons 
between two groups were usually performed using unpaired two-tailed Student’s t-test; for 
body weight comparisons within the same group the paired Student’s t-test was employed. A 
difference was considered to be statistically significant for a p-value lower than 0.05            
(p < 0.05). 
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V.4. RESULTS 
 
V.4.1 EFFECTS OF THE SIMULTANEOUS CO-ADMINISTRATION OF PAULLINIA CUPANA ON 
AMIODARONE PHARMACOKINETICS 
 
The mean plasma concentration-time profiles (n = 6) of AM and its main metabolite 
(MDEA) obtained after intragastric co-administration of rats with a single-dose of P. cupana 
extract (821 mg/kg, p.o.) or vehicle (control group) and a single-dose of AM (50 mg/kg, p.o.) 
are shown in Figure V.2.  
 
Figure V.2 – Mean plasma concentration-time profiles of amiodarone (AM) and mono-N-
desethylamiodarone (MDEA) obtained, over a period of 24 h, from rats simultaneously 
treated in single-dose with Paullinia cupana extract (821 mg/kg, p.o.), or vehicle (0.5% 
carboxymethylcellulose aqueous solution), and AM (50 mg/kg, p.o.) by oral gavage. Symbols 
represent the mean values ± standard error of the mean (SEM) of six determinations per 
time point (n = 6). *p < 0.05 and #p < 0.001 compared to control (vehicle). 
 
AM plasma concentrations were similar in both groups only at the first two time-
points post-dose (up to 0.5 h). AM plasma concentrations in the group treated with P. 
cupana extract were significantly lower than those in the control group over the 1-24 h 
post-dose time period (at least, p < 0.05). For MDEA, the plasma concentrations were only 
detected (not quantified) in the rats treated with P. cupana extract and in the rats of the 
control group the plasma concentrations were also low with values near or below the LOQ 
Chapter V 
 
 
166 
(0.100 µg/mL). The main plasma pharmacokinetic parameters estimated for AM and MDEA 
after non-compartmental analysis of their concentration-time profiles are summarized in 
Table V.1.  
 
Table V.1 – Pharmacokinetic parameters estimated by non-compartmental analysis of the 
plasma concentration-time profiles of amiodarone (AM) and mono-N-desethylamiodarone 
(MDEA, major metabolite of AM) obtained in rats after the simultaneous co-administration 
in single-dose of Paullinia cupana extract (821 mg/kg, p.o.), or vehicle (0.5% 
carboxymethylcellulose aqueous solution), with AM (50 mg/kg, p.o.) by oral gavage (n = 6, 
unless otherwise noted). 
Parameter AM Paullinia 
 AM Vehicle 
AM MDEA  AM MDEA 
tmax (h) 3.67 ± 1.17 NA  1.83 ± 0.48 7.20 ± 1.36
a 
Cmax (µg/mL) 0.370 ± 0.043* NA  1.378 ± 0.179 0.125 ± 0.012
a 
AUC0-t (µ.h/mL) 5.387 ± 0.619* ND  12.774 ± 0.688 ND 
AUC0-∞ (µg.h/mL) 12.050 ± 2.118
# ND  21.431 ± 2.077 ND 
kel (1/h) 0.0310 ± 0.0044 ND  0.0433 ± 0.0082 ND 
t1/2el (h) 24.18 ± 2.75 ND  20.73 ± 5.74 ND 
MRT (h) 36.87 ± 4.28 ND  28.64 ± 7.74 ND 
NA, not available; ND, not determined. 
an = 5. 
*p < 0.001, significantly different from the control group. 
#p < 0.05, significantly different from the control group. 
 
With the co-administration of P. cupana extract the mean Cmax of AM was 
significantly lower than that obtained in the control (vehicle) group (p < 0.001), while the 
mean time to reach Cmax (tmax) was attained later in the experimental group (3.67 ± 1.17 h) 
comparatively to the control group (1.83 ± 0.48 h). Statistically significant differences were 
also observed for the AUC0-t pharmacokinetic parameter (p < 0.001) calculated from the 
plasma concentration-time data obtained for AM in both groups; these differences were also 
evident for the AUC0-∞ parameter (p < 0.05) (Table V.1). Taking into consideration the 
information derived from Figure V.3, it is clear that following the simultaneous co-
administration of P. cupana extract and AM a remarkable decrease (73.2%) in the Cmax of the 
drug was observed, as well as a reduction of 57.8% in the extent of systemic drug exposure 
(as assessed by AUC0-t). 
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Figure V.3 – Ratios for the main plasma pharmacokinetic parameters (Cmax, AUC0-t and    
AUC0-∞) estimated for amiodarone (AM) in rats simultaneously treated in single-dose with 
Paullinia cupana extract (821 mg/kg, p.o.), or vehicle (0.5% carboxymethylcellulose aqueous 
solution), and AM (50 mg/kg, p.o.) by oral gavage.  
 
The mean values estimated for the elimination pharmacokinetic parameters are 
similar in both groups (P. cupana extract versus vehicle). Considering the paucity of 
quantifiable plasma concentrations obtained for MDEA, it was only possible to present the 
Cmax and tmax parameters to the control (vehicle) group (Table V.1). 
In addition, to examine some aspects related to the biodistribution of AM and MDEA 
in rats, both in the presence or absence of the co-administration with P. cupana, the animals 
were sacrificed at 24 h after dosing and several tissues were excised and analysed. The mean 
concentrations of AM and MDEA determined in heart, lung, liver and kidney tissues, and also 
their plasma concentrations at the same time (24 h) are shown in Figure V.4.  
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Figure V.4 – Mean plasma and tissue (heart, lung, liver and kidney) concentrations of 
amiodarone (AM) and mono-N-desethylamiodarone (MDEA) obtained, at 24 h post-dose, 
from rats simultaneously treated in single-dose with Paullinia cupana extract (821 mg/kg, 
p.o.), or vehicle (0.5% carboxymethylcellulose aqueous solution), and AM (50 mg/kg, p.o.) by 
oral gavage. Data are expressed as the mean values ± standard error of the mean (SEM) of 
six determinations (n = 6). *p < 0.05 and #p < 0.001 compared to control (vehicle). 
 
As indicated in Figure V.4, the tissue concentrations of AM and MDEA were 
markedly higher than those determined in plasma, and were absolutely noteworthy the 
levels found for both compounds (AM and MDEA) in the lung tissue. In addition, significant 
differences were found in the concentrations of AM and MDEA in tissues (heart, liver, 
kidney and lung) collected from experimental (P. cupana extract) and control (vehicle) 
groups (p < 0.001) at 24 h post-dose. As expected, the tissue concentrations in the group 
treated with P. cupana were lower than those measured in the control group, reflecting the 
differences observed in the extent of systemic drug exposure. 
 
 
 
 
 
 
Herb-drug interaction of Paullinia cupana (Guarana) seed extract on the pharmacokinetics of AM in rats 
 
 
169 
V.4.2 EFFECTS OF THE SUB-CHRONIC PRE-TREATMENT WITH PAULLINIA CUPANA ON AMIODARONE 
PHARMACOKINETICS 
 
The rats were administered for 14 days with P. cupana extract (821 mg/kg, p.o.) or 
vehicle (control group) in order to investigate a possible interference of the P. cupana sub-
chronic treatment on the pharmacokinetics of AM. The animals were administered with     
50 mg/kg AM (p.o.) one day after the last treatment with P. cupana extract or vehicle, and 
the mean plasma concentration-time profiles (n = 6) of AM and its main metabolite (MDEA) 
are depicted in Figure V.5. 
 
Figure V.5 – Mean plasma concentration-time profiles of amiodarone (AM) and mono-N-
desethylamiodarone (MDEA) obtained, over a period of 24 h, from rats submitted to a 14-
day pre-treatment period with Paullinia cupana extract (821 mg/kg/day, p.o.), or vehicle 
(0.5% carboxymethylcellulose aqueous solution), and treated on the 15th day with a single-
dose of AM (50 mg/kg, p.o.) by oral gavage (n = 6). Symbols represent the mean values ± 
standard error of the mean (SEM) of six determinations per time point (n = 6). 
 
The corresponding pharmacokinetic parameters, calculated by using non-
compartmental analysis, are listed in Table V.2.  
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Table V.2 – Pharmacokinetic parameters estimated by non-compartmental analysis of the 
plasma concentration-time profiles of amiodarone (AM) and mono-N-desethylamiodarone 
(MDEA, major metabolite of AM) obtained in rats submitted to a 14-day pre-treatment 
period with Paullinia cupana extract (821 mg/kg/day, p.o.), or vehicle (0.5% 
carboxymethylcellulose aqueous solution), and treated on the 15th day with a single-dose of 
AM (50 mg/kg, p.o.) by oral gavage (n = 6, unless otherwise noted). 
Parameter AM Paullinia 
 AM Vehicle 
AM MDEA  AM MDEA 
tmax (h) 1.50 ± 0.22 2.00 ± 0.00
a  2.00 ± 0.63 9.00 ± 2.12b 
Cmax (µg/mL) 1.483 ± 0.203 0.112 ± 0.00
a  1.046 ± 0.151 0.106 ± 0.004b 
AUC0-t (µg.h/mL) 13.422 ± 1.266 ND  12.282 ± 1.047 ND 
AUC0-∞ (µg.h/mL) 23.489 ± 1.970 ND  22.057 ± 2.905 ND 
kel (1/h) 0.0416 ± 0.0079 ND  0.0442 ± 0.0108 ND 
t1/2el (h) 23.07 ± 7.58 ND  21.62 ± 5.85 ND 
MRT (h) 32.65 ± 10.41 ND  31.02 ± 8.29 ND 
ND, not determined. 
an = 1; bn = 4. 
 
Overall, it was observed a close overlap between the AM plasma pharmacokinetic 
profiles at the early absorption phase (up to 0.5 h) and at the elimination phase (4-24 h). AM 
plasma concentrations in the group treated with P. cupana were higher than those in the 
control group over the 1-2 h post-dose time period (Figure V.5). However, no significant 
differences (p > 0.05) in the pharmacokinetic parameters were detected for AM and its main 
metabolite (MDEA) among the two groups (P. cupana versus vehicle pre-treatment) (Table 
V.2). The plasma concentrations of MDEA were near or below the LOQ (0.100 µg/mL) of 
the method in both groups of rats. Regarding the data shown in Figure V.6, it  appears  that 
the magnitude of systemic exposure (as assessed by Cmax) is slightly higher in the rats pre-
treated with P. cupana extract, whereas the extent of systemic exposure to AM is similar 
among experimental and control groups (ratios near to unity; as assessed by AUC0-t and 
AUC0-∞). 
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Figure V.6. – Ratios for the main plasma pharmacokinetic parameters (Cmax, AUC0-t and    
AUC0-∞) estimated for amiodarone (AM) in rats submitted to a 14-day pre-treatment period 
with Paullinia cupana extract (821 mg/kg/day, p.o.), or vehicle (0.5% carboxymethylcellulose 
aqueous solution), and treated on the 15th day with a single-dose of AM (50 mg/kg, p.o.) by 
oral gavage.  
 
To examine the influence of a 14-day pre-treatment period with P. cupana extract 
(experimental group) or vehicle (control group) on the distribution and metabolism of AM in 
rats, the concentrations of AM and its major metabolite (MDEA) were also determined in 
various tissues (additionally to plasma) at 24 h post-dose, and the data are shown in Figure 
V.7.  
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Figure V.7 – Mean plasma and tissue (heart, lung, liver and kidney) concentrations of 
amiodarone (AM) and mono-N-desethylamiodarone (MDEA) obtained, at 24 h post-dose, 
from rats submitted to a 14-day pre-treatment period with Paullinia cupana extract (821 
mg/kg/day, p.o.), or vehicle (0.5% carboxymethylcellulose aqueous solution), and treated on 
the 15th day with a single-dose of AM (50 mg/kg, p.o.) by oral gavage. Data are expressed as 
the mean values ± standard error of the mean (SEM) of six determinations (n = 6). 
 
As pointed out in Figure V.7, the concentrations of both compounds (AM and 
MDEA) in tissues were distinctly greater than those measured in plasma, and the 
concentration levels found in lung tissue were extremely high in experimental (P. cupana) 
and control (vehicle) groups. As it was expected from the plasma/systemic pharmacokinetic 
profiles obtained, no significant differences were detected in tissue concentrations between 
both groups. 
 
V.4.3 EFFECT OF THE SUB-CHRONIC PAULLINIA CUPANA TREATMENT ON BODY WEIGHT 
 
The resulting changes in body weight of the rats submitted to a 14-day treatment 
period with P. cupana extract (821 mg/kg/day, p.o) or vehicle are demonstrated in Figure 
V.8.  
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Figure V.8 – Effects on the body weight of the rats induced by the sub-chronic treatment     
(14-day period) with Paullinia Cupana extract (821 mg/kg/day, p.o.) and vehicle (0.5% 
carboxymethylcellulose aqueous solution) by oral gavage (n = 6). *p < 0.01.  
 
From the analysis of the data it was found an increase statistically significant in body 
weight of rats treated with vehicle (control group) between the 1st and 14th day (p < 0.01), 
but differences were not observed in the group of rats administered with P. cupana extract   
(p > 0.05). On the other hand, by comparing the weight changes in both groups (P. cupana 
extract versus vehicle) a statistically significant difference was found, showing that the 
treatment with P. cupana extract was able to suppress gains in body weight of rats. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter V 
 
 
174 
V.5. DISCUSSION 
 
In literature, some interactions have been reported describing the interference of 
compounds, including herbal products, on the pharmacokinetics of AM. Between them, 
grapefruit juice can inhibit dramatically AM metabolism (LIBERSA et al., 2000); in addition, 
orlistat can reduce significantly the systemic exposure to AM and MDEA (ZHI et al., 2003); 
and, more recently, the exposure of rats to β-naphthoflavone (a polycyclic aromatic 
hydrocarbon) was found to increase the formation of MDEA probably through cytochrome 
P450 (CYP) induction (ELSHERBINY, EL-KADI and BROCKS, 2010). The present work was 
designed to investigate in vivo the potential of interaction between P. cupana extract and 
AM, using adult male Wistar rats (a whole-animal model). Taking into account that drug-drug 
or herb-drug interactions mainly occur at the level of absorption and/or metabolic (inhibition 
or induction) pathways, the pharmacokinetic studies reported herein were designed to 
examine the interference of P. cupana extract on the gastrointestinal absorption 
(simultaneous co-administration study) and on the metabolism of AM (14-day P. cupana pre-
treatment study). 
Our results clearly evidenced a significant decrease (73.2%) in the peak plasma 
concentration (Cmax) of the drug following the simultaneous co-administration of the P. 
cupana extract and AM, as well as a reduction of 57.8% in the extent of systemic drug 
exposure (as assessed by AUC0-t). On the other hand, an increase was also observed on the 
magnitude of systemic exposure to AM (as assessed by Cmax) while no important differences 
were found in the extent of systemic drug exposure (as assessed by AUC0-t and AUC0-∞) 
after the administration of the drug to pre-treated rats one day after the last treatment with 
P. cupana extract or vehicle. Hence, it is apparent that P. cupana extract or its components 
interact with AM in the gastrointestinal tract, reducing significantly the bioavailability of the 
drug after their simultaneous co-administration in a single-dose. However, the similarity 
observed in the extent of systemic exposure to AM in rats pre-treated for 14 days with P. 
cupana extract or vehicle excludes the impact of P. cupana-induced metabolism on the 
bioavailability of the drug. In fact, in the rats pre-treated for 14 days with P. cupana extract it 
was apparent an increasing of the magnitude of systemic exposure to AM but this difference 
was not statistically significant. Thus, the concomitant administration of P. cupana extract 
and AM in a single dose study supports the significance of the interaction at the level of the 
gastrointestinal tract. A significant reduction of the absorption of AM induced by orlistat in 
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healthy volunteers was also observed (ZHI et al., 2003); this drug, a lipase inhibitor, 
significantly reduced the systemic exposure to AM by approximately 25% and a decrease of 
similar magnitude (~25%) was detected in the generation of the metabolite MDEA (the 
major metabolite of AM). According to ZHI et al. (2003) the absorption of highly lipophilic 
drugs such as AM may depend on the presence of a lipid phase in the gastrointestinal 
environment, which may be affected by the pharmacological action of orlistat. The magnitude 
(Cmax) and extent (AUC0-t) of absorption of AM was also enhanced in healthy volunteers who 
received a single-dose of the drug immediately after consuming a high-fat meal versus 
following an overnight fast (MENG et al., 2001). SHAYEGANPOUR, JUN and BROCKS (2005) also 
studied the effects of food on the pharmacokinetics of AM in rats. The results obtained 
concerning the interference of lipids on the oral bioavailability of AM corroborated those 
reported in humans. 
Taking into account the great diversity of components present in P. cupana extract, 
especially methylxantines (caffeine) and large quantity of tannins (CARLINI, 2003), we 
hypothesize the occurrence of a physical-chemical interaction between those compounds 
and AM in the gastrointestinal tract of rats to explain the considerable decrease in the 
systemic exposure/bioavailability of AM observed after the simultaneously co-administration 
with P. cupana extract. However, further studies are needed to understand the mechanism 
associated to this herb-drug interaction (P. cupana extract/AM), which is reported herein for 
the first time.  
The central role that CYPs induction or inhibition plays on drug-drug and herb-drug 
interactions is well recognised. Hence, to check the possible interference of P. cupana 
extract on the CYP activity, the extract was administered for 14 days (821 mg/kg/day, p.o.) 
until 24 h before applying AM; however, only an apparent influence was observed on the 
magnitude of systemic (plasma) exposure to AM in these circumstances. Although this 
finding has not had in this case a significant impact on the magnitude of systemic exposure to 
AM, it is an interesting aspect to explore in further studies directed to evaluate the potential 
of enzyme induction or inhibition by P. cupana. 
Globally, considering the rat plasma data generated in the present work and that 
reported from clinical studies following oral administration of AM, it is clear that MDEA is 
the major metabolite of AM in both species, despite differences will exist in their metabolite-
to-parent ratios. Indeed, in our pharmacokinetic studies, the plasma concentrations of 
MDEA found in rat were significantly lower than those of AM, and were found at levels near 
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or below the LOQ (0.100 µg/mL) of the bioanalytical assay. Furthermore, AM and MDEA 
were found in concentrations considerably lower in plasma than in tissues (heart, liver, lungs 
and kidneys) at 24 h post-dose, supporting their great plasma/tissue distribution; these 
differences were absolutely remarkable for plasma/lung tissue. These rat tissues were 
selected for bioanalysis of AM and MDEA because they represent important targets from 
therapeutic (heart), toxicological (liver and lungs) and pharmacokinetic (liver and kidneys) 
viewpoints. 
Based on the data of herb-drug interaction between P. cupana extract and AM 
derived from this non-clinical investigation in rat, it is suggested that patients who are taking 
AM should avoid the concurrent administration of herbal medicines/supplements containing 
P. cupana. However, taking also into account the absence of a significant herb-drug 
interaction between the extract and AM in the 14-day P. cupana pre-treatment study, it is 
not expected an important impact on the drug efficacy if medicinal products containing P. 
cupana extract and AM were administered separately in the time. It is also true that results 
from animal experiments cannot be directly extrapolated to humans however, bearing in 
mind the studies of SHAYEGANPOUR, JUN and BROCKS (2005) and MENG et al. (2001) the rat 
appears to be an appropriate animal model for man in this situation. Nevertheless, to reliably 
assess the clinical outcomes of the interaction between P. cupana extract and AM specific 
clinical trials are needed.  
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V.7. SUPPLEMENTARY DATA 
 
Certificate of analysis of Guarana (Paullinia cupana L.) extract 12% caffeine provided by Bio 
Serae Laboratories (Ref. 41004 – Batch 0904627). 
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INVESTIGATING HERB-DRUG INTERACTIONS: THE EFFECT OF CITRUS AURANTIUM 
FRUIT EXTRACT ON THE PHARMACOKINETICS OF AMIODARONE IN RATS 
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VI. INVESTIGATING HERB-DRUG INTERACTIONS: THE EFFECT OF CITRUS AURANTIUM FRUIT 
EXTRACT ON THE PHARMACOKINETICS OF AMIODARONE IN RATS  
 
VI.1. ABSTRACT  
 
Citrus aurantium extract has been largely used in weight loss and sports performance 
dietary supplements. However, the safety of C. aurantium-containing products has been 
questioned mainly due to the association of its use with adverse events in the cardiovascular 
system. Therefore, this work aimed to assess the potential for herb-drug interactions among 
a standardized C. aurantium extract (GMP certificate) and amiodarone (AM; narrow 
therapeutic index drug) in rats. In a first pharmacokinetic study, rats were simultaneously co-
administered with a single-dose of C. aurantium (164 mg/kg, p.o.) and AM (50 mg/kg, p.o.); in 
a second study, rats were pre-treated during 14 days with C. aurantium (164 mg/kg/day, 
p.o.) and received AM (50 mg/kg, p.o.) on the 15th day. Rats of the control groups received 
the corresponding volume of vehicle. Overall, after analysis of the pharmacokinetic data, it 
deserves to be highlighted the significant increase of the peak plasma concentration of AM in 
rats pre-treated with C. aurantium extract, while the extent of systemic exposure was 
comparable between both groups. For the first time, data on the potential of herb-drug 
interaction between C. aurantium extract and AM were reported. However, specific clinical 
trials should be performed to confirm these results in humans. 
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VI.2. INTRODUCTION 
 
Citrus aurantium, previously called as Fructus aurantii, is the botanical name of a 
plant commonly known as bitter orange, sour orange, green orange, Seville orange or zhi shi 
(BOUCHARD et al., 2005; HAAZ et al., 2006). The extract of the immature fruit or peel of C. 
aurantium has been widely used in weight loss dietary supplements and in sports 
performance products (STOHS, PREUSS and SHARA, 2011a). In particular, after the ban of the 
sale of all ephedra-containing supplements by the Food and Drug Administration (FDA) in 
2004, C. aurantium has gained an additional popularity as a safe alternative to Ephedra in 
herbal weight loss products (FOOD AND DRUG ADMINISTRATION and HHS, 2004; HANSEN et 
al., 2012, 2013). C. aurantium has been used as an ingredient of the dietary supplements 
marketed for weight loss aid due to its claimed effects on metabolism, increasing the basal 
metabolic rate and lipolysis, and also as appetite suppressant (STOHS, PREUSS and SHARA, 
2012). However, C. aurantium has not been traditionally employed for weight loss (HAAZ et 
al., 2006). Historically, this herb has been mainly used in traditional Chinese medicine to 
treat gastrointestinal disorders like abdominal distension, dysentery and constipation 
(MATTOLI et al., 2005; STOHS, PREUSS and SHARA, 2011a).  
Synephrine, also called p-synephrine or oxedrine, is considered to be the main 
pharmacologically active protoalkaloid present in the extracts of immature fruit or peel of C. 
aurantium, which comprises more than 85% of the total protoalkaloid content. Additionally, 
other minor protoalkaloids constituents include the biogenic amines octopamine, hordenine, 
tyramine and N-methyltyramine (FUGH-BERMAN and MYERS, 2004; STOHS, PREUSS and SHARA, 
2011a; HANSEN et al., 2012). Structurally, synephrine is closely related to ephedrine (one of 
the main active constituents found in the genus Ephedra) (HANSEN et al., 2012, 2013). 
However, despite their great structural similarities, synephrine contrary to ephedrine seems 
to exhibit little or no stimulant activity on the cardiovascular and central nervous system; 
the small chemical differences between synephrine and ephedrine also appear to significantly 
change their pharmacokinetic properties, particularly their ability to cross the blood-brain 
barrier (STOHS, PREUSS and SHARA, 2011b). Based on receptor binding studies, synephrine 
exhibited poor affinity for β-1, β-2 and α-adrenoreceptors, which are usually associated with 
cardiovascular effects (particularly β-1 and α-adrenoreceptors); instead, synephrine showed 
β-3 adrenergic activity which is responsible for increased thermogenesis and lipolysis (STOHS, 
PREUSS and SHARA, 2011a). Even so, the safety and efficacy of supplements containing C. 
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aurantium have been questioned (BENT, PADULA and NEUHAUS, 2004; FUGH-BERMAN and 
MYERS, 2004). 
A large number of case reports have emerged over the last years associating the use 
of C. aurantium-containing products with serious clinical adverse events, most of them 
involving the cardiovascular system, such as syncope and prolongation of the QT interval 
(NASIR et al., 2004), myocardial infarction (NYKAMP, FACKIH and COMPTON, 2004; THOMAS et 
al., 2009), ischemic stroke (BOUCHARD et al., 2005), angina (GANGE et al., 2006) and 
tachycardia (FIRENZUOLI, GORI and GALAPAI, 2005), bradycardia and hypotension (GRAY and 
WOOLF, 2005), vasospasm and stroke (HOLMES JR. and TAVEE, 2008), ventricular fibrillation 
(STEPHENSEN and SARLAY JR., 2009) and ischemic colitis (SULTAN et al., 2006). Furthermore, a 
pharmacokinetic herb-drug interaction involving a decoction of C. aurantium and 
cyclosporine was also reported (HOU et al., 2000). 
Hence, considering that C. aurantium has been extensively used as a replacement of 
Ephedra in the composition of weight loss dietary supplements and considering that the 
obesity and overweight are increasing at an alarming rate (PITTLER, SCHMIDT and ERNST, 
2005), representing major independent risk factors for cardiovascular diseases (SCAGLIONE 
et al., 2004; BODARY, IGLAY and EITZMAN, 2007; ZALESIN et al., 2011), an increase on the 
consumption of herbal supplements containing C. aurantium is still expected. Thus, as the 
concurrent use of these herbal products and conventional drugs may lead to significant 
clinical herb-drug interactions, it is therefore absolutely pertinent to investigate the potential 
for pharmacokinetic interactions between C. aurantium and narrow therapeutic index drugs, 
as is the case of amiodarone (AM). 
AM [2-n-butyl-3-(3,5-diiodo-4-diethylaminoethoxy-benzoyl)-benzofuran; (Figure VI.1)] 
still remains one of the most widely prescribed antiarrhythmic drugs for the treatment of 
atrial fibrillation and ventricular arrhythmias despite the availability of novel antiarrhythmic 
agents (PAPIRIS et al., 2010). From a pharmacological viewpoint AM has unusual and complex 
pharmacokinetic properties (SHAYEGANPOUR, HAMDY and BROCKS, 2008; VAN HERENDAEL and 
DORIAN, 2010). AM has a variable oral bioavailability (20-80%) and the great lipophilicity of 
AM and its main metabolite [mono-N-desethylamiodarone (MDEA)] (Figure VI.1) leads to a 
high volume of distribution and a variable accumulation into tissues (VAN HERENDAEL AND 
DORIAN, 2010). MDEA is the product of the most predominant metabolic route of AM, the 
N-deethylation which is catalyzed by cytochrome P450 (CYP) isoenzymes (TRIVIER et al., 
1993; SOYAMA et al., 2002). Moreover, AM is recognised as a drug of narrow therapeutic 
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window (0.5-2.0 µg/mL) (PÉREZ-RUIZ et al., 2002; SHAYEGANPOUR, HAMDY and BROCKS, 2008) 
and it has also been associated to important clinical drug interactions (SIDDOWAY, 2003; 
EDWIN, JENNINGS and KALUS, 2010; KARIMI et al., 2010; ROUGHEAD et al., 2010).  
 
Figure VI.1 – Chemical structures of amiodarone (AM) and its major metabolite mono-N-
desethylamiodarone (MDEA). 
 
Taking into account all the reasons previously referred and bearing in mind the 
potential for co-administration of C. aurantium medicinal products and AM, this work was 
planned to investigate if a standardized extract of the green fruit of C. aurantium may 
influence the pharmacokinetics of AM in rats, following their simultaneous oral co-
administration, and after a 14-day C. aurantium pre-treatment period. 
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VI.3. MATERIALS AND METHODS  
 
VI.3.1 DRUGS AND MATERIALS 
 
C. aurantium hidroalcoholic extract 10% synephrine (11.1% synephrine by high-
performance liquid chromatography-ultraviolet detection batch analysis; approximately 94% 
of the total content in potent amines consists of synephrine) obtained from green fruit was 
purchased from Bio Serae Laboratories (Bram, France); the corresponding certificate of 
analysis ref. 410039 (batch 0907799) is provided as Supplementary data. 
Carboxymethylcellulose sodium salt for preparation of extract suspension was obtained 
from Sigma (St. Louis, MO, USA). A commercial formulation (ampoules) of AM 
hydrochloride 50 mg/mL solution for intravenous injection was used for oral administration 
to rats after appropriate dilution with 5% glucose intravenous solution for infusion (B. Braun 
Medical, Portugal). Other compounds used were sodium chloride 0.9% solution for injection 
(Labesfal, Portugal); heparin sodium 5000 U.I./mL for injection (B. Braun Medical, Portugal); 
ketamine for injection (Imalgene 1000) and xylazine for injection (Vetaxilaze 20). Introcan® 
Certo IV indwelling cannula (22G; 0.9 × 2.5 mm) made of polyurethane from B. Braun 
Melsungen AG (Melsungen, Germany). 
 
VI.3.2 ANIMALS 
 
Adult male Wistar rats (361 ± 26 g) of approximately 10 weeks old were obtained 
from local animal facilities (Faculty of Health Sciences of the University of Beira Interior, 
Covilhã, Portugal). The rats were maintained under controlled environmental conditions 
(temperature 20 ± 2 ºC; relative humidity 55 ± 5%; 12-h light/dark cycle). The animals were 
allowed free access to a standard rodent diet (4RF21, Mucedola, Italy) during almost all 
experimental procedures and tap water was available ad libitum. At night on the day before 
dosing with AM, a lateral tail vein of each rat was cannulated, under anaesthesia [ketamine 
(90 mg/kg)/xylazine (10 mg/kg); i.p. injection], by insertion of an Introcan® Certo IV 
indwelling cannula (22G; 0.9 × 2.5 mm) used for serial blood sampling. The rats fully 
recovered from anaesthesia overnight and were fasted for 12-14 h before AM administration 
and maintained with free access to water; in order to avoid the effect of food on the oral 
bioavailability of AM an additional fasting period was considered (4 h post-dose). Oral 
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treatments of the rats with C. aurantium extract and AM were performed by gavage. Blood 
sampling was conducted in conscious and freely moving rats, which were appropriately 
restrained only at the moment of blood collection, except for the last blood sampling that 
was taken by a terminal procedure (decapitation and exsanguination under anaesthesia). All 
the animal experiments were conducted in accordance with the European Directive 
(2010/63/EU) for the accommodation and care of laboratory animals and the experimental 
procedures were reviewed and approved by the Portuguese Veterinary General Division. 
 
VI.3.3 EXPERIMENTAL DESIGN AND PHARMACOKINETIC STUDIES 
 
Two separate and independent pharmacokinetic studies were designed to investigate 
the effects of C. aurantium on the kinetics of AM: (1) a single oral co-administration study of 
C. aurantium extract and AM; and (2) a 14-day repeated oral pre-treatment study with C. 
aurantium extract and on the 15th day a single oral dose of AM was given. The dose of C. 
aurantium was selected based on the dose recommended to humans by the supplier of the 
extract (Bio Serae Laboratories) and taking into account the FDA Guidance for Industry on 
conversion of animal doses to human equivalent doses, which considers the body surface 
area (GUIDANCE FOR INDUSTRY, 2005); additionally, a 10-fold potentiating interaction factor 
was applied. The experimental dose of herbal extract selected is greater than the typical 
human daily dose to avoid false negative results and considering potential differences in the 
extrapolation between species (rat versus human). On the other hand, the single oral dose 
of AM (50 mg/kg) was established because it has provided plasma concentrations of AM in 
rats within the plasma therapeutic range (SHAYEGANPOUR, JUN and BROCKS, 2005). In each 
day of the experiments C. aurantium extract was suspended in 0.5% carboxymethylcellulose 
aqueous solution affording a suspension of herbal extract at 16.4 mg/mL. AM commercial 
injectable solution (50 mg/mL) was also appropriately diluted with 5% glucose solution to 
extemporaneously prepare an AM solution at 12.5 mg/mL. Appropriate volumes of C. 
aurantium extract suspension (10 mL/kg of body weight) and of AM solution (4 mL/kg of 
body weight) were orally administered to rats by oral gavage. 
In the first pharmacokinetic study, twelve Wistar rats were randomly divided into 
two groups (experimental and control groups). The rats of the experimental group (n = 6) 
were concomitantly treated with a single-dose of C. aurantium extract (164 mg/kg, p.o.) and 
a single-dose of AM (50 mg/kg, p.o.); the extract suspension was administered just before 
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AM. The rats of the control group (n = 6) received, instead of the C. aurantium extract 
suspension, the corresponding volume of 0.5% carboxymethylcellulose aqueous solution 
(vehicle of the extract). 
In the second pharmacokinetic study, twelve Wistar rats were also randomly divided 
into two groups. The rats assigned to the experimental group (n = 6) were orally pre-
treated with C. aurantium extract (164 mg/kg, p.o.) once daily for 14 consecutive days 
(short-term repeated dose pre-treatment study), whereas the rats allocated to the control 
group (n = 6) were administered with an equivalent volume of vehicle for the same period of 
time. During the pre-treatment period, the rats were kept in 12-h light/dark cycle animal 
room with controlled temperature and humidity, as indicated above (section VI.3.2); free 
access to a standard rodent diet and tap water was allowed. On 15th day, the rats of both 
groups (experimental and control) were gavaged with a single-dose of AM (50 mg/kg, p.o.).  
In both pharmacokinetic studies the treatments with C. aurantium extract (or 
vehicle) and/or AM were always carried out on the morning between 9:00 am and 11:45 am. 
At night on the day before AM administration, the rats were anaesthetized for cannulation of 
a lateral tail vein and were fasted overnight as described above (section VI.3.2). On the day 
after, multiple serial blood samples (approximately 0.3 mL) were collected through the 
cannula into heparinized tubes before dosing and at 0.25, 0.5, 1, 2, 4, 6, 8 and 12 h following 
AM administration; the blood samples were collected from all 6 rats in each treatment group 
at each time-point. Then, at 24 h post-dose, blood and tissues (heart, liver, kidneys and 
lungs) were also harvested after decapitation of the rats. The blood samples were 
centrifuged at 4000 rpm for 10 min (4 ºC) to separate the plasma which was stored at         
–20 ºC until analysis. After exsanguination, liver, kidneys, heart and lungs were excised and 
stored at –20 ºC; the organs were weighed and homogenized in distilled water (3 mL of 
water per gram of tissue) before analysis of tissue homogenates samples. 
 
VI.3.4 DRUG ANALYSIS 
 
Plasma and tissue concentrations of AM and its main metabolite MDEA were 
determined by using a liquid-liquid extraction procedure coupled to the high-performance 
liquid chromatography-diode array detection assay previously developed and validated 
(RODRIGUES et al., 2013a).  
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VI.3.5 PHARMACOKINETIC ANALYSIS 
 
The plasma concentration versus time data for AM and MDEA obtained from each 
individual rat were submitted to a non-compartmental pharmacokinetic analysis using the 
WinNonlin® version 4.1 (Pharsight Co, Mountain View, CA, USA). The peak concentrations 
of AM and MDEA in plasma (Cmax) and the time to reach Cmax (tmax) were directly obtained 
from the experimental data. Other pharmacokinetic parameters estimated from the 
individual plasma concentration-time profiles  were: area under the concentration-time 
curve (AUC) from time zero to the last sampling time at which concentrations were at or 
above the limit of quantification (LOQ; 0.100 µg/mL) of the method (AUC0-t), calculated by 
the linear trapezoidal rule; AUC from time zero to infinite (AUC0-∞), calculated from    
AUC0-t + (Clast/kel), where Clast is the last quantifiable concentration and kel is the apparent 
terminal elimination rate constant calculated by log-linear regression of the terminal segment 
of the concentration-time profile; apparent terminal elimination half-life (t1/2el) and mean 
residence time (MRT). The concentrations lower than the LOQ of the assay were taken as 
zero for all calculations. 
 
VI.3.6 SHORT-TERM REPEATED DOSE EFFECT OF CITRUS AURANTIUM ON BODY WEIGHT 
 
In the pre-treatment study (a 14-day C. aurantium treatment period), the body 
weight of the rats administered with C. aurantium extract (164 mg/kg/day, p.o.; experimental 
group) or vehicle (control group) was adequately registered on the first day and on the last 
day (14th) of the treatments in order to evaluate the effect of C. aurantium extract on body 
weight changes. 
 
VI.3.7 STATISTICAL ANALYSIS 
 
Data were reported as the mean ± standard error of the mean (SEM). Comparisons 
between two groups were usually performed using unpaired two-tailed Student’s t-test; for 
body weight comparisons within the same group the paired Student’s t-test was employed. A 
difference was considered to be statistically significant for a p-value lower than 0.05 (p < 
0.05). 
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VI.4. RESULTS 
 
VI.4.1 SIMULTANEOUS CO-ADMINISTRATION OF CITRUS AURANTIUM AND AMIODARONE 
 
The mean plasma concentration-time profiles (n = 6) of AM and its main metabolite 
(MDEA) obtained after the intragastric simultaneous co-administration of rats with a single-
dose of C. aurantium extract (164 mg/kg, p.o.) or vehicle (control group) and a single-dose 
of AM (50 mg/kg, p.o.) are shown in Figure VI.2.  
 
Figure VI.2 – Mean plasma concentration-time profiles of amiodarone (AM) and mono-N-
desethylamiodarone (MDEA) obtained, over a period of 24 h, from rats simultaneously 
treated in single-dose with Citrus aurantium extract (164 mg/kg, p.o.), or vehicle (0.5% 
carboxymethylcellulose aqueous solution), and AM (50 mg/kg, p.o.) by oral gavage. Symbols 
represent the mean values ± standard error of the mean (SEM) of six determinations per 
time point (n = 6). #p < 0.001 compared to control (vehicle). 
 
Overall, the mean plasma concentrations of AM were found to be statistically 
different only at 24 h post-dose (p < 0.001). In the case of MDEA, the plasma concentrations 
were similar in both groups, with values near or below the LOQ (0.100 µg/mL) of the 
method. The mean plasma pharmacokinetic parameters estimated for AM and MDEA after 
non-compartmental analysis of each individual concentration-time profile are summarized in 
Table VI.1.  
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Table VI.1 – Mean pharmacokinetic parameters estimated by non-compartmental analysis of 
the plasma concentration-time profiles of amiodarone (AM) and mono-N-
desethylamiodarone (MDEA, major metabolite of AM) obtained in rats after the 
simultaneous co-administration in single-dose of Citrus aurantium extract (164 mg/kg, p.o.), 
or vehicle (0.5% carboxymethylcellulose aqueous solution), with AM (50 mg/kg, p.o.) by oral 
gavage (n = 6, unless otherwise noted). 
Parameter AM Citrus 
 AM Vehicle 
AM MDEA  AM MDEA 
tmax (h) 3.17 ± 0.75 12.00 ± 0.00
a  1.83 ± 0.48 7.20 ± 1.36b 
Cmax (µg/mL) 1.405 ± 0.174 0.109 ± 0.006
a  1.378 ± 0.179 0.125 ± 0.012b 
AUC0-t (µg.h/mL) 16.417 ± 1.553 ND  12.774 ± 0.688 ND 
AUC0-∞ (µg.h/mL) 25.797 ± 1.185 ND  21.431 ± 2.077 ND 
kel (1/h) 0.0472 ± 0.0068 ND  0.0433 ± 0.0082 ND 
t1/2el (h) 16.57 ± 2.78 ND  20.73 ± 5.74 ND 
MRT (h) 24.63 ± 4.32 ND  28.64 ± 7.74 ND 
ND, not determined. 
an = 2; bn = 5 
 
From the observation of mean plasma concentration-time profiles of AM (Figure 
VI.2), it is evident that the time to reach Cmax (tmax) was attained later in the experimental (C. 
aurantium) group than in the control (vehicle) group. Taking into consideration the 
information derived from Figure VI.3, it is clear that following the simultaneous co-
administration of C. aurantium and AM, the magnitude of systemic exposure (as assessed by 
Cmax) is similar among experimental and control groups and the extent of systemic exposure 
to AM (as assessed by AUC0-t and AUC0-∞) is slightly higher in the rats co-administered with 
C. aurantium extract and AM.  
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Figure VI.3 – Ratios for the main plasma pharmacokinetic parameters (Cmax, AUC0-t and   
AUC0-∞) estimated for amiodarone (AM) in rats simultaneously treated in single-dose with 
Citrus aurantium extract (164 mg/kg, p.o.), or vehicle (0.5% carboxymethylcellulose aqueous 
solution), and AM (50 mg/kg, p.o.) by oral gavage.   
 
However, no statistically significant differences in the mean pharmacokinetic 
parameters for AM were detected among the two groups (C. aurantium versus vehicle) 
(Table VI.1). These data show that the treatment of rats with C. aurantium extract does not 
significantly affect the extent of systemic exposure to AM (as assessed by AUC0-t and    
AUC0-∞) despite the slight increase of these parameters in the group of rats co-administered 
with C. aurantium extract and AM, but the maximum exposure to the drug is delayed. 
Considering the scarcity of quantifiable plasma concentrations obtained for MDEA in both 
groups, only the Cmax and tmax pharmacokinetic parameters are presented in Table VI.1. 
To examine the biodistribution of AM and MDEA in rats, either in the presence or 
absence of the co-administration with C. aurantium, at 24 h after dosing all animals were 
sacrificed and several organs were excised and analysed. The mean concentrations of AM 
and MDEA determined in heart, lung, liver and kidney tissues, and also the plasma 
concentrations at the same time (24 h), are shown in Figure VI.4.  
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Figure VI.4 – Mean plasma and tissue (heart, lung, liver and kidney) concentrations of 
amiodarone (AM) and mono-N-desethylamiodarone (MDEA) obtained, at 24 h post-dose, 
from rats simultaneously treated in single-dose with Citrus aurantium extract (164 mg/kg, 
p.o.), or vehicle (0.5% carboxymethylcellulose aqueous solution), and AM (50 mg/kg, p.o.) by 
oral gavage. Data are expressed as the mean values ± standard error of the mean (SEM) of 
six determinations (n = 6). *p < 0.05 and #p < 0.001 compared to control (vehicle). 
 
The tissue concentrations of AM and MDEA were markedly higher than those 
measured in plasma, and the concentration levels found for both compounds (AM and 
MDEA) in the lung tissue were absolutely noteworthy. However, despite the significant 
differences detected at 24 h post-dose for AM plasma concentrations (p < 0.001), at the 
same time only for heart tissue were also found statistically significant differences (p < 0.05), 
and the concentrations of AM were higher in the group of rats treated with the extract. 
 
VI.4.2 SHORT-TERM REPEATED DOSE PRE-TREATMENT STUDY WITH CITRUS AURANTIUM FOLLOWED 
BY AMIODARONE ADMINISTRATION 
 
The rats were administered for 14 days with C. aurantium extract (164 mg/kg/day, 
p.o.; experimental group) or vehicle (control group) in order to investigate a possible 
interference of the short-term repeated dose pre-treatment with the extract on the 
pharmacokinetics of AM. The day after the last treatment with C. aurantium extract or 
vehicle, all animals received a single-oral dose of 50 mg/kg AM and the mean plasma 
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concentration-time profiles (n = 6) of the drug and its main metabolite (MDEA) are depicted 
in Figure VI.5.  
 
Figure VI.5 – Mean plasma concentration-time profiles of amiodarone (AM) and mono-N-
desethylamiodarone (MDEA) obtained, over a period of 24 h, from rats submitted to a 14-
day pre-treatment period with Citrus aurantium extract (164 mg/kg/day, p.o.), or vehicle 
(0.5% carboxymethylcellulose aqueous solution), and treated on the 15th day with a single-
dose of AM (50 mg/kg, p.o.) by oral gavage (n = 6). Symbols represent the mean values ± 
standard error of the mean (SEM) of six determinations per time point (n = 6). *p < 0.05 
compared to control (vehicle). 
 
Comparing the mean plasma concentrations for AM in both groups, they were found 
to be statistically different only at 2 h post-dose (p < 0.05), and they were higher in the 
group treated with C. aurantium. The mean plasma pharmacokinetic parameters for AM and 
MDEA determined by applying non-compartmental analysis to each individual concentration-
time profile are listed in Table VI.2. 
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Table VI.2 – Mean pharmacokinetic parameters estimated by non-compartmental analysis of 
the plasma concentration-time profiles of amiodarone (AM) and mono-N-
desethylamiodarone (MDEA, major metabolite of AM) obtained in rats submitted to a 14-
day pre-treatment period with Citrus aurantium extract (164 mg/kg/day, p.o.), or vehicle 
(0.5% carboxymethylcellulose aqueous solution), and treated on the 15th day with a single-
dose of AM (50 mg/kg, p.o.) by oral gavage (n = 6, unless otherwise noted). 
ND, not determined. 
an = 2; bn = 4. 
*p < 0.01, significantly different from the control group. 
 
 The pre-treatment with C. aurantium extract determined a significantly higher Cmax 
value for AM (p < 0.01), while for the other pharmacokinetic parameters no significant 
differences were found between both groups. The plasma concentrations of MDEA were 
near or below the LOQ (0.100 µg/mL) of the method in both groups. From the data shown 
in Figure VI.6, it is evident that the degree of systemic exposure to AM (as assessed by Cmax) 
is higher in the rats pre-treated with C. aurantium extract comparatively with those of the 
control group, whereas the extent of systemic exposure to AM is similar among 
experimental and control groups (ratios near to unity; as assessed by AUC0-t and AUC0-∞).   
 
 
 
 
 
Parameter AM Citrus 
 AM Vehicle 
AM MDEA  AM MDEA 
tmax (h) 2.67 ± 0.61 7.00 ± 1.00
a  2.00 ± 0.63 9.00 ± 2.12b 
Cmax (µg/mL) 1.654 ± 0.103* 0.107 ± 0.003
a  1.046 ± 0.151 0.106 ± 0.004b 
AUC0-t (µg.h/mL) 14.318 ± 1.158 ND  12.282 ± 1.047 ND 
AUC0-∞ (µg.h/mL) 23.901 ± 4.047 ND  22.057 ± 2.905 ND 
kel (1/h) 0.0485 ± 0.0074 ND  0.0442 ± 0.0108 ND 
t1/2el (h) 16.38 ± 2.93 ND  21.62 ± 5.85 ND 
MRT (h) 23.97 ± 3.89 ND  31.02 ± 8.29 ND 
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Figure VI.6 – Ratios for the main plasma pharmacokinetic parameters (Cmax, AUC0-t and   
AUC0-∞) estimated for amiodarone (AM) in rats submitted to a 14-day pre-treatment period 
with Citrus aurantium extract (164 mg/kg/day, p.o.), or vehicle (0.5% carboxymethylcellulose 
aqueous solution), and treated on the 15th day with a single-dose of AM (50 mg/kg, p.o.) by 
oral gavage. 
 
To investigate the influence of a 14-day pre-treatment period with C. aurantium 
extract (experimental group) or vehicle (control group) on the distribution and metabolism 
of AM in rats, the concentrations of AM and its major metabolite (MDEA) were also 
determined in various tissues (additionally to plasma) at 24 h post-dose and the results are 
shown in Figure VI.7.  
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Figure VI.7 – Mean plasma and tissue (heart, lung, liver and kidney) concentrations of 
amiodarone (AM) and mono-N-desethylamiodarone (MDEA) obtained, at 24 h post-dose, 
from rats submitted to a 14-day pre-treatment period with Citrus aurantium extract (164 
mg/kg/day, p.o.), or vehicle (0.5% carboxymethylcellulose aqueous solution), and treated on 
the 15th day with a single-dose of AM (50 mg/kg, p.o.) by oral gavage. Data are expressed as 
the mean values ± standard error of the mean (SEM) of six determinations (n = 6). 
 
The concentrations of both compounds (AM and MDEA) in tissues were manifestly 
greater than those measured in plasma, and the concentration levels found in lung tissue 
were extremely high in both experimental (C. aurantium) and control (vehicle) groups. 
However, at 24 h post-dose, no significant differences were observed for AM and MDEA 
concentrations between both groups (AM Citrus versus AM Vehicle). 
 
VI.4.3 SHORT-TERM REPEATED DOSE EFFECT OF CITRUS AURANTIUM ON BODY WEIGHT 
 
The changes in body weight of the rats submitted to a 14-day pre-treatment period 
with C. aurantium extract (164 mg/kg/day, p.o) or vehicle are demonstrated in Figure VI.8.  
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Figure VI.8 – Effects on the body weight of the rats induced by the short-term repeated dose 
treatment (14-day period) with Citrus aurantium extract (164 mg/kg/day, p.o.) and vehicle 
(0.5% carboxymethylcellulose aqueous solution) by oral gavage. *p < 0.05 and **p < 0.01, 1st 
day versus 14th day. 
 
Statistically significant increases in body weight of rats treated either with C. 
aurantium extract (p < 0.05) or with vehicle (p < 0.01) between the 1st and 14th day of the 
experiments were observed. Furthermore, the increase in body weight of the rats of both 
groups (C. aurantium versus vehicle) was comparable. Hence, under these experimental 
conditions, the C. aurantium extract was shown to be ineffective to control the body weight 
gain in rats. 
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VI.5. DISCUSSION 
 
Over the last years several interactions have been reported in literature describing 
the interference of herbal products and other compounds on the pharmacokinetics of AM. 
For instance, the grapefruit juice dramatically inhibited the metabolism of AM (LIBERSA et al., 
2000), the co-administration of orlistat and AM significantly reduced the systemic exposure 
to AM and its main metabolite MDEA (ZHI et al., 2003), the exposure of rats to                 
β-naphthoflavone (a polycyclic aromatic hydrocarbon) was found to increase the formation 
of MDEA probably through CYP induction (ELSHERBINY, EL-KADI and BROCKS, 2010) and, 
more recently, our research group documented the occurrence of herb-drug interactions 
between Fucus vesiculosus extract or Paullinia cupana extract and AM in rats (RODRIGUES et 
al., 2012; RODRIGUES et al., 2013b). 
Accordingly, the present work was delineated to investigate the potential of 
interaction between C. aurantium extract and AM in vivo, using adult male Wistar rats. The 
pharmacokinetic studies herein reported were designed to examine the interference of C. 
aurantium extract on the gastrointestinal absorption (simultaneous co-administration study) 
and on the metabolism of AM (14-day C. aurantium pre-treatment study). In fact, drug-drug 
or herb-drug interactions mainly occur at the level of absorption process and/or metabolic 
(inhibition or induction) pathways. 
Overall, our results show that the simultaneous co-administration of a single-dose of 
C. aurantium extract and AM caused an apparent delay to reach the peak plasma 
concentration of the drug, but it did not change significantly the magnitude and the extent of 
systemic exposure to AM (as assessed by Cmax and AUC0-t respectively). This increase in the 
time to achieve Cmax is not expected to alter the efficacy of AM and it is unlikely to be 
clinically important. At this point, it deserves to be mentioned that after the co-
administration of AM with other herbal extracts (F. vesiculosus extract and P. cupana 
extract), which are also claimed to be useful for weight loss, a delay in the time to reach Cmax 
was also observed; however, in these studies a significant decrease in the systemic exposure 
to AM was clearly evident in the rats treated with herbal extracts (RODRIGUES et al., 2012; 
RODRIGUES et al., 2013b). 
Moreover, because of the central role that the induction of CYPs and P-glycoprotein 
(P-gp) plays on drug-drug and herb-drug interactions, and bearing in mind that the induction 
mechanisms are time-dependent, the interference of C. aurantium extract on the 
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pharmacokinetics of AM was also investigated by administering the extract for 14 
consecutive days (164 mg/kg/day, p.o.) until 24 h before applying AM. In fact, AM is 
metabolized by several CYP isoenzymes including CYP1A1/2, CYP2C8, CYP2C19, CYP2D6 
and CYP3A4 (OHYAMA et al., 2000; ELSHERBINY, EL-KADI and BROCKS, 2010) and is a 
substrate of P-gp (SHAPIRO and SHEAR, 2002; KALITSKY-SZIRTES et al., 2004). The only 
significant change was an increase in the level of systemic exposure to AM (as assessed by 
Cmax) in the rats pre-treated during 14 days with C. aurantium extract (versus vehicle). No 
significant differences were found in the extent of systemic drug exposure (as assessed by 
AUC0-t and AUC0-∞). Therefore, to explain the increase of the Cmax in the group of rats pre-
treated with C. aurantium we hypothesise that the extract or some of its constituents could 
change (increase) the gastrointestinal motility, thus increasing the rate at which AM passes to 
the intestine. Actually, the absorption of AM across the intestinal membrane occurs by 
passive diffusion, which is a non-saturable process (MARTÍN-ALGARRA et al., 1997). According 
to the studies of JINZHAO et al. (2005), the C. aurantium may improve the gastric emptying in 
rats with functional dyspepsia. Furthermore, extracts of C. aurantium also increased the rate 
of gastrointestinal motility enhancing, therefore, the absorption function of gastrointestinal 
tract (LI et al., 2007). In addition, Citrus aurantium can also antagonise the inhibition of the 
intestinal advance induced by atropine (XUE-BAO et al., 2005). In a study conducted by FANG 
et al. (2009) the effects of constituents of C. aurantium on the gastrointestinal movement 
were evaluated; the hesperidin had a stimulatory effect on the gastrointestinal muscle 
contraction while synephrine had an inhibitory effect.  
Another possibility to explain the higher Cmax values for AM in the group of rats pre-
treated with C. aurantium extract could be related to a time-dependent inhibitory effects 
induced by C. aurantium or some of its phytochemicals on the CYPs and/or P-gp–mediated 
efflux activity. Actually, in a non-clinical study was reported that a decoction of C. aurantium 
increased the bioavailability of cyclosporine (HOU et al., 2000).  
Based on the herb-drug interaction data obtained in the present work involving C. 
aurantium and AM, it is suggested that the tested C. aurantium extract has no significant 
impact on the pharmacokinetic of AM, even using an experimental dose of extract in rats 
higher than the typical recommended dose in humans. Even so, it should be taken in account 
that results from animal experiments cannot be directly extrapolated to humans; however, 
bearing in mind the studies of SHAYEGANPOUR, JUN and BROCKS (2005) and MENG et al. 
(2001), the rat appears to be an appropriate animal model for man in this case. 
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Nevertheless, to reliably assess the safety of the administration of C. aurantium extract and 
AM specific clinical trials are required. 
Additionally, in our study the increase of body weight of the rats pre-treated with C. 
aurantium extract or vehicle was comparable. These data are in accordance with other 
results found in the literature for C. aurantium extract. ARBO et al. (2008) also reported that 
the body weight gain did not change significantly comparing with the control group in rats 
treated during 28 days with 400, 2000 and 4000 mg/kg of C. aurantium extract. Only was 
observed a reduction in the gain of body weight for rats treated with 30 and 300 mg/kg of 
synephrine during 28 days (ARBO et al., 2008). 
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VI.7. SUPPLEMENTARY DATA 
 
Certificate of analysis of Citrus aurantium extract 10% synephrine provided by Bio Serae 
Laboratories (Ref. 410039 – Batch 0907799). 
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VII. HERB-DRUG PHARMACOKINETIC INTERACTION BETWEEN CARICA PAPAYA EXTRACT 
AND AMIODARONE IN RATS 
 
VII.1. ABSTRACT 
  
Carica papaya extracts have been used for various ailments in humans, including obesity. 
However, scientific information is lacking on the potential for herb-drug interactions 
involving C. papaya and conventional drugs. Thus, this work aimed to investigate the 
interferences of a standardized C. papaya extract (GMP certificate) on the systemic 
exposure of amiodarone (AM; a narrow therapeutic index drug) in rats. In the first 
pharmacokinetic study, rats were simultaneously co-administered with a single-dose of C. 
papaya (1230 mg/kg, p.o.) and AM (50 mg/kg, p.o.); in the second study, rats were pre-
treated for 14 days with C. papaya (1230 mg/kg/day, p.o.) and received AM (50 mg/kg, p.o.) 
on the 15th day. Rats of the control groups received the herbal extract vehicle. Despite the 
delay observed in both studies in attaining the maximum plasma concentrations of AM in the 
rats treated with the extract, the marked increase found in the extent of systemic exposure 
to AM (60-70%) in the rats pre-treated with C. papaya must be highlighted. For the first 
time, an herb-drug interaction between C. papaya extract and AM was reported, which 
clearly increase the drug bioavailability. To reliably assess the clinical impact of these findings 
appropriate clinical trials should be conducted. 
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VII.2. INTRODUCTION 
 
Carica papaya, also traditionally known as pawpaw or papaya, is a tree-like 
herbaceous plant belonging to the family of Caricaceae (CANINI et al., 2007; SADEK et al., 
2012). Mainly by its edible fruits, C. papaya is widely cultivated in several tropical, sub-
tropical and temperate regions, including Australia, Brazil, China, Hawaii, Malaysia and India 
(CANINI et al., 2007; AFZAN et al., 2012). Different parts of the plant (fruits, leaves, barks, 
roots, flowers, seeds, and latex) as well as some of their extracts have been traditionally 
used worldwide in folk medicine to treat a wide range of ailments in humans (ANUAR et al., 
2008; NGUYEN et al., 2013).  
The fruits of C. papaya are one of the most commonly consumed throughout the 
world (ATHESH et al., 2012), constituting a nutritional source rich in fibre, minerals and 
antioxidant nutrients (SADEK et al., 2012). More specifically, papaya fruit is a good source of 
bioactive phytochemicals such as carotenoids (β-carotene, α-carotene, β-cryptoxanthin,      
α-cryptoxanthin, lutein, 9-cis-β-carotene), phenolic compounds (ferulic acid, caffeic acid, p-
coumaric acid, rutin, quercetin, kaempferol), and glucosinolates (benzyl glucosinolate, benzyl 
isothiocyanate) (NGUYEN et al., 2013). Unripe pulp of C. papaya also contains cardenolides 
which seem to have medicinal value for the treatment of congestive heart failure (ANUAR et 
al., 2008). Additionally, among other biologically active constituents, papaya also includes 
cysteine proteinases as chymopapain and papain (KOVENDAN et al., 2012; SADEK et al., 2012) 
and its biological activity is often analysed through the proteolytic activity, particularly the 
papain activity (ANUAR et al., 2008). 
The extracts of ripe fruits are used for a variety of medicinal purposes including 
treatment of ringworm, malaria, hypertension (SADEK et al., 2012), whereas extracts of 
unripe fruits have been used in the treatment of ulcers (EZIKE et al., 2009) and diabetes 
(SADEK et al., 2012). In addition, the hypoglycemic and hypolipidemic effects of the aqueous 
seed extract of C. papaya in rats have been reported (ADENEYE and OLAGUNJU, 2009). The 
ethanolic extract and water-soluble fraction of C. papaya also showed anti-hyperlipidemic 
activity in olive-treated rats (IVER et al., 2011). More recently, ATHESH et al. (2012) reported 
the anti-obesity effect of aqueous fruit extract of C. papaya in rats fed on high fat cafeteria 
diet. Effectively, besides the proteolytic enzymes, chymopapain and papain, C. papaya also 
has a lipase enzyme that can contribute to its lipolytic action, supporting its use in the 
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management of obesity and digestive disorders (IZZO, 2004; KOVENDAN et al., 2012; SADEK 
et al., 2012).  
Despite people have used medicinal herbs since ancient times (CALIXTO, 2000), a 
dramatic increase in the use of herbal products around the world has been observed in 
recent years (BENT, 2008). As consequence, there is an increased risk for herb-drug 
interactions because the phytochemicals are handled in the body through the same type of 
mechanisms involved in drug biodisposition (VENKATARAMANAN, KOMOROSKI and STROM, 
2006). Importantly, C. papaya extract was associated to an increase of the international 
normalized ratio (INR) in a patient taking warfarin concomitantly (SHAW et al., 1997). Hence, 
it has been suggested that C. papaya is contraindicated in patients receiving warfarin therapy 
(SHAW et al., 1997; NUTESCU et al., 2006). 
Bearing in mind that obesity and overweight are increasing at an alarming rate 
worldwide (PITTLER, SCHMIDT and ERNST, 2005), representing major independent risk factors 
for cardiovascular diseases (SCAGLIONE et al., 2004; BODARY, IGLAY and EITZMAN, 2007; 
ZALESIN et al., 2011), and considering the anti-obesity effects recently reported for the 
aqueous fruit extract of C. papaya (ATHESH et al., 2012), an increase in the consumption of 
herbal supplements containing C. papaya is still expected. Thus, as the occurrence of herb-
drug interactions represents a major safety concern, especially when the affected (object) 
drug has a narrow therapeutic index (ZHOU et al., 2007; BUTTERWECK and DERENDORF, 
2008), it is absolutely pertinent to investigate the potential for pharmacokinetic-based 
interactions between C. papaya extract and amiodarone (AM; a narrow therapeutic index 
drug).  
Actually, despite its narrow therapeutic index, AM [2-n-butyl-3-(3,5-diiodo-4-
diethylaminoethoxy-benzoyl)-benzofuran; (Figure VII.1)] is one of the most widely prescribed 
antiarrhythmic agents (PAPIRIS et al., 2010). Furthermore, the pharmacokinetics of AM and of 
its main metabolite, mono-N-desethylamiodarone (MDEA; Figure VII.1), are complex and 
have shown large inter-individual variability (OHYAMA et al., 2000; VAN HERENDAEL and 
DORIAN, 2010). In fact, AM has a variable oral bioavailability and undergoes extensive 
enterohepatic recirculation after intestinal absorption (VAN HERENDAEL and DORIAN, 2010); 
moreover, the parent drug and its main metabolite are highly lipophilic and tend to 
accumulate extensively in several tissues (WOLKOVE and BALTZAN, 2009). On the other hand, 
AM has been associated with a variety of life-threatening adverse events, including thyroid 
dysfunction, pulmonary toxicity and hepatic toxicity (KAHALY et al., 2007; WOLKOVE and 
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BALTZAN, 2009; LAHBABI et al., 2012), and the drug has also been implicated in relevant 
clinical drug interactions (SIDDOWAY, 2003; EDWIN, JENNINGS and KALUS, 2010; KARIMI et al., 
2010; ROUGHEAD et al., 2010). Thus, taking into account all the reasons previously referred, 
this work was planned in order to investigate whether a standardized extract of the fruit of 
C. papaya influence the rate and extent of exposure to AM in rats, following their 
simultaneous oral co-administration and after a pre-treatment period for 14-day with C. 
papaya extract. 
 
Figure VII.1. – Chemical structures of amiodarone (AM) and its major metabolite mono-N-
desethylamiodarone (MDEA). 
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VII.3. MATERIALS AND METHODS 
 
VII.3.1 DRUGS AND MATERIALS 
 
C. papaya extract with a proteolytic activity higher than 6000 NFPU/mg obtained 
from papaya fruit was purchased from Bio Serae Laboratories (Bram, France). The certificate 
of analysis number 420015 - batch 0810960 is provided as Supplementary data. 
Carboxymethylcellulose sodium salt for preparation of extract suspension was obtained 
from Sigma (St. Louis, MO, USA). A commercial formulation (ampoules) of AM 
hydrochloride 50 mg/mL solution for intravenous injection was used for oral administration 
to rats after appropriate dilution with 5% glucose intravenous solution for infusion (B. Braun 
Medical, Portugal). Other compounds used were sodium chloride 0.9% solution for injection 
(Labesfal, Portugal); heparin sodium 5000 U.I./mL for injection (B. Braun Medical, Portugal); 
ketamine for injection (Imalgene 1000) and xylazine for injection (Vetaxilaze 20). Introcan® 
Certo IV indwelling cannula (22G; 0.9 × 2.5 mm) made of polyurethane from B. Braun 
Melsungen AG (Melsungen, Germany). 
 
VII.3.2 ANIMALS 
 
Adult male Wistar rats (355 ± 28 g) of approximately 10 weeks old were obtained 
from local animal facilities (Faculty of Health Sciences of the University of Beira Interior, 
Covilhã, Portugal). The rats were maintained under controlled environmental conditions 
(temperature 20±2 ºC; relative humidity 55±5%; 12-h light/dark cycle). The animals were 
allowed free access to a standard rodent diet (4RF21, Mucedola, Italy) during almost all 
experimental procedures and tap water was available ad libitum. At the night of the day 
before AM administration, a lateral tail vein of each rat was cannulated, under anaesthesia 
[ketamine (90 mg/kg)/xylazine (10 mg/kg); i.p. injection], by insertion of an Introcan® Certo 
IV indwelling cannula (22G; 0.9 × 2.5 mm) used for serial blood sampling. The rats fully 
recovered from anaesthesia overnight and were fasted for 12-14 h before AM administration 
and maintained with free access to water. In order to avoid the effect of the food on the oral 
bioavailability of AM an additional fasting period was considered (4 h post-dose). Oral 
treatments of the rats with C. papaya extract and AM were performed by gavage. Blood 
sampling was conducted in conscious and freely moving rats appropriately restrained only at 
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the moment of blood collection; the exception was at the last blood sampling that was taken 
by a terminal procedure (decapitation and exsanguination under anaesthesia). All the animal 
experiments were conducted in accordance with the European Directive (2010/63/EU) for 
the accommodation and care of laboratory animals and the experimental procedures were 
reviewed and approved by the Portuguese Veterinary General Division. 
 
VII.3.3 EXPERIMENTAL DESIGN AND PHARMACOKINETIC STUDIES 
 
A simultaneous oral co-administration study with a single-dose of C. papaya extract 
and AM, and a 14-day repeated oral pre-treatment study with C. papaya extract followed by 
an oral dose of AM on the 15th day were performed to investigate the effects of C. papaya 
fruit extract on the pharmacokinetics of AM. The dose established for AM was 50 mg/kg 
since it provides plasma concentrations in rats within the drug therapeutic range (0.5-2 
µg/mL) (SHAYEGANPOUR, JUN and BROCKS, 2005; SHAYEGANPOUR, HAMDY and BROCKS, 2008). 
On the other hand, the dose of C. papaya was selected based on the average dose 
recommended to humans by the supplier of the extract (Bio Serae Laboratories) and taking 
into account the Food and Drug Administration (FDA) Guidance for Industry on conversion 
of animal doses to human equivalent doses based on body surface area (GUIDANCE FOR 
INDUSTRY, 2005); additionally, a 10-fold potentiating interaction factor was considered in 
order to avoid potential false-negative results for herb-drug interaction associated to 
interspecies differences. In each day of the experiments C. papaya extract was suspended in 
0.5% carboxymethylcellulose aqueous solution affording a suspension of herbal extract at 
123 mg/mL. AM commercial injectable solution (50 mg/mL) was also appropriately diluted 
with 5% glucose solution to extemporaneously prepare an AM solution at 12.5 mg/mL. 
Appropriate volumes of C. papaya extract suspension (10 mL/kg of body weight) and of AM 
solution (4 mL/kg of body weight) were orally administered to rats by gavage. 
In the first pharmacokinetic study, twelve Wistar rats were randomly divided into 
two groups (experimental and control groups). Rats of the experimental group (n = 6) were 
concomitantly treated with a single-dose of C. papaya extract (1230 mg/kg, p.o.) and a single-
dose of AM (50 mg/kg, p.o.); the extract suspension was administered immediately before 
AM. Rats of the control group (n = 6) received, instead of the C. papaya extract suspension, 
the corresponding volume of 0.5% carboxymethylcellulose aqueous solution (extract 
vehicle). 
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In the second pharmacokinetic study, twelve Wistar rats were also randomly divided 
into two groups. Rats assigned to the experimental group (n = 6) were orally pre-treated 
with C. papaya extract (1230 mg/kg, p.o.) once daily for 14 consecutive days (short-term 
repeated dose pre-treatment). Rats allocated to the control group (n = 6) were 
administered with an equivalent volume of vehicle for the same period of time. During the 
pre-treatment period, the rats were kept in 12-h light/dark cycle animal room with 
controlled temperature and humidity, as indicated in section VII.3.2, and the free access to a 
standard rodent diet and tap water was allowed. On the 15th day, the rats of both groups 
(experimental and control) were gavaged with the single-dose of AM (50 mg/kg, p.o.).  
In both pharmacokinetic studies the treatments with C. papaya extract (or vehicle) 
and/or AM were always carried out on the morning between 9:00 am and 11:45 am. At the 
night of the day before AM administration, the rats were anaesthetized for cannulation of a 
lateral tail vein and were fasted overnight as described above (section VII.3.2). On the day 
after, multiple serial blood samples (approximately 0.3 mL per sample) were collected 
through the cannula into heparinized tubes before dosing and at 0.25, 0.5, 1, 2, 4, 6, 8 and 12 
h following AM administration; then, at 24 h post-dose, blood and tissues (heart, liver, 
kidneys and lungs) were also harvested after decapitation of the rats. The blood samples 
were centrifuged at 4000 rpm for 10 min (4 ºC) to separate the plasma which was stored at 
–20 ºC until analysis. After exsanguinations, liver, kidneys, heart and lungs were excised and 
stored at –20 ºC; the organs were weighed and homogenized in distilled water (3 mL of 
water per gram of tissue) before analysis of tissue homogenates samples. 
 
VII.3.4 ANALYSIS OF AMIODARONE AND MONO-N-DESETHYLAMIODARONE 
 
Plasma and tissue concentrations of AM and its main metabolite MDEA were 
determined by using a liquid-liquid extraction procedure followed by high-performance liquid 
chromatography-diode array detection assay previously developed and validated (RODRIGUES 
et al., 2013a).  
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VII.3.5 PHARMACOKINETIC ANALYSIS 
 
The plasma concentration versus time data for AM and MDEA obtained from each 
individual rat were submitted to a non-compartmental pharmacokinetic analysis using the 
WinNonlin® version 4.1 (Pharsight Co, Mountain View, CA, USA). The peak plasma 
concentrations (Cmax) of AM and MDEA and the time to reach Cmax (tmax) were obtained 
directly from the experimental data. Other pharmacokinetic parameters estimated from the 
individual plasma concentration-time profiles included: area under the concentration-time 
curve (AUC) from time zero to the last sampling time at which concentrations were at or 
above the limit of quantification (LOQ; 0.100 µg/mL) of the method (AUC0-t), calculated by 
the linear trapezoidal rule; AUC from time zero to infinite (AUC0-∞), calculated from    
AUC0-t + (Clast/kel), where Clast is the last quantifiable concentration and kel is the apparent 
terminal elimination rate constant calculated by log-linear regression of the terminal segment 
of the concentration-time profile; apparent terminal elimination half-life (t1/2el) and mean 
residence time (MRT). The concentrations lower than the LOQ of the assay were taken as 
zero for all calculations. 
 
VII.3.6 SHORT-TERM REPEATED DOSE EFFECT OF CARICA PAPAYA EXTRACT ON BODY WEIGHT 
 
In the short-term C. papaya repeated dose study the body weight of the rats treated 
with C. papaya extract (1230 mg/kg/day, p.o.; experimental group) or vehicle (control group) 
were adequately registered on the first day and also on the last day (14th) of these 
treatments in order to investigate the effect of the herbal extract on body weight changes. 
 
VII.3.7 STATISTICAL ANALYSIS 
 
Data were reported as the mean ± standard error of the mean (SEM). Comparisons 
between two groups were usually performed using unpaired two-tailed Student’s t-test; for 
body weight comparisons within the same group the paired Student’s t-test was applied. The 
differences were considered to be statistically significant for a p-value lower than 0.05        
(p < 0.05). 
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VII.4. RESULTS 
 
VII.4.1 SIMULTANEOUS CO-ADMINISTRATION OF CARICA PAPAYA AND AMIODARONE 
 
The mean plasma concentration-time profiles (n = 6) of AM and its main metabolite 
(MDEA) obtained after the co-administration of rats with a single-dose of C. papaya extract 
(1230 mg/kg, p.o.) or vehicle (control group) and a single-dose of AM (50 mg/kg, p.o.) are 
shown in Figure VII.2. 
 
Figure VII.2 – Mean plasma concentration-time profiles of amiodarone (AM) and mono-N-
desethylamiodarone (MDEA) obtained, over a period of 24 h, from rats simultaneously 
treated with a single-dose of Carica papaya extract (1230 mg/kg, p.o.), or vehicle (0.5% 
carboxymethylcellulose aqueous solution), and AM (50 mg/kg, p.o.) by oral gavage. Symbols 
represent the mean values ± standard error of the mean (SEM) of six determinations per 
time point (n = 6).  
 
Up to 24 h post-dosing no statistically significant differences (p > 0.05) were found 
between both groups of rats (C. papaya versus vehicle) regarding the mean plasma 
concentrations of AM achieved at each sampling time points. The plasma concentrations of 
MDEA were similar in both groups, showing concentration values near or below the LOQ 
(0.100 µg/mL) of the analytical method, which were manifestly lower than those obtained for 
AM. The main pharmacokinetic parameters estimated for AM and MDEA after a non-
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compartmental analysis of their individual plasma concentration-time profiles are 
summarized in Table VII.1.  
 
Table VII.1 – Pharmacokinetic parameters estimated by non-compartmental analysis of the 
plasma concentration-time profiles of amiodarone (AM) and mono-N-desethylamiodarone 
(MDEA, major metabolite of AM) obtained in rats after the simultaneous co-administration 
in single-dose of Carica papaya extract (1230 mg/kg, p.o.), or vehicle (0.5% 
carboxymethylcellulose aqueous solution), with AM (50 mg/kg, p.o.) by oral gavage (n = 6, 
unless otherwise noted). 
Parameter AM Carica 
 AM Vehicle 
AM MDEA  AM MDEA 
tmax (h) 2.50 ± 0.50 6.00 ± 0.00
a  1.83 ± 0.48 7.20 ± 1.36b 
Cmax (µg/mL) 1.530 ± 0.409 0.127 ± 0.020
a  1.378 ± 0.179 0.125 ± 0.012b 
AUC0-t (µg.h/mL) 15.588 ± 3.414 ND  12.774 ± 0.688 ND 
AUC0-∞ (µg.h/mL) 25.693 ± 3.488 ND  21.431 ± 2.077 ND 
kel (1/h) 0.0470 ± 0.0102 ND  0.0433 ± 0.0082 ND 
t1/2el (h) 19.87 ± 5.32 ND  20.73 ± 5.74 ND 
MRT (h) 29.79 ± 8.04 ND  28.64 ± 7.74 ND 
ND, not determined. 
an = 3; bn = 5. 
 
Considering the paucity of quantifiable plasma concentrations obtained for MDEA, it 
was only possible to present the Cmax and tmax parameters (Table VII.1). Overall, the Cmax of 
AM was attained later in the group treated with C. papaya comparatively to the vehicle 
(control) group. No statistically significant differences in the mean pharmacokinetic 
parameters were found in terms of magnitude and extent of systemic exposure to AM and 
its main metabolite (MDEA) among both groups (Table VII.1). Taking into consideration the 
information derived from Figure VII.3, it also appears that following the simultaneous co-
administration of C. papaya and AM the magnitude of systemic exposure (as assessed by 
Cmax) and the extent of systemic exposure to AM (as assessed by AUC0-t and AUC0-∞) are 
similar among experimental and control groups (ratios near to unity).  
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Figure VII.3. – Ratios for the main plasma pharmacokinetic parameters (Cmax, AUC0-t and  
AUC0-∞) estimated for amiodarone (AM) in rats simultaneously treated in single-dose with 
Carica papaya extract (1230 mg/kg, p.o.), or vehicle (0.5% carboxymethylcellulose aqueous 
solution), and AM (50 mg/kg, p.o.) by oral gavage.   
 
To evaluate the distribution of AM and MDEA in the presence and absence of the co-
administration with the C. papaya extract, the animals were sacrificed at 24 h post-dosing 
and several tissues were excised and analysed. The mean concentrations of AM and MDEA 
in heart, lung, liver and kidney tissues, and also in plasma at the same time point (24 h post-
dose) are shown in Figure VII.4.  
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Figure VII.4 – Mean plasma and tissue (heart, lung, liver and kidney) concentrations of 
amiodarone (AM) and mono-N-desethylamiodarone (MDEA) obtained, at 24 h post-dose, 
from rats simultaneously treated with a single-dose of Carica papaya extract (1230 mg/kg, 
p.o.), or vehicle (0.5% carboxymethylcellulose aqueous solution), and AM (50 mg/kg, p.o.) by 
oral gavage. Data are expressed as the mean values ± standard error of the mean (SEM) of 
six determinations (n = 6). *p < 0.05 compared to control (vehicle). 
 
The tissue concentrations of AM and MDEA were markedly higher than those 
determined in plasma. However, taking into account the comparisons performed between 
the experimental (C. papaya) and the control (vehicle) groups, statistically significant 
differences were only detected for AM concentrations in kidney tissue (p < 0.05), being 
significantly higher in the kidney tissue of rats treated with the herbal extract. 
 
VII.4.2 SHORT-TERM REPEATED DOSE PRE-TREATMENT WITH CARICA PAPAYA FOLLOWED BY 
ADMINISTRATION OF AMIODARONE 
 
The rats were administered for 14 days with C. papaya extract (1230 mg/kg, p.o.) or 
vehicle (control group) in order to investigate the influence of a short-term repeated dose 
pre-treatment with C. papaya extract on the pharmacokinetics of AM, which was only 
administered on the 15th day as a single-dose of 50 mg/kg (p.o.). The mean plasma 
concentration-time profiles (n = 6) for AM and its main metabolite (MDEA) are depicted in 
Figure VII.5.  
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Figure VII.5 – Mean plasma concentration-time profiles of amiodarone (AM) and mono-N-
desethylamiodarone (MDEA) obtained, over a period of 24 h, from rats submitted to a 14-
day pre-treatment period with Carica papaya extract (1230 mg/kg/day, p.o.), or vehicle (0.5% 
carboxymethylcellulose aqueous solution), and treated on the 15th day with a single-dose of 
AM (50 mg/kg, p.o.) by oral gavage (n = 6). Symbols represent the mean values ± standard 
error of the mean (SEM) of six determinations per time point (n = 6). *p < 0.05 compared to 
control (vehicle). 
 
Comparing the mean plasma concentrations for AM in both groups, there are 
statistically significant differences at 6, 8 and 24 h post-dosing (p < 0.05) which were higher 
in the group pre-treated with C. papaya extract. The corresponding pharmacokinetic 
parameters are listed in Table VII.2.  
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Table VII.2 – Pharmacokinetic parameters estimated by non-compartmental analysis of the 
plasma concentration-time profiles of amiodarone (AM) and mono-N-desethylamiodarone 
(MDEA, major metabolite of AM) obtained in rats submitted to a 14-day pre-treatment 
period with Carica papaya extract (1230 mg/kg/day, p.o.), or vehicle (0.5% 
carboxymethylcellulose aqueous solution), and treated on the 15th day with a single-dose of 
AM (50 mg/kg, p.o.) by oral gavage (n = 6, unless otherwise noted). 
ND, not determined. 
an = 4; bn = 3. 
*p < 0.05, significantly different from the control group. 
#p < 0.005, significantly different from the control group. 
 
Regarding the data shown in Figure VII.6, it was evident an increase (50.8%) in the 
mean peak plasma concentration (Cmax) of AM, but this did not reach statistical significance, 
as well as an increase of approximately 60.8-73.8% in the extent of systemic drug exposure 
(as assessed by AUC0-t and AUC0-∞) in the rats pre-treated with C. papaya extract.  
 
 
Parameter AM Carica 
 AM Vehicle 
AM MDEA  AM MDEA 
tmax (h) 3.17 ± 0.54 10.50 ± 2.12
a  2.17 ± 0.60 7.33 ± 2.40b 
Cmax (µg/mL) 1.436 ± 0.224 0.135 ± 0.011
a  0.952 ± 0.157 0.119 ± 0.014b 
AUC0-t (µg.h/mL) 16.932 ± 2.560* ND  10.532 ± 0.889 ND 
AUC0-∞ (µg.h/mL) 26.635 ± 2.527
# ND  15.325 ± 0.949 ND 
kel (1/h) 0.0541 ± 0.0127 ND  0.0533 ± 0.0082 ND 
t1/2el (h) 18.30 ± 5.07 ND  14.36 ± 1.85 ND 
MRT (h) 27.05 ± 7.07 ND  20.97 ± 2.42 ND 
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Figure VII.6. – Ratios for the main plasma pharmacokinetic parameters (Cmax, AUC0-t and  
AUC0-∞) estimated for amiodarone (AM) in rats submitted to a 14-day pre-treatment period 
with Carica papaya extract (1230 mg/kg/day, p.o.), or vehicle (0.5% carboxymethylcellulose 
aqueous solution), and treated on the 15th day with a single-dose of AM (50 mg/kg, p.o.) by 
oral gavage. 
 
Indeed, the C. papaya extract pre-treatment of the rats only determined a statistically 
significant increase in the extent of systemic exposure to AM (as assessed by  AUC0-t and 
AUC0-∞). In the experimental (C. papaya) group, it was also observed a considerable delay in 
reaching Cmax of AM. The plasma concentrations of MDEA were near or below the LOQ 
(0.100 µg/mL) of the method in both groups of rats. 
To assess the impact of a 14-day pre-treatment period with C. papaya extract 
(experimental group) on the distribution and metabolism of AM in rats, the concentrations 
of AM and its major metabolite (MDEA) were also determined in various tissues 
(additionally to plasma) at 24 h post-dose and the data are shown in Figure VII.7.  
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Figure VII.7 – Mean plasma and tissue (heart, lung, liver and kidney) concentrations of 
amiodarone (AM) and mono-N-desethylamiodarone (MDEA) obtained, at 24 h post-dose, 
from rats submitted to a 14-day pre-treatment period with Carica papaya extract (1230 
mg/kg/day, p.o.), or vehicle (0.5% carboxymethylcellulose aqueous solution), and treated on 
the 15th day with a single-dose of AM (50 mg/kg, p.o.) by oral gavage. Data are expressed as 
the mean values ± standard error of the mean (SEM) of six determinations (n = 6). *p < 0.05 
and #p < 0.01 compared to control (vehicle). 
 
Once again, the concentrations of both compounds (AM and MDEA) in the tissues 
were distinctly greater than those measured in plasma. However, despite the statistically 
significant differences detected in the plasma concentrations of AM at 6, 8 and 24 h post-
dose between both groups (Figure VII.5), statistically significant differences in the mean tissue 
concentrations of AM were only found in the lung tissue, while MDEA concentrations 
obtained from rats pre-treated with C. papaya extract were higher in lung and heart tissue. 
 
VII.4.3 SHORT-TERM REPEATED DOSE EFFECT OF CARICA PAPAYA EXTRACT ON BODY WEIGHT 
 
The changes in body weight of the rats submitted to a 14-day treatment period with 
C. papaya extract (1230 mg/kg/day, p.o) or vehicle are pointed out in Figure VII.8.  
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Figure VII.8 – Effects on the body weight of the rats induced by the short-term repeated 
dose treatment (14-day period) with Carica papaya extract (1230 mg/kg/day, p.o.) and 
vehicle (0.5% carboxymethylcellulose aqueous solution) by oral gavage. *p < 0.01 and         
**p < 0.001, 1st day versus 14th day.  
 
Between the 1st and the 14th day, statistically significant increases in the body weight 
of rats treated with C. papaya extract (p < 0.01) or vehicle (p < 0.001) were observed. 
However, the magnitude of the increase in their body weight was similar in both groups (C. 
papaya versus vehicle).  
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VII.5. DISCUSSION 
 
Most of the herb-drug interaction studies found in literature have been conducted in 
vitro employing concentrations usually higher than those clinically relevant ones 
(VENKATARAMANAN, KOMOROSKI and STROM, 2006) and, up to date, few significant drug 
interactions have actually been accurately predicted from in vitro assays (MARKOWITZ, VON 
MOLTKE and DONOVAN, 2008). Thus, taking into account these limitations, the present work 
evaluated the potential of interaction between C. papaya extract and AM in a whole animal 
model, the Wistar rat.  
Overall, our results showed that the single-dose co-administration of C. papaya 
extract and AM caused an apparent delay in the tmax, but did not alter the extent of systemic 
exposure to AM (as assessed by AUC0-t and AUC0-∞). This apparent delay in tmax is not 
expected to change the efficacy of AM and it is unlikely to be clinically important. At this 
time point it is interesting to be emphasised that after the co-administration of AM with 
other herbal extracts claimed to be useful in weight loss/weight management (e.g. Citrus 
aurantium extract, Fucus vesiculosus extract and Paullinia cupana extract) a delay in the time 
to reach Cmax was also observed; however, the co-administration with F. vesiculosus extract 
or P. cupana extract significantly decreased the systemic exposure to AM in the rats treated 
with the herbal extracts (RODRIGUES et al., 2012; RODRIGUES, ALVES and FALCÃO, 2013; 
RODRIGUES et al., 2013b). 
Moreover, because of the central role that the induction of cytochrome P450 (CYP) 
isoenzymes and P-glycoprotein (P-gp) plays on drug-drug and herb-drug interactions, and 
bearing in mind that the induction mechanisms are time-dependent, the interference of C. 
papaya extract on the pharmacokinetics of AM was also evaluated by administering the 
herbal extract for 14 consecutive days until 24 h before administering a single-dose of drug. 
In the rats pre-treated with C. papaya extract during the 14 days, a statistically significant 
increase in the extent of systemic drug exposure was observed comparatively with control 
group (as assessed by AUC0-t and AUC0-∞). However, no significant differences were found in 
the peak of systemic exposure to AM (as assessed by Cmax). Thus, to explain the greater 
systemic exposure to AM in the experimental (C. papaya) group we hypothesize that the 
herbal extract or some of its phytochemical constituents could have antimotility properties 
determining the inhibition of the intestinal propulsion movements (EZIKE et al., 2009). The 
reduction of gastrointestinal motility can prolong the transit time of drugs and, consequently, 
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it can increase the extent of the absorption of slightly soluble drugs, such as AM (TARIRAI, 
VILJOEN and HAMMAN, 2010). In fact, the rate-limiting step of AM intestinal absorption is its 
low aqueous solubility, given that it occurs by passive diffusion (a non-saturable transport 
process) (MARTÍN-ALGARRA et al., 1994, 1997).  
Another possibility to explain the higher AUC0-t and AUC0-∞ values for AM in the 
group of rats pre-treated with Carica papaya extract could be related to a time-dependent 
inhibitory effect on CYP isoenzymes and/or P-gp-mediated efflux activity. Theoretically, a 
drug that is a dual substrate for CYPs and P-gp has much higher potential for drug 
interactions with herbs that also modulate CYP3A4 and P-gp (ZHOU et al., 2007). In fact, AM 
is metabolized by several CYP isoenzymes including CYP1A1/2, CYP2C8, CYP2C19, 
CYP2D6 and CYP3A4 (OHYAMA et al., 2000; ELSHERBINY, EL-KADI and BROCKS, 2010) and is 
also a substrate of P-gp (SHAPIRO and SHEAR, 2002; KALITSKY-SZIRTES et al., 2004). In addition, 
there are some evidences of effects of C. papaya on CYPs and/or P-gp activity; the fruit of C. 
papaya seems to produce inhibitory effects on CYP3A activity and CYP2E1 activity in human 
and mouse liver microsomes respectively (HIDAKA et al., 2004; CHATUPHONPRASERT and 
JARUKAMJORN, 2012). The juice of C. papaya has also shown a weak inhibitory effect on the 
CYP2C9 activity in human liver microsomes (HIDAKA et al., 2008). OGA et al. (2012) also 
reported the inhibition of P-gp in  Caco-2 cells mediated by the leaf extract of C. papaya. In 
addition, the aqueous extract of C. papaya leaves significantly increased (54.5%) the apparent 
permeability of the P-gp substrate digoxin in the mucosal-to-serosal direction in intestinal 
segments mounted in Ussing chambers (OGA, SEKINE and HORIE, 2013). However, the co-
administration of the leaf extract of C. papaya and digoxin to rats did not determine a 
significant increase in the extent of systemic drug exposure (OGA, SEKINE and HORIE, 2013).  
Based on the herb-drug interaction data obtained in the present work between C. 
papaya extract and AM, it is suggested that the herbal extract has impact on the 
pharmacokinetics of AM, particularly after the repeated treatment with the C. papaya 
extract; indeed, the 14-day pre-treatment period with C. papaya induced an increase in the 
bioavailability of AM. Even so, it should be taken in account that results from animal 
experiments cannot be directly extrapolated to humans; however, bearing in mind the 
studies of MENG et al. (2001) and SHAYEGANPOUR, JUN and BROCKS (2005), the rat appears to 
be an appropriate model for man in this case. Nevertheless, to reliably assess the safety of 
administration of C. papaya extract and AM specific clinical trials should be performed.  
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Additionally, in the present study, the increase of body weight of the rats pre-treated 
during 14 days with C. papaya extract or vehicle was comparable. Despite there are 
evidence in literature that C. papaya have anti-obesity effects, our data do not support these 
findings. In a study conducted by ATHESH et al. (2012) in which rats fed with high fat diet 
were treated during a 14-day period with C. papaya extract at doses in the range of 200-600 
mg/kg only a slight reduction in body weight gain was observed. Indeed, the anti-obesity 
effect was more evident after 45 days of treatment with C. papaya fruit extract. In other 
studies the treatment with C. papaya seed extract induced a reduction in body weight gain 
of rats when doses of 100 to 400 mg/kg were administered over 30 days and doses of 2000 
mg/kg were administered during 14 days (ADENEYE and OLAGUNJU, 2009); moreover, a  28-
day treatment period with 5 to 20% of ground bark extract of C. papaya in the diet also 
determined a reduction in body weight gain of rats comparatively to the control group 
(DURU et al., 2012). At last, in a study conducted by GOYAL et al. (2010) no significant 
changes were observed in the body weight of the rats treated during 52 days with doses of 
50 to 500 mg/kg of the methanol sub-fraction of C. papaya seeds .  
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VII.7. SUPPLEMENTARY DATA 
 
Certificate of analysis of Carica papaya extract provided by Bio Serae Laboratories (Ref. 
420015 – Batch 0810960). 
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VIII. GENERAL DISCUSSION 
 
VIII.1. DISCUSSION 
 
Although each of the experimental chapters covering the research work performed 
has its own discussion (from Chapter II to VII), this section is intended to discuss in a more 
integrated and broader manner all the research studies presented in this thesis. The work 
underlying the present thesis aimed at the general objectives proposed at the beginning of 
this dissertation. 
 
In recent years, the increasing interdependence between countries gave rise to the 
need of international acceptance of the results from the analytical methods and, 
consequently, to ensure a common minimum level of quality the use of validated analytical 
methods is becoming an indispensable condition. Actually, since a long time that the results 
generated by non-validated methods are devoid of any meaning and are not recognized by 
the authorities (HARTMANN et al., 1998).  
In fact, the analytical methods for the quantification of drugs and metabolites in 
biological samples play a decisive role, by the quality of the data provided, in the evaluation 
and interpretation of results arising from preclinical, clinical and biopharmaceutical studies 
(SHAH et al., 2000; GUIDANCE FOR INDUSTRY, 2001). In this regard, the role of bioanalytical 
sciences is of the utmost importance in development programs of new drugs and novel 
formulations and even in the implementation of therapy. Analytical data inaccurate or 
unreliable can be the cause of a wrong diagnosis or treatment (BUICK et al., 1990; 
CHANDRAN and SINGH, 2007). To counteract these undesirable issues and to obtain reliable 
results which can be satisfactorily interpreted, the application of an analytical technique fully 
validated is essential (SHAH et al., 2000). 
Thus, before a bioanalytical method can be implemented for routine use it must be 
validated in order to demonstrate its reliability for the determination of an analyte of 
interest in a specific biological matrix. The validation of an analytical method is the systematic 
process that aims to demonstrate that the methodology used is acceptable for the required 
application and ensures a better confidence of the data obtained (SHAH et al., 2000; 
GUIDANCE FOR INDUSTRY, 2001; CHANDRAN and SINGH, 2007). Nowadays the validation of 
bioanalytical methods to quantify small molecules in biological samples is based on the 
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conference report published by SHAH et al. (2000) on Bioanalytical Method Validation – A 
Revisit with a Decade of Progress, on the present Guidance for Industry – Bioanalytical 
Method Validation (GUIDANCE FOR INDUSTRY, 2001) and on the recent Guideline on 
bioanalytical method validation (EUROPEAN MEDICINES AGENCY, 2011a). Accordingly, at least 
the following parameters should be evaluated: selectivity, calibration model (linearity), limit 
of quantification (LOQ), precision, accuracy, recovery and stability of compounds. The 
success of the validation process implies, however, the previous existence of an analytical 
method appropriately developed (DADGAR et al., 1995). In this way, it is not possible that the 
process of validating an analytical method is staked out of the respective conditions of 
development, since the validation studies determine if the state of development of the 
method is quite satisfying or if alterations are required to improve the analytical procedures 
and subsequent revalidation (CHANDRAN and SINGH, 2007).  
In the process of development and validation of bioanalytical methods also should be 
considered multiple variables at once meet the biological matrix used (which should be the 
same of specimens intended), the procedure for collecting the sample and the time that 
elapses until the analysis, the chromatographic separation of the analyte, the detection 
system and the data processing (BRESSOLE, BROMET-PETIT and AUDRAN, 1996; SHAH et al., 
2000). As a result, the development of a new analytical method is the most critical stage of 
the process and depending on the desired objectives and the experience of the investigator 
may be carried out in various ways. When considering the two extreme situations, the 
development may involve only the adaptation of an existing method, with minor changes 
appropriate to the new application, or may involve innovative ideas and methodologies 
requiring harder work and often it is uncertain whether the degree of development required 
will be achieved (EURACHEM GUIDE, 1998). 
 
Taking into account these considerations about validation of bioanalytical methods 
and the general scope of the work to be developed, the first task considered was the 
development and fully validation of a HPLC method to simultaneously quantify amiodarone 
(AM) and mono-N-desethylamiodarone (MDEA) in human plasma using a sample preparation 
involving microextraction by packed sorbent (MEPS). In this way, it was possible to make 
available a novel and innovative bioanalytical tool using for the first time MEPS as sample 
preparation procedure. The method proved to be selective, sensitive enough, precise and 
accurate, and linear in a wide concentration range, making it an important analytical tool for 
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supporting the therapeutic drug monitoring of AM in clinical practice and also to support 
pharmacokinetic-based studies, such as bioequivalence and bioavailability studies. The MEPS 
procedure developed presents several advantages in comparison with conventional sample 
preparation techniques frequently used in bioanalysis. In addition, this technique was 
successfully applied to real plasma samples of highly polymedicated patients receiving AM 
treatment. 
Hence, with the knowledge acquired during the optimization and validation of the 
previous technique in human plasma, a new HPLC-DAD method was then faster developed 
and fully validated for the quantitative determination of AM and MDEA in rat matrices 
(plasma and heart, liver, kidney and lung tissue homogenates). The development of a 
technique in human plasma enable to acquire some experience in the bioanalytical field, 
enabling in this way to reduce the number of animals to the minimum necessary, following 
the 3Rs principle, in the development of the technique in rat matrices (BALANI et al., 2008; 
FENWICK, GRIFFIN and GAUTHIER, 2009). The method developed presents several 
improvements over the assays previously published for the quantification of AM and MDEA 
in rat plasma and tissue samples. Between them, this bioanalytical method enables the fast 
chromatographic analysis of AM and MDEA using simple instrumentation and uncomplicated 
chromatographic conditions. The sample preparation procedures employed are relatively 
similar to previous published methods but lower volumes of organic solvents for the 
extraction and lower volumes of sample were used. This aspect is fundamental when serial 
blood sample collection from small laboratory animals (usually rodents) is required in the 
course of non-terminal pharmacokinetic studies. Indeed, the experimental design planned for 
the following in vivo studies to be conducted in rats involved the harvesting of multiple 
blood samples from each animal. 
 
After the development and validation of the HPLC techniques for the determination 
of AM and its main metabolite (MDEA) the following steps of the present thesis consisted in 
the evaluation of pharmacokinetic herb-drug interactions between the antiarrhythmic drug, 
AM, and four standardized herbal extracts used in the management of obesity (Fucus 
vesiculosus, Paullinia cupana, Citrus aurantium and Carica papaya). These herbal extracts 
were selected because they are frequently used in commercial dietary/medicinal products 
and were relatively easy to acquire commercially; in addition, these herbal extracts are 
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standardized using different bioactive phytochemicals which are probably responsible for the 
properties and pharmacological actions of the extracts on the body weight loss. 
The extracts of F. vesiculosus, P. cupana, C. aurantium and C. papaya exist 
commercially under the form of tablets of the supplier Arkocapsulas® (Arkocapsulas Algas®, 
Arkocapsulas Guarana®, Arkocapsulas Laranja amarga® and Arkocapsulas Papaia®). All the 
four extracts evaluated in this thesis are present simultaneously in the multicomponent 
commercial product EasySlim Depur Max®. These extracts are also present in several other 
commercially available products; for example, F. vesiculosus extract is present in Celulase 
Gold Pearls®;  P. cupana extract is present in Depuralina Raspberry Power®, Depuralina 
Ampola® and Depuralina Concentrado Sport®, Slimexcell Refirme®, Turboslim Men 24® and 
Drena Slim®; the combination of P. cupana and C. aurantium extracts is present in Drenafast 
Intense Solução Oral Cereja® and Hot Drink Slim®; P. cupana and C. papaya extract is 
present in Splendid Celu®; C. aurantium extract is present in Depuralina Concentrado 
Solução® and Drena Slim Raspberry Ketone®; C. papaya extract is present in YMEA 
Silhouette®. This short list of products is very illustrative of the multiplicity of herbal 
preparations freely accessible in the market. 
The use of complementary and alternative therapies such as herbal or natural 
products is widespread and has increased worldwide over the last decade despite the 
paucity of scientific evidence about their safety and efficacy. Consequently, unexpected and 
significant herb-drug interactions may occur and put individuals at risk, particularly those 
people who use multiple medicines for co-morbid conditions. These interactions may lead to 
therapeutic failure and/or toxic effects, especially for drugs characterized by a narrow 
therapeutic index (e.g. AM) (TACHJIAN, MARIA and JAHANGIR, 2010). Undoubtedly, the 
information now available on herb-drug interactions is scarce and, in many cases, 
inappropriate. Indeed, the information published about herb-drug interactions has derived 
mainly from in vitro studies; however, as suggested by some authors, numerous herb-drug 
interactions reported in literature are irrelevant and misleading due to the use of 
inappropriately high concentrations of the extracts or their constituents lacking, therefore, 
in vivo relevance when their bioavailability is considered (COTT, 2008; MARKOWITZ, VON 
MOLTKE and DONOVAN, 2008). Therefore, the in vitro studies are valuable in this context for 
evaluating multiple products and multiple components, providing mechanistic information 
and are also easily performed (VENKATARAMANAN, KOMOROSKI and STROM, 2006). Since the 
in vitro data on herb-drug interactions cannot usually be directly extrapolated to the in vivo 
General discussion 
 
 
245 
conditions, it is important to conduct well-designed in vivo non-clinical studies with enough 
potency for human extrapolation. The in vivo non-clinical studies can be conducted in small 
laboratory animals (e.g. mice and rats). These studies have advantages of being less expensive 
than human clinical studies and can often provide an initial assessment of the bioavailability 
either for phytochemicals in pure form or in the context of a complex extract (GURLEY, 
2012). The herb-drug interaction studies can also be conducted in vivo in humans. Indeed, 
the in vivo clinical studies are valuable to confirm the clinical significance of herb-drug 
interactions identified from non-clinical assays conducted in in vivo animal models or in in 
vitro conditions. These studies are the only ones that are definitive. However, the clinical 
studies are often carried out in healthy humans and not in patients; and these studies are 
generally expensive and several times does not provide mechanistic information 
(VENKATARAMANAN, KOMOROSKI and STROM, 2006). 
The work developed in this thesis was performed using adult male Wistar rat as a 
whole-animal model. The use of female rats was also hypothesized during the experimental 
design of these studies; however, only male Wistar rats were included because it has been 
reported that the pharmacokinetics of AM is not gender-dependent and also to avoid the 
potential interference of menstrual cycle hormones (possible confounding factors) (SANOFI-
SYNTHELABO PFIZER CANADA INC., 2010). As previously referred, the rat was selected 
because this rodent species shares many of the pharmacokinetics properties of AM with 
humans and has been regarded as one of the best models among the small laboratory 
animals for studying pharmaco-toxicological aspects concerning AM; although some 
metabolic differences exist, it has also been demonstrated that MDEA is the principal 
metabolite of AM in both species (rat and human) (PLOMP et al., 1987; NAJJAR, 2001; 
ELSHERBINY and BROCKS, 2010; ELSHERBINY, EL-KADI and BROCKS, 2010). 
 
Globally, from the results obtained with the four herbal extracts tested we can 
conclude that F. vesiculosus, P. cupana and C. papaya extracts have more pronounced effects 
on the pharmacokinetics of AM. Briefly, F. vesiculosus extract and P. cupana extract 
following the co-administration with AM showed a significant reduction of the peak 
concentration of AM as well as a reduction in the extent of systemic exposure to AM. In 
both cases we hypothesize the occurrence of physical-chemical interactions between 
components of each of the extracts and AM in the gastrointestinal tract to explain these 
results. From the literature, a significant reduction of the absorption of AM induced by 
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orlistat in healthy volunteers was also observed (ZHI et al., 2003); this drug, a lipase inhibitor, 
significantly reduced the systemic exposure to AM by approximately 25% and a decrease of 
similar magnitude (~25%) was detected in the generation of the metabolite MDEA (the 
major metabolite of AM). According to ZHI et al. (2003) the absorption of highly lipophilic 
drugs such as AM may depend on the presence of a lipid phase in the gastrointestinal 
environment, which may be affected by the pharmacological action of orlistat. The magnitude 
(Cmax) and extent (AUC0-t) of absorption of AM were also enhanced in healthy volunteers 
who received a single-dose of the drug immediately after consuming a high-fat meal versus 
following an overnight fast (MENG et al., 2001). SHAYEGANPOUR, JUN and BROCKS (2005) also 
studied the effects of food on the pharmacokinetics of AM in rats. The results obtained 
concerning the interference of lipids on the oral bioavailability of AM corroborated those 
reported in humans. 
Despite further studies are needed to understand the mechanism associated to the 
herb-drug interaction reported herein between F. vesiculosus extract and AM. It should be 
highlighted the overview recently published by COLALTO (2010) about herbal interactions on 
the absorption of drugs and the underlying interaction mechanisms. On the other hand, the 
dietary fibre may also reduce the drug absorption when both are assumed nearly by a 
mechanism of action similar to bile sequestration; herb-drug interactions at absorption level 
associated with dietary fibre have been reported, as instance, for lovastatin (RICHTER, JACOB 
and SCHWANDT, 1991), digoxin (BROWN and JUHL, 1976; BROWN, JUHL and WARNER, 1978), 
metformin (GIN, ORGERIE and AUBERTIN, 1989) and glibenclamide (NEUGEBAUER, AKPAN and 
ABSHAGEN, 1983). In addition, LODEIRO et al. (2012) recently reported that F. vesiculosus 
interacts with aluminum of acidic waters by a mechanism of adsorption, suggesting that these 
physicochemical data may be of interest in modeling drug-food interactions, particularly 
those referring to aluminum-containing antacids-food pharmacokinetic process produced in 
the gastrointestinal tract. Therefore, similar physicochemical adsorption mechanisms may 
occur between F. vesiculosus and AM.  
In fact, for the first time were reported herb-drug interactions between F. 
vesiculosus extract and P. cupana extract with AM, which determined a considerable 
decrease on AM bioavailability in rats. Therefore, the therapeutic efficacy of AM may be 
compromised by the concurrent administration of herbal slimming medicines/dietary 
supplements containing F. vesiculosus or P. cupana. 
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On the other hand, it should be highlighted that the pre-treatment with C. aurantium 
extract significantly increased the peak concentration of AM, while the extent of systemic 
exposure was comparable between both groups. To explain this increase of the Cmax in the 
group of rats pre-treated with C. aurantium we hypothesize that the extract or some of its 
constituents could change (increase) the gastrointestinal motility, thus increasing the rate at 
which AM passes to the intestine. Actually, the absorption of AM across the intestinal 
membrane occurs by passive diffusion, which is a non-saturable process (MARTÍN-ALGARRA et 
al., 1997). According to the studies of JINZHAO et al. (2005), the C. aurantium may improve 
the gastric emptying in rats with functional dyspepsia. Furthermore, extracts of C. aurantium 
also increased the rate of gastrointestinal motility enhancing, therefore, the absorption 
function of gastrointestinal tract (LI et al., 2007). In addition, C. aurantium can also 
antagonise the inhibition of the intestinal advance induced by atropine (XUE-BAO et al., 
2005). In a study conducted by FANG et al. (2009) the effects of constituents of C. aurantium 
on the gastrointestinal movement were evaluated; the hesperidin had a stimulatory effect on 
the gastrointestinal muscle contraction while synephrine had an inhibitory effect. Another 
possibility to explain the higher Cmax values for AM in the group of rats pre-treated with C. 
aurantium extract could be related to a time-dependent inhibitory effects induced by C. 
aurantium or some of its phytochemicals on the cytochrome P450 (CYP) isoenzymes and/or 
P-glycoprotein (P-gp)–mediated efflux activity.  
At last, in the rats pre-treated with C. papaya extract was observed a significant 
increase in the systemic exposure of AM (as assessed by AUC0-t and AUC0-∞). C. papaya 
extract or some of its phytochemical constituents could have antimotility properties 
determining the inhibition of the intestinal propulsion movements (EZIKE et al., 2009). This 
reduction of gastrointestinal motility can prolong the transit time of drugs and, consequently, 
it can increase the extent of the absorption of slightly soluble drugs, such as AM (TARIRAI, 
VILJOEN and HAMMAN, 2010). Another possibility to explain the higher AUC0-t and AUC0-∞ 
values for AM in the group of rats pre-treated with C. papaya extract could be related to a 
time-dependent inhibitory effect on CYP isoenzymes and/or P-gp-mediated efflux activity. 
  
In the pharmacokinetic studies performed were evaluated the effects of four herbal 
extracts separately, but also could be interesting to evaluate the effect of the combination of 
these herbal extracts in order to approximate to the commercially available products that 
normally are composed by a mixture of several components. These studies would also allow 
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realizing if the resulting effects could be additive, synergistic or antagonistic by the 
combination of the extracts. Taking into account our results, the combination of F. 
vesiculosus and P. cupana extract could probably result in a more significant decrease in the 
bioavailability of AM which could be quite problematic. 
Overall, despite the safety and efficacy of C. aurantium-containing supplements have 
been frequently questioned, our results showed that the C. aurantium extract has minor 
effects on the pharmacokinetics of AM. These results reinforced that the C. aurantium 
extract should be maintained in the herbal dietary supplements. 
Furthermore, taking into account the results obtained with C. aurantium extract and 
C. papaya extract in vitro studies to evaluate the impact of these extracts on the metabolism 
of AM should be also conducted using, for instance, a recent and promising in vitro 
hepatocellular model, the HepaRG cells. 
 
The changes in body weight of the rats submitted to a 14-days treatment period with 
each of the extracts or the vehicle of the extract were not exactly the expected. The 
extracts of F. vesiculosus, C. aurantium and C. papaya were shown to be ineffective to 
control de body weight gain in rats during the period of 14 days. The only exception was P. 
cupana extract which was able to suppress gains in body weight of rats. Despite the evidence 
from the literature that these extracts have anti-obesity effects, our data do not support 
these findings, probably due to the short period of repeated administration of the extracts 
(only two weeks). 
 
During the elaboration of this thesis, the European Medicines Agency (EMA) 
established an action Plan for Herbal Medicines 2010-2011 in which one of the objectives 
was to improve the output of the Committee on Herbal Medicinal Products, in particular by 
increasing the quality and number of Monographs and List entries. Effectively, the Committee 
on Herbal Medicinal Products (HMPC) of European Medicines Agency launched a call to 
encourage submission of scientific data on P. cupana (Guarana) in order to prepare the 
corresponding herbal monograph (EUROPEAN MEDICINES AGENCY, 2011b). The final document 
Monograph was already published and the information about drug interactions was included. 
This call for Monographs could be related to the widespread use of herbal products and 
probably to the increased risk of potential herb-drug interactions. In addition, this call for 
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Monographs demonstrates that the authorities have increasing interest in this field and with 
the work presented in this thesis we can give our contribute.  
 
In the thesis we decide to evaluate the effects of the herbal extracts of F. vesiculosus, 
P. cupana, C. aurantium and C. papaya by the reasons explained previously but also could be 
interesting to evaluate in vivo the potential herb-drug interactions between AM and other 
commonly used weight loss herbal extracts such as Garcinia cambogia, Hoodia gordonii or 
Ilex paraguariensis. In addition, could also be interesting to evaluate the interactions between 
these extracts with other high-risk cardiovascular drugs of narrow therapeutc index such as 
warfarin and digoxin, which are frequentely involved in relevant herb-drug interactions. 
 
In conclusion, despite the widespread use of herbal medicines, documented herb-
drug interactions are sparse and many of the observed herb-drug interactions are based in in 
vitro studies. Although some herb-drug interactions may be beneficial by enhancing the 
efficacy and reducing the toxicities of the co-administered drugs, in most of the cases the 
herb-drug interactions may increase drug toxicity. Therefore, more studies are needed to 
confirm and assess the clinical significance of these potential herb-drug interactions. Our 
results provide an evidence of the effects of these extracts on the pharmacokinetics of AM 
in rats. Even so, to reliably assess the clinical effects of these standardized herbal extracts or 
of the commercially available products containing these extracts on the pharmacokinetics of 
AM clinical trials specifically designed to evaluate these potential herb-drug interactions are 
needed. These clinical trials would allow obtaining more information that could be included 
in the summary of product characteristics of AM and/or in Herbal Monographs.  
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IX. FINAL CONCLUSIONS 
 
IX.1. – CONCLUSIONS  
 
The experimental work presented in this thesis consisted in the development and full 
validation of bioanalytical methods for the quantification of amiodarone (AM) and its major 
metabolite (mono-N-desethylamiodarone, MDEA). After that, a lot of studies were 
conducted in order to evaluate the potential for herb-drug pharmacokinetic interactions 
between various slimming herbal extracts and AM. 
  
Briefly, the most relevant achievements and conclusions obtained throughout the 
work subjacent to the present thesis are the following: 
 
 The development and full validation of the first high-performance liquid 
chromatography-diode array detection (HPLC-DAD) method for the simultaneous 
determination of AM and MDEA in human plasma using microextraction by packed 
sorbent (MEPS) was achieved. The MEPS procedure developed for plasma sample 
preparation has several advantages; it does not require the evaporation and 
reconstitution steps usually needed in most of the liquid-liquid extraction (LLE) or 
solid-phase extraction (SPE) techniques; MEPS presents a cost per analysis minimal 
compared to conventional SPE because each MEPS sorbent can be re-used several 
times before being discarded while SPE cartridges are indicated for single use only, 
and MEPS also enables the reduction of the organic solvent consumption and the 
sample preparation time. 
 
 A new HPLC-DAD method using LLE was developed and fully validated in order to 
simultaneously quantify AM and MDEA in rat matrices (plasma and heart, liver, kidney 
and lung tissue homogenates). Its major advantages include the short 
chromatographic run time (only 5 min) using simple instrumentation and 
uncomplicated chromatographic conditions (isocratic elution and detection in UV 
spectral region); these aspects suggest that the method is appropriate for 
implementation in almost all laboratories, and fast bioanalytical assays are essential 
whenever a large number of samples have to be analysed. 
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 A significant decrease (55.4%) in the peak plasma concentration of AM was clearly 
demonstrated following the simultaneous co-administration of the Fucus vesiculosus 
extract and AM, as well as a reduction of approximately 30% in the extent of 
systemic drug exposure. On the other hand, no important effects were detected 
either on the rate or extent of systemic exposure to AM after the administration of 
the drug to pre-treated rats one day after the last treatment with F. vesiculosus 
extract. Hence, taking these findings together, it is apparent that F. vesiculosus 
extract or some of its components interact with AM in the gastrointestinal tract, 
reducing significantly the bioavailability of the drug; actually, this interaction was 
identified as relevant only after the simultaneous co-administration of F. vesiculosus 
extract and AM. 
 
 The simultaneous co-administration of the Paullinia cupana extract and AM 
determined a significant decrease (73.2%) in the peak plasma concentration of the 
drug, as well as a reduction of approximately 60% in the extent of systemic drug 
exposure. A decrease in the tissue concentrations of AM and MDEA was also 
observed. On the other hand, no important effects were detected either on the rate 
or extent of systemic exposure to AM after the administration of the drug to pre-
treated rats one day after the last treatment with P. cupana extract. Hence, taking 
these findings together, it is apparent that P. cupana extract or its components 
interact with AM in the gastrointestinal tract, reducing significantly the bioavailability 
of the drug. 
 
 The simultaneous co-administration of the Citrus aurantium extract and AM has no 
important effects either on the magnitude or extent of systemic exposure to AM. 
However, in rats pre-treated with C. aurantium extract it should be highlighted the 
significant increase of the peak plasma concentration of AM, while the extent of 
systemic exposure was comparable between both groups. Overall, C. aurantium 
extract have only minor effects on the pharmacokinetics of AM in rats.  
 
 The simultaneous co-administration of the Carica papaya extract and AM show also 
minor effects either on the magnitude or extent of systemic exposure to AM. 
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However, in the rats pre-treated with C. papaya extract it should be highlighted a 
marked increase in the extent of systemic exposure to AM (60-70%). Hence, taking 
these findings together, it is evident that C. papaya extract or its components interact 
with AM increasing significantly the bioavailability of the drug but this interaction was 
identified as relevant only after the continued administration of C. papaya extract. 
 
In conclusion, the findings reported along this thesis showed the relevance of 
screening herb-drug pharmacokinetic interactions. The knowledge of relevant herb-drug 
interactions is certainly useful to help in the preparation of appropriate herbal monographs 
such those in course by the Herbal Medicinal Products Committee (HMPC) of the European 
Medicines Agency (EMA). The availability of this kind of information gathered together in a 
single and easily accessible document (monograph) may be of great value to promote a more 
rational and safer use of herbal products, having high importance in terms of protecting the 
public health. 
 
 
